2018

Welding Fume Exposure and Lung Cancer: Evidence of Lung Toxicity and Tumor Promotion from in vivo Studies in AJ Mice

Lauryn Falcone

Follow this and additional works at: <https://researchrepository.wvu.edu/etd>

Recommended Citation

Falcone, Lauryn, "Welding Fume Exposure and Lung Cancer: Evidence of Lung Toxicity and Tumor Promotion from in vivo Studies in AJ Mice" (2018). *Graduate Theses, Dissertations, and Problem Reports*. 5567.

<https://researchrepository.wvu.edu/etd/5567>

This Dissertation is protected by copyright and/or related rights. It has been brought to you by the The Research Repository @ WVU with permission from the rights-holder(s). You are free to use this Dissertation in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you must obtain permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license in the record and/ or on the work itself. This Dissertation has been accepted for inclusion in WVU Graduate Theses, Dissertations, and Problem Reports collection by an authorized administrator of The Research Repository @ WVU. For more information, please contact researchrepository@mail.wvu.edu.

**Welding Fume Exposure and Lung Cancer: Evidence of Lung Toxicity
and Tumor Promotion from *in vivo* Studies in A/J Mice**

Lauryn Falcone

Dissertation submitted to the West Virginia University School of Medicine

in partial fulfillment of the requirements for the degree of

Doctor of Philosophy in Cellular and Integrative Physiology

David Siderovski, Ph.D., Chair

Patti Erdely, Ph.D.

Salik Hussain, Ph.D.

Stanley Hileman, Ph.D.

Kristin Cummings, M.D.

Timothy Nurkiewicz, Ph.D.

Chengfeng Yang, Ph.D.

Department of Physiology and Pharmacology

Morgantown, WV 2018

Keywords: welding fumes, lung cancer, A/J mice

Copyright Lauryn Falcone 2018

ABSTRACT

Welding Fume Exposure and Lung Cancer: Evidence of lung toxicity and tumor promotion from *in vivo* studies in A/J mice

Lauryn Falcone

Welding fumes were recently reclassified as *carcinogenic to humans* (Group 1) by the International Agency for Research on Cancer (IARC) based on sufficient epidemiological evidence and limited evidence in animals. It is estimated that 11 million workers worldwide weld full-time, and an additional 110 million have had some type of welding-related exposure. Welding exposures are complex because of the diversity of welding modalities used in the workplace; these modalities include exposures to non-carcinogenic and/or carcinogenic metal containing fumes.

The objective of this dissertation was to determine which welding fumes and their component metals are the most toxic and have the greatest tumorigenic potential. Male A/J mice received intraperitoneal injections of corn oil or the initiator 3-methylcholanthrene (MCA; 10 $\mu\text{g/g}$) and one week later were exposed by whole body inhalation to air or gas metal arc-stainless steel (GMA-SS), GMA-mild steel (MS), or Copper-Nickel welding aerosols for 4 hours/day x 4 days/week x 8-9 weeks at a target concentration of 40 mg/m^3 . Lung nodules were enumerated at 30 weeks post-initiation. GMA-SS and GMA-MS fumes significantly promoted lung tumor multiplicity in A/J mice initiated with MCA (16.11 ± 1.18 ; 21.86 ± 1.50 , respectively) compared to MCA/air-exposed mice (7.93 ± 0.82 ; 8.34 ± 0.59 , respectively). Cu-Ni welding aerosols significantly decreased lung tumor multiplicity compared to MCA/air controls (7.11 ± 0.93 tumors vs. 15.57 ± 0.75 tumors, respectively). A separate group of mice also received intraperitoneal injections of MCA or corn oil and beginning one week later were exposed to NiO, Fe₂O₃, Cr₂O₃ + CaCrO₄ or sham once per week for 5 weeks via oropharyngeal aspiration.

Component Fe_2O_3 was the only metal to promote lung tumors in A/J mice. To study lung pneumotoxicity of the welding fumes and their component metals, mice were given a single bolus low or high dose of NiO , Fe_2O_3 , $\text{Cr}_2\text{O}_3 + \text{CaCrO}_4$, total GMAW-SS fume or sham at sacrificed at 1 day, 7 days, 28 days, and 84 days post-exposure. An additional group of mice were exposed to GMAW-MS via inhalation for 4 hours/day for 10 days at a target concentration of 40 mg/m^3 and sacrificed at the same time points. Bronchoalveolar lavage fluid was collected and analyzed for markers of inflammation and cytotoxicity. GMA-SS fume was more pneumotoxic than the individual components. Component Fe_2O_3 was the most toxic of the metal oxides. Inhalation of GMAW-MS did not induce inflammation or cytotoxicity in A/J mice.

In conclusion, these studies demonstrates that inhalation of GMA-SS and GMA-MS welding fume as well as Fe_2O_3 promote lung tumor formation *in vivo* and provides support for the epidemiology that shows welders, using mild and/or stainless steel, are at an increased risk for lung cancer. It is unclear why Cu-Ni welding aerosols decreased tumor size and number. However, the findings in this dissertation provide a framework for future epidemiological, *in vivo*, and *in vitro* studies of welding fumes to further understand the association between lung cancer and welding. A better understanding of which welding fumes and metal oxides are most toxic or tumorigenic could lead to more appropriate worksite regulations and even the development of safer welding consumables which lack the more dangerous components.

Acknowledgements

A tremendous number of people helped me to have a successful graduate school experience, and it would be difficult to mention all of them here. However, I would like to thank some of the most influential people.

To begin, I would like to thank my mentor, Dr. Patti Erdely. Patti paved the way for me to immediately hit the ground running from day 1 in her lab. Throughout my graduate school training, she offered invaluable mentorship guidance that lead me to complete great science, present at numerous conferences, win research awards, and most important grow as a student, a writer, and a researcher. I appreciated that she was always looking out for my best interest and highly concerned with helping to advance my career. Rebecca Salmen also deserves recognition; we spent many hours in lab together, and I always appreciated her guidance, support, and encouragement. She was my go-to person for anything NIOSH-related, from learning how to mail a package to finding someone's office in the building. I would also like to thank all of my committee members, especially Dr. Siderovski and Dr. Brock. Dr. Siderovski has been someone I have worked with closely the past few years as he led the MD/PhD scholars program, and I always felt like he was highly supportive of my goals and ambitions. No matter what I wanted to do, he was always optimistic and willing to stand behind any endeavors I chose to pursue. I have a significant amount of gratitude towards Dr. Brock; he has been an undeniable pillar in building my success these past three years. I especially appreciated how supportive he was of my career goals, even when they were outside the scope of my PhD focus. Of anyone I met during my PhD training, I felt like he was most supportive of the training of an MD/PhD student. He was instrumental in getting me back into the clinic during my PhD years by creating a clinical immersion program that let me get elective credit to rotate in my desired field, dermatology. In

particular, he went through great lengths to help me schedule an early away rotation through this clinical immersion program in dermatology at Children's National Medical Center, an experience I regard as one of the highlights of my career thus far.

I would also like to thank my parents, Frank and Lisa, my sisters, Morgan, Kelsey, and Justine, and my grandparents, Anna, Frank, Thom, and Marlene. My family has been supportive of my career aspirations for a very long time, and I could not be where I am today without their encouragement and assistance. Lastly, I would like to thank my running and triathlon training partners in the surrounding area who helped me to have a thriving life outside of science and medicine during graduate school.

Table of Contents

List of Symbols, Abbreviations, and Nomenclature	viii
Chapter 1: Introduction	1
Overview of Welding.....	1
Types of Welding Processes and Welding Fumes.....	3
Hazards of Welding	7
Bibliography	11
Chapter 2: Lung Cancer and Welding: A Review.....	16
Abstract.....	17
Introduction	18
Methods.....	22
Results and Discussion	22
Epidemiological and worker studies	22
<i>In vivo</i> studies.....	25
<i>In vitro</i> studies.....	31
Conclusions	33
Bibliography	33
Tables	47
Chapter 3: Gas Metal Arc – Stainless Steel Welding Fume Promotes Lung Tumorigenesis in A/J Mice	49
Abstract.....	50
Introduction	51
Methods.....	52
Results.....	56
Discussion.....	61
Bibliography	65
Figure Legends	70
Figures.....	72
Tables	77
Chapter 4: Inhalation of Iron-Abundant Gas Metal Arc – Mild Steel Welding Fume Promotes Lung Tumors in Mice.....	80
Abstract.....	81
Introduction	82

Methods.....	84
Results.....	89
Discussion.....	94
Bibliography	98
Tables	108
Figures.....	113
Chapter 5: Pulmonary Toxicity and Lung Tumorigenic Potential of Metal Oxides in Gas Metal Arc – Stainless Steel Welding Fume: Iron Oxide as a Lung Tumor Promoter	118
Abstract.....	119
Introduction	120
Methods.....	121
Results.....	130
Discussion.....	136
Bibliography	141
Figure legends	147
Figures.....	150
Tables	160
Chapter 6: Lack of Lung Tumor Promotion after Inhalation of a Copper- Nickel Welding Fume in A/J Mice	165
Abstract.....	166
Introduction	167
Methods.....	168
Results.....	173
Discussion.....	176
Bibliography	178
Figure legends	185
Figures.....	187
Tables.....	192
Chapter 7: Conclusions	195
Bibliography	199

List of Symbols, Abbreviations, and Nomenclature

CO – Corn oil

Cr – Chromium

Cr⁶⁺ - Hexavalent chromium

Cu – Copper

Fe – Iron

FCAW – flux-cored arc welding

GMAW-SS – Gas metal arc welding – stainless steel

GMAW-MS – Gas metal arc welding – mild steel

GTAW – gas tungsten arc welding

MCA – 3-methylcholanthrene

MMA – Manual metal arc welding

Mn - Manganese

Ni – Nickel

PAW – Plasma arc welding

SAW – submerged arc welding

SMAW – Shielded manual metal arc welding

Chapter 1: Introduction

Overview of Welding

For centuries, the ability to join metal parts has been a crux of our society. Prior to the late 1800s, the only method to metallurgically connect metals was a laborious process known as forge welding, in which metals were heated and repeatedly pounded until a bond was formed [1]. It is unknown exactly when forge welding began. However, it is believed that the shaping of metals which formed the foundations for welding started in ancient tribes many centuries ago. There is also some evidence that ancient Egyptians used a type of welding similar to gas welding today by which they used a blowpipe and flames to melt the surface of metals [2]. By the late 1800s, increased electrical power allowed more methods of welding to emerge, including arc welding, resistance welding, and oxyacetylene welding [1-3]. It is believed that an Englishman named Widdle was the first person to intentionally weld two metals, fusing two small pieces of iron in 1865 and receiving the first patent for a welding process[1].

By the early 1900s, arc welding, the most popular and commercially useful method of welding, had made its way to the United States [1]. Four manufacturers of arc welding equipment were established by 1917, including Lincoln Electric Company, which is still the largest supplier of welding equipment today. The popularity of welding continued to grow over time, but the first major demands on the industry came during World War I, with a sudden need for fleets of ships, aircraft and war supplies. Welding allowed for faster production of these transportation devices compared to earlier methods. After the war, welding was still not used extensively, but with the approach of World War II, the need for welding picked up again and welding became increasingly important [1].

Today, our ability to fuse metals has led to the production of everything from ships,

automobiles, and bridges to mp3 players, medical devices, and computers [1-3]. When it comes to fastening or connecting metals, many options are available including simple bolts and screws, adhesives such as tapes and glues, riveting, brazing, soldering, and welding. Each method has its advantages, with some techniques like bolts, screws, and adhesives requiring only basic skills but providing a less durable union [4]. Welding, brazing, and soldering are similar processes in that they are three stronger methods of joining metals and require more skill to be performed.

Depending on the strength of the union desired and the types of metals being joined, one process may be preferred over another. Soldering and brazing are very similar processes except that brazing is performed at higher temperatures above 450°C while soldering occurs at lower temperatures below 450°C [4]. Unlike soldering and brazing, which only melt the filler metal, welding is a true fusion process as it involves melting of both the work pieces and filler material. Thus, welding has the advantage of being the strongest possible method of joining metals, making it a highly utilized process in the construction and manufacturing industries.

The American Welding Society was founded in 1919 with the mission of advancing the science, technology, and application of welding processes worldwide. It is estimated that there are more than 110 million workers across the world that receive some sort of welding exposure, whether they are full-time or part-time welders or employed in other industries such as construction, farming, pipefitting, ship making, or automobile services [4, 5]. The welding industry is expected to grow 4% from 2014 to 2024, especially as the workforce ages and infrastructure degrades and needs to be replaced and repaired [4, 6]. In 2010, the manufacturing industry employed 61% of all welders, followed by the construction industry (11%), wholesale trade (5%), and maintenance and repair (5%) [4]. Welding is a popular career choice as the skills

of a welder are versatile and transferable; a welder who gets laid off in the manufacturing industry, for example, may easily find work building pipelines in the oil and gas industry [6].

Nearly 80 types of different welding processes exist but all welding processes are similar in that they generally require high heat and a filler material which is usually a stick or wire [3, 4]. The vast majority of metals are fused by an electric arc welding process. It is believed that the electric arc was discovered by Sir Humphrey Davy in 1801 when experimenting with electricity[1]. Davy discovered that this arc could be maintained and created with a high voltage electric circuit and noticed that it gave off significant amounts of light and heat. In arc welding, high temperatures of 5,000°C or more melt the joint between two metal work pieces as well as a filler material placed between them [4]. This extremely high heat capable of melting metals is produced by the electric arc which is established between the work pieces and a consumable wire electrode. As temperatures cool, the bond solidifies, firmly fusing the work pieces together. The bond created by welding is unique in that it is a mixture of the metal work pieces and the electrode filler material, making the bond extremely strong as it retains the strength of both initial metal parts [1, 4]. This bond is unique to welding, as brazing, soldering, and adhesives are considered non-fusion methods of joining metals since the bond is not a mixture of both work pieces and filler material [4].

Types of Welding Processes and Welding Fumes

Welding processes are largely classified as either arc or non-arc welding, with arc welding being considerably more popular. Specific types of arc welding include shielded metal arc welding (SMAW), gas metal arc welding (GMAW), Flux-cored arc welding (FACW), gas tungsten arc welding (GTAW), submerged arc welding (SAW), and plasma arc welding (PAW) [7]. With arc welding, some type of shielding of the weld is needed, because the metals at high temperatures will chemically react with nitrogen and oxygen in the air, creating oxide and

nitrides which would weaken the strength and toughness of the weld [1]. Shielding may be provided by a gas, vapor, or slag which serves to prevent contact of the molten weld puddle that is created with air. Non-arc welding includes resistance welding, oxyfuel gas welding, solid state welding, and high energy density welding. Choice of which type of welding to use depends on a variety of factors including desired strength of the weld, cost, speed of welding, and position and thickness of the material [4].

SMAW is also known as stick welding or manual metal arc (MMA) welding. It is the most commonly used arc welding process as it is the cheapest and simplest method of welding [4]. As the name suggests, in SMAW a welder manually guides an electrode along the metal to be welded after creating an arc between the electrode and the metal [3]. The electrode is coated with a material which decomposes under high heat and shields the weld puddle from reacting with the atmosphere. Unlike some other types of welding, no pressure is used in SMAW and the filler material is provided by the consumable wire electrode. GMAW, also known as metal inert gas (MIG) welding, is a method commonly used commercially as it can be automated and performed at higher speeds [1, 4]. In GMAW, an electric arc is established between the work piece and a consumable wire electrode. Unlike SMAW, the electrode in GMAW is bare rather than coated, so the weld is instead protected by an external gas source such as argon, helium, or carbon dioxide. A disadvantage of GMAW is that it produces a significant amount of welding fume, primarily from the consumable wire electrode [4]. FCAW is similar to GMAW in that an arc is again established between the work piece and a consumable electrode and in both processes a significant amount of fume is produced. However, in FCAW, shielding is primarily provided by a flux within the electrode as well as a central core which may contain scavengers, slag, deoxidizers or other shielding agents, rather than a coating on the electrode or solely an external

gas [1, 4]. Sometimes, additional shielding will also be provided by an external gas. In GTAW, an arc is still established between the work piece and electrode, but the electrode is non-consumable tungsten and serves only to maintain the arc rather than shield the welding process. Shielding instead is provided by external gases. Pressure is sometimes used. Unlike GMAW and SMAW, very little welding fume is generated during GTAW. SAW is similar to GMAW in that an electric arc is established between the work piece and a bare electrode. It is the ideal welding process for fusing thick plates as it provides a high metal deposition rate and is among the fastest welding process [1]. Unlike other welding processes, the electric arc is not visible and shielding is provided by a granular flux which covers the work piece. This results in a much more contained welding process, without the production of sparks, radiation, and fume which is generated in other welding processes. The filler material is provided primarily by the bare electrode and pressure is not used. Lastly, PAW is most similar to GTAW in which an arc is established between the work piece and a non-consumable electrode. While the arc supplies heat, unlike with other welding processes, the arc is not diffused but rather forced through a small hole, constricting the arc [1, 4].

Despite the overwhelming popularity of arc welding, other types of non-arc welding are sometimes employed, such as resistance welding, oxyfuel gas welding, solid state welding, and high energy density welding[1, 4]. Resistance welding refers to processes such as spot welding, induction welding, and flash welding in which the weld is created by heat provided from resistance to the flow of an electric current as well as pressure. Resistance spot welding is sometimes utilized in the production of automobiles or aircraft as it can be performed repetitively at high speeds to product a joint similar to a rivet although significantly stronger. In oxyfuel gas welding, a nozzle directs gas at the work piece surface and a combustion process between air,

gas, and oxygen joins the metals. This type of welding generates some fume but not as much as some of the arc welding processes as it is performed at lower temperatures. However, oxyfuel gas welding is infrequently used in the industry as it produces a lower quality weld compared to arc welding. Solid state welding includes friction welding, diffusion welding, hot and cold pressure welding, ultrasonic welding, and explosive welding. It is unique in that no melting occurs and metals are instead joined by pressure and occasionally heat. However, solid state welding is very expensive and therefore not utilized for large production jobs. Lastly, high energy density welding includes processes like electron beam welding and laser beam welding. In these types of welding, lasers or a stream of electrons create high temperatures which allows melting and vaporization to fuse work pieces. However, like solid state welding, high energy density welding is very expensive and not widely used commercially [1, 4].

Welding fumes are created as a byproduct of many of the welding processes, particularly arc welding [4]. The welding fume composition varies depending on the specific type of welding process. However, it is typically composed of a mixture of vaporized metal oxides from the electrode and/or flux material which are small enough in size to be respired and reach the alveoli of the lungs [4]. Gases produced during welding can vary depending on the type of welding process and other conditions. Ozone can be formed during welding by reaction of atmospheric oxygen and UV radiation from the welding arc [4]. While the rate at which ozone can form varies greatly with the materials being welded, the shielding gas used, the welding process being performed and properties of the welding arc, ozone is generally unstable in the atmosphere [8]. The metal oxides of the fume also increase the rate of degradation of ozone. Thus, while ozone is well known to be a respiratory irritant, production during welding is typically negligible. CO can also sometimes be formed during the welding process by reduction

of CO₂ at high temperatures or from decomposition of compounds coating the electrode [4]. CO is a colorless, odorless gas which can be deadly if inhaled. NO is also sometimes formed during welding when high temperatures oxidize atmospheric nitrogen. NO is irritating to eyes, lungs, and mucous membranes [4, 9].

Hazards of Welding

Welders are exposed to a number of health and safety hazards owing to dangerous work environments and exposures from the welding process [6]. Welders may work indoors or outdoors, in confined or wide open spaces that may be well or poorly ventilated, and can sometimes be exposed to inclement weather. When welding in confined spaces lacking proper ventilation, welding fumes can rapidly accumulate, pushing out breathable air and causing suffocation of the welder [1]. When working outdoors, welders may work on scaffolds or platforms high above the ground. Some jobs involve heavy lifting and frequent bending and stooping down in uncomfortable, awkward positions [3, 6]. In addition to a dangerous work environment, welders work with extremely hot materials and strong light [1, 6]. Electrical shock and even potential explosions if combustible gases are mishandled or if welding sparks hit flammable materials are possible dangers of welding [1, 3]. Work areas should be kept very clean as even dust particles have been known to become volatile in the heat of the arc, quickly oxidize, and cause a flash fire or explosion[1]. Because of these hazards, welders have higher rates of injury and illness than the national average for workers [6]. Injuries and illness can be minimized by following safety protocols and with the use of personal protective equipment such as gloves, goggles, ear plugs, masks, and heat resistance clothing [1, 6].

Welders are also exposed to a number of hazards from heat, noise, or radiation [4]. Additionally, both respiratory and non-respiratory health effects have been reported in welders,

including dermal toxicities, neurological changes, cardiovascular damage, and reproductive impairments.

Notably, the UV radiation from the welding arc can result in erythema of unprotected areas of welders' skin, most commonly in the head and neck regions [4]. Many welders suffer burns. The severity of the UV radiation exposure depends on a number of factors including distance from the source, susceptibility of the host, use of protective clothing, exposure time, and wavelength [8]. Some reports have suggested that welders have increased incidences of nonmelanoma skin cancers including basal cell carcinomas and actinic keratosis, a potential precursor to squamous cell carcinomas [4, 10-14].

Neurological effects from welding exposures largely stem from the presence of manganese in welding fumes [4, 15]. Manganese is a known neurotoxin and is present in many types of welding fumes. Most reported instances of neurological toxicities in workers occurred when welding fumes were abnormally high or when welding in confined, poorly ventilated or unmaintained workplaces [4, 16, 17]. Situations such as these can lead to manganese overexposure which may cause a Parkinson disease-like syndrome. It is believed that some inhaled welding fumes can deposit in the airways of the head and neck where they may reach the brain through areas such as the olfactory neurons in the nose [18]. Manganese then accumulates in the basal ganglia, an area of the brain that aids in movement control, and can cause irreversible brain damage. As the disease progresses, patients suffer from manganism which presents similarly to Parkinson's disease with tremor, gait abnormalities, muscle weakness or rigidity, and slow movements [19, 20]. While the mechanism of this manganese toxicity is not entirely known, Criswell et al. demonstrated that the caudate regions of the brain in Mn-exposed welders took up significantly less fluorinated L-DOPA compared to controls, suggesting

dysfunction of pre-synaptic dopaminergic neurons [21]. Chronic exposure to high levels of manganese has also shown to inhibit motor function and affect thalamic GABA levels in welders [22]. It is currently not clear if exposure to chronic, low levels of manganese may result in similar adverse neurological effects long term [15].

Because airborne pollution, a metal-rich particulate matter, is known to cause adverse cardiovascular effects in high risk populations such as the very young or old or those with underlying cardiac conditions, it has been suggested that welding fumes may have similar adverse effects [23]. However, because workers are typically healthier than the general population, they are unlikely to be members of a high risk, susceptible group, making risks of adverse cardiovascular events potentially less likely [4]. Nevertheless, some animal and epidemiological studies do suggest welding fumes may negatively impact the cardiovascular system. Li et al. found that welders had a moderate, but significant, increase in blood pressure compared to controls [24]. While no changes were noted in endothelial cells or other markers, the increase in blood pressure does suggest welding fume exposure has an effect on the cardiovascular system. Zheng et al. observed no differences in blood pressure or heart rate in rats after exposure to GMA-MS or MMA-hard surfacing welding fumes yet did note these fumes decreased left ventricular end diastolic pressure [25]. Erdely et al. noted that mice exposed to stainless steel welding fume developed increased atherosclerotic lesions [26]. Studies have also shown that exposure to stainless steel welding fumes may reduce contraction of cardiomyocytes isolated from rats [27]. It is possible that some of the adverse cardiovascular effects of welding fumes may be due to hypomethylation of coagulation factor II receptor-like 3 gene (F2RL3), a known marker for cardiovascular morbidity and mortality [28]. However, more studies are

needed to investigate the association between welding fume exposure and adverse cardiovascular events to confirm a potential mechanistic link.

Concerns have also been raised about the potential for welding fumes to impair the reproductive system. In particular, some studies have shown that semen quality and quantity are decreased in welders [29]. Metals have also been shown to accumulate in the reproductive organs of rats and lead to changes in testosterone levels [30]. One epidemiological study observed an association between paternal exposure to low dose welding fumes and UV radiation and the development of spina bifida in offspring [31]. There is some evidence that maternal exposure to welding fumes may hinder fetus growth and that paternal exposure to welding fumes may increase the risk of premature delivery [32]. In general, however, very few studies have fully evaluated the risk to the fetus after maternal or paternal exposure to welding fumes. Further research is needed to more clearly investigate the potential effects of welding fume exposure on pregnancy and fetal outcomes.

Despite potential dermal, neural, or reproductive toxicities of welding fume exposure, most adverse health issues are pulmonary in nature [4]. In fact, most welders report experiencing respiratory problems due to welding at some point in their lifetime. These may include metal fume fever, bronchitis, siderosis, pulmonary fibrosis, asthma, and infection. However, perhaps the most severe adverse effect from welding fume exposure is the potential development of lung cancer. Numerous epidemiological studies have indicated that welders are at an increased risk of lung cancer [4, 5]. Because of substantial epidemiological evidence and some evidence in animal studies, welding fumes were classified as a Group 1 carcinogen by the International Agency for Research on Cancer in 2017 [5]. The following dissertation begins with a comprehensive literature review on welding fume exposure and the development of lung cancer

followed by *in vivo* studies our laboratory has performed investigating GMAW-SS, GMAW-MS, and Cu-Ni fumes.

Bibliography

1. *The Procedure Handbook of Arc Welding*. 14 edn. The James F. Lincoln Arc Welding Foundation; 2000.
2. Ferguson: *Careers in Focus Technicians*. New York: Infobase Publishing; 2010.
3. Ferguson: *Careers in Focus Construction*. New York: Ferguson; 2010.
4. Antonini JM: **Health Effects Associated with Welding**. 2014:49-70.
5. Guha N, Loomis D, Guyton KZ, Grosse Y, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, Vilahur N, Muller K, Straif K: **Carcinogenicity of welding, molybdenum trioxide, and indium tin oxide**. *Lancet Oncol* 2017, **18**:581-582.
6. **Welders, cutters, solderers, and brazers**
7. Antonini JM: **Health effects of welding**. *Crit Rev Toxicol* 2003, **33**:61-103.
8. Vilaume JE WK, Liss-Suter D, Hsiao S.: *Effects of Welding on Health*. Miami, FL: American Welding Society; 1979.
9. Payen DM: **Inhaled nitric oxide and acute lung injury**. *Clin Chest Med* 2000, **21**:519-529, ix.
10. Heltoft KN, Slagor RM, Agner T, Bonde JP: **Metal arc welding and the risk of skin cancer**. *Int Arch Occup Environ Health* 2017, **90**:873-881.
11. Zamanian Z, Mortazavi SM, Asmand E, Nikeghbal K: **Assessment of Health Consequences of Steel Industry Welders' Occupational Exposure to Ultraviolet Radiation**. *Int J Prev Med* 2015, **6**:123.

12. Wolfe CM, Green WH, Cognetta AB, Jr., Hatfield HK: **Multiple squamous cell carcinomas and eruptive keratoacanthomas in an arc welder.** *Dermatol Surg* 2013, **39**:328-330.
13. Dixon A: **Arc welding and the risk of cancer.** *Aust Fam Physician* 2007, **36**:255-256.
14. Currie CL, Monk BE: **Welding and non-melanoma skin cancer.** *Clin Exp Dermatol* 2000, **25**:28-29.
15. Antonini JM, Santamaria AB, Jenkins NT, Albini E, Lucchini R: **Fate of manganese associated with the inhalation of welding fumes: potential neurological effects.** *Neurotoxicology* 2006, **27**:304-310.
16. **Confined Spaces.** In *Safety and Health Fact Sheets*. Miami, FL: American Welding Society; 1998
17. *Ventilation Guide for Weld Fume.* Miami, FL: American Welding Society; 2001.
18. McClellan RO: **Particle Interactions with the Respiratory Tract.** In *Particle-Lung Interactions*. Edited by Lenfant C. New York: Marcel Dekker, Inc.; 2000: 3-56
19. Wennberg A, Iregren A, Struwe G, Cizinsky G, Hagman M, Johansson L: **Manganese exposure in steel smelters a health hazard to the nervous system.** *Scand J Work Environ Health* 1991, **17**:255-262.
20. Mergler D, Baldwin M: **Early manifestations of manganese neurotoxicity in humans: an update.** *Environ Res* 1997, **73**:92-100.
21. Criswell SR, Nielsen SS, Warden M, Perlmutter JS, Moerlein SM, Flores HP, Huang J, Sheppard L, Seixas N, Checkoway H, Racette BA: **[18F]FDOPA positron emission tomography in manganese-exposed workers.** *Neurotoxicology* 2017.

22. Ma RE, Ward EJ, Yeh CL, Snyder S, Long Z, Gokalp Yavuz F, Zauber SE, Dydak U: **Thalamic GABA levels and occupational manganese neurotoxicity: Association with exposure levels and brain MRI.** *Neurotoxicology* 2017.
23. Brook RD, Rajagopalan S, Pope CA, 3rd, Brook JR, Bhatnagar A, Diez-Roux AV, Holguin F, Hong Y, Luepker RV, Mittleman MA, et al: **Particulate matter air pollution and cardiovascular disease: An update to the scientific statement from the American Heart Association.** *Circulation* 2010, **121**:2331-2378.
24. Li H, Hedmer M, Karedal M, Bjork J, Stockfelt L, Tinnerberg H, Albin M, Broberg K: **A Cross-Sectional Study of the Cardiovascular Effects of Welding Fumes.** *PLoS One* 2015, **10**:e0131648.
25. Zheng W, Antonini JM, Lin YC, Roberts JR, Kashon ML, Castranova V, Kan H: **Cardiovascular effects in rats after intratracheal instillation of metal welding particles.** *Inhal Toxicol* 2015, **27**:45-53.
26. Erdely A, Hulderman T, Salmen-Muniz R, Liston A, Zeidler-Erdely PC, Chen BT, Stone S, Frazer DG, Antonini JM, Simeonova PP: **Inhalation exposure of gas-metal arc stainless steel welding fume increased atherosclerotic lesions in apolipoprotein E knockout mice.** *Toxicol Lett* 2011, **204**:12-16.
27. Popstojanov R, Antonini JM, Salmen R, Ye M, Zheng W, Castranova V, Fekedulegn DB, Kan H: **Alterations in cardiomyocyte function after pulmonary treatment with stainless steel welding fume in rats.** *J Toxicol Environ Health A* 2014, **77**:705-715.
28. Hossain MB, Li H, Hedmer M, Tinnerberg H, Albin M, Broberg K: **Exposure to welding fumes is associated with hypomethylation of the F2RL3 gene: a cardiovascular disease marker.** *Occup Environ Med* 2015, **72**:845-851.

29. Bonde JP: **Semen quality and sex hormones among mild steel and stainless steel welders: a cross sectional study.** *Br J Ind Med* 1990, **47**:508-514.
30. Krajnak K, Sriram K, Johnson C, Roberts JR, Mercer R, Miller GR, Wirth O, Antonini JM: **Effects of pulmonary exposure to chemically-distinct welding fumes on neuroendocrine markers of toxicity.** *J Toxicol Environ Health A* 2017, **80**:301-314.
31. Blatter BM, Hermens R, Bakker M, Roeleveld N, Verbeek AL, Zielhuis GA: **Paternal occupational exposure around conception and spina bifida in offspring.** *Am J Ind Med* 1997, **32**:283-291.
32. Quansah R, Jaakkola JJ: **Paternal and maternal exposure to welding fumes and metal dusts or fumes and adverse pregnancy outcomes.** *Int Arch Occup Environ Health* 2009, **82**:529-537.

Chapter 2: Lung Cancer and Welding: A Review

LM Falcone^{1,2}, JM Antonini², PC Zeidler-Erdely^{1,2}

¹West Virginia University, School of Medicine, Morgantown, WV; ²Health Effects Laboratory
Division, National Institute for Occupational Safety and Health, Morgantown, WV

Abstract

Nearly 11 million people hold the job title of welder, and more than 110 million people around the world have some sort of welding-related exposure. While welding is a crucial industrial process, the hazardous fumes created during welding are known to cause acute and chronic health effects when inhaled. In 2017, the International Agency for Research on Cancer (IARC) classified welding fumes as Group 1 (carcinogenic to humans). This classification was based on sufficient epidemiological evidence and limited evidence in animals. This review summarizes the current literature surrounding epidemiological, *in vivo*, and *in vitro* research on lung cancer in welders. Although the epidemiological evidence is at times contradictory, it generally points to an increased risk. Additional animal and *in vitro* studies are needed to further explore the association between welding and lung cancer and help to understand a potential mechanistic link.

Keywords: welding, lung cancer, A/J mice, gas metal arc, stainless steel, mild steel

Introduction

Approximately 11 million welders perform 80 different types of welding processes around the world to produce everything from ships, automobiles, and bridges to mp3 players, medical devices, and computers [1-5]. The vast majority of metals are fused by an electric arc welding process. Specific types of arc welding include manual metal arc welding [MMA; also known as shielded manual metal arc welding (SMAW)], gas metal arc welding (GMAW), Flux-cored arc welding (FCAW), gas tungsten arc welding (GTAW), submerged arc welding (SAW), and plasma arc welding (PAW) [6]. In arc welding, high temperatures of 5,000°C or more melt the joint between two metal work pieces as well as a filler material placed between them [1]. This extremely high heat capable of melting metals is produced by the electric arc which is established between the work pieces and, in most instances, a consumable wire electrode. As temperatures cool, the bond solidifies, firmly fusing the work pieces together. The bond created by welding is unique in that it is a mixture of the metal work pieces and the electrode filler material, making the bond extremely strong as it retains the strength of both initial metal parts [1, 4]. Given the variety of welding processes used in the workplace, welders' exposure are diverse, rather than homogenous [7].

Welding fumes are created as a byproduct of many of the welding processes, particularly arc welding [1]. The concentration of the fume in the personal breathing space of the welder depends on the volume of the space the welder is in as well as how well the area is ventilated.[8] Welding fume is generated by a process called nucleation, whereby metal oxides are vaporized at high temperature and then condense to form particles [9]. Coagulation then occurs in which particles collide to form clumped aggregates. These aggregates are held together by electrostatic forces, magnetism, and/or van der Waals forces [9-11]. The size of the welding fume particles formed vary depending on the welding process but can range from less than 0.1 μm to over 20

μm . However, the mass median aerodynamic diameter of most welding fumes has been measured to be in the range of 0.2 to 0.5 μm [9-12]. The size of the fume particles is important as this affects where they will end up in the lung. Particles that are larger may not make it beyond the upper airways while the smallest particles of $\sim 0.1\text{-}0.3\ \mu\text{m}$ have the potential to reach the alveolar space of the lungs [13]. The mucocilliary escalator helps to quickly clear particles from the middle and upper airways, sweeping debris towards the mouth to be swallowed and removed from the body [14]. Some remaining particles may be carried by macrophages or neutrophils into the lymphatic system while other particles may be directly taken up by type I pneumocytes and enter the bloodstream. However, clearance is slower in the alveoli compared to the upper airways. Here, it is likely that particles are engulfed by macrophages where they may remain for some time. The half-life of welding fume particles in the lungs is estimated to be almost 2 years [1, 15].

The welding aerosol composition varies depending on the specific type of welding process. However, it is typically composed of a mixture of vaporized metal oxides from the electrode and/or flux material which are small enough in size to be respired and reach the alveoli of the lungs [1]. Surface coatings or paint on the base metal or electrode can also contribute to the aerosol. Due to the contribution by the flux, MMA fume is much more complex than GMAW fume [9, 11]. The presence of alkali metals in the flux also make MMA fume highly soluble compared to GMAW fumes which are mostly insoluble [16]. Nevertheless, welding generates a complex fume composed of potentially hazardous metals as well as gases such as carbon monoxide (CO), nitrogen oxide (NO), and ozone (O_3) [1]. While the metal composition of the fume varies depending on the type of welding process, it may include iron, chromium, manganese, and nickel with typically lower amounts of zinc, aluminum, cadmium, or fluorides.

Table 1 summarizes the major metal composition of SS and MS welding fumes. Iron is one of the major metals in many welding fumes, and reports indicate that 70 mg of iron are deposited in full-time welders' lungs each year [17]. Workers typically clear this iron slowly, and it is known to persist in their lungs for many years, with some estimates indicating retired welders only clear 10 to 20% of their accumulated iron burden each year [1, 17]. Interestingly, iron exposure may cause a benign lung condition known as siderosis [1]. Increased incidences of lung cancer have been observed in iron-exposed workers such as iron-ore mining and welding, but because these do not represent pure exposures to iron, iron is currently not classified as a carcinogen by IARC [18]. Chromium is found in stainless steel welding fumes in both Cr^{3+} and Cr^{6+} oxidation states [19]. Cr^{3+} cannot enter cells and is therefore considered less toxic. Cr^{6+} is highly toxic as it can enter cells and is classified as a carcinogen [20]. The permissible exposure limit (PEL) of chromium was lowered to $5 \mu\text{m}/\text{m}^3$ in 2006 due to its harmful effects [21]. Manganese is used in welding because it hardens and strengthens the weld while minimizing cracking and can become a component in the fume [1, 22]. Manganese is not considered carcinogenic, but has been reported to cause neurotoxic effects in humans and animals [23-27]. Nickel (Ni) is a component of stainless steel welding fume and Ni alloys are becoming increasingly popular in welding as a potential alternative to welding with chromium-containing materials. However, Ni is also known to be toxic and is classified as a human carcinogen [20].

Because the respiratory hazards associated with welding are due to inhalation of the fume, ventilation and respiratory controls can help to minimize these adverse effects [1]. Ventilation options include both local exhaust ventilation and general ventilation [4]. Local exhaust ventilation removes the welding fume right at the source without disrupting the welding process. General ventilation systems include natural ventilation through windows, doors, and

vents as well as mechanical ventilation. However, in some situations, achieving proper ventilation can be difficult or not possible, and no local exhaust ventilation will capture 100% of generated welding fume [28]. In some situations, welding is performed in confined spaces which amplifies the hazards as fumes can rapidly accumulate. These confined spaces can include storage tanks, holds of ships, furnaces and boilers, tunnels, ducts, sewers, silos, pipelines, and underground utility vaults [29]. Respirators can help protect workers when engineering controls fail, but some studies have shown that respirators are not completely effective in protecting welders from welding fumes [30]. Despite the use of engineering controls, cases of adverse respiratory effects among welders are still reported.

Metal fume fever is among the most common respiratory condition in welders, presenting with flu-like symptoms such as cough, dyspnea, and malaise [1, 6]. Typically symptoms of metal fume fever occur 2 days after exposure and resolve 24 to 48 hours later. Given the symptoms and this time frame, cases of metal fume fever may be underreported and underdiagnosed. While the mechanism of metal fume fever is not fully understood, it is believed that metals in the welding fume cause a hypersensitivity reaction when inhaled due to the release of cytokines [31]. Chronic bronchitis is also not uncommon among welders [32, 33]. This disease presents with a chronic productive cough characterized by copious mucus production and dyspnea [34]. Confounders complicate studies of bronchitis in welders, most notably smoking which is a known cause of the disease [1, 35]. However, some studies have shown increased incidence of chronic bronchitis in welders, even when controlling for smoking status [36]. Siderosis, iron oxide deposits in the lung, is a well-documented yet usually nonthreatening and asymptomatic finding in long-term welders [1, 37]. In some instances siderosis has been known to progress to pulmonary fibrosis, a restrictive lung disease which impairs lung function [38, 39]. In the absence of pulmonary

fibrosis, however, chronic welding fume exposure does not seem to lead to long term changes in lung function [40]. Some reports have indicated that exposure to welding fumes may cause an occupational asthma which would present as an obstructive lung disease when symptomatic [1, 41, 42]. Epidemiological studies have indicated that welders are more susceptible to lung infections such as pneumonia and have higher rates of mortality due to these infections [43-46]. Some case reports suggest that welders may even be at greater risk of infection and disease from generally benign, harmless organisms [45, 47].

While a number of respiratory complications are possible from welding fume exposure, by far the most feared adverse effect is the potential development of lung cancer. Numerous epidemiological studies have indicated that welders are at an increased risk of lung cancer [1]. Because of substantial epidemiological evidence and some evidence in animal studies, welding fumes were classified as a Group 1 (carcinogenic to humans) by the International Agency for Research on Cancer in 2017 [3]. The following report is meant to be a critical evaluation of the literature surrounding lung cancer in welders.

Methods

A comprehensive literature search was conducted using the databases PubMed and GoogleScholar. To identify applicable literature the following keywords were used: lung cancer, welding, tumorigenesis, adenocarcinoma, gas metal arc, stainless steel, and mild steel. All relevant literature published in English in the last 50 years was considered for this review.

Results and Discussion

Epidemiological and worker studies

The American Welding Society became concerned about possible adverse health effects from welding in the 1970s and conducted an in-depth literature review of epidemiological,

animal, and *in vitro* studies [48]. They determined that epidemiological studies at the time were inconclusive as they did not account for factors such as smoking, asbestos exposure, previous type of work, family history, or genetics and that the potential carcinogenicity of welding fumes was “highly controversial.”

In the years to follow, many worker studies reported an increased risk of lung cancer in welders [49-69]. However, whether confounders such as smoking can account for this increased risk has been controversial. Smoking is a well-known risk factor for lung cancer, and some studies have indicated that welders and metal workers are more likely to be smokers than the general population [70, 71]. Stern et al. analyzed 22 epidemiological studies in the literature up until the 1980s. They concluded that welders have an approximately 30% increased risk of lung cancer compared to non-welders and this risk persisted even when considering potential confounders such as tobacco use or asbestos exposure in shipyards. Many other studies agreed with the finding that welders are at an increased risk of lung cancer even when considering and controlling for smoking status [53, 55, 58, 70-72]. Kendzia et al. analyzed a large database containing occupation and smoking status[70]. They adjusted for smoking status, concluding that while smoking may explain about 20% of the increased lung cancer risk in welders, it cannot explain all of it. They also noted that lung cancer risk was greater in never or light smokers compared to heavy smokers, further suggesting a direct carcinogenic effect of welding fumes [70]. Vallieres et al. agreed with this finding, observing that there was an excess risk of lung cancer in welders among light but not heavy smokers [73]. However, the epidemiological studies concerning smoking, welding, and lung cancer are conflicting, with some studies claiming confounding from smoking accounts for most of the excess lung cancer risk and other studies do not control for or consider smoking status in their analysis [54, 58, 74-77]. The general

consensus seems to be that while smoking may contribute to increased lung cancer risk in welders, it cannot account for all of it.

Asbestos exposure has also been suggested to contribute to the increased lung cancer risk in welders. Asbestos is known to cause lung cancer and mesothelioma and in some workplaces, such as shipyards, workers can be exposed to this material. While asbestos fibers are not stable at the high temperatures created by welding, welders could sometimes still be exposed to it when asbestos was used as a filler material or for insulation [70]. It has been reported that welders have an increased mesothelioma risk [78]. A number of studies have concluded that the excess lung cancer risk in welders cannot be attributed to asbestos, however [58, 70, 72]. Kendzia et al. 2013 concluded that the excess risk of lung cancer in welders cannot be sufficiently explained by exposure to asbestos. Mannetje et al. adjusted for asbestos exposure in welders and still found an excess lung cancer risk [79]. However, the epidemiological studies are controversial, with some studies concluding that asbestos does account for the higher frequency of lung cancer in welders [54-56, 75, 76, 80-82]. While some of these reports indicate that asbestos may be a confounder in their study, not all of them adjusted for asbestos exposure. Like was found with smoking, while asbestos may account for some of the increased risk of lung cancer in welders, it likely cannot account for all of it.

It is also frequently debated whether SS fume, containing the known carcinogens Ni and Cr, is largely responsible for the increased lung cancer risk in welders compared to MS fume which contains mostly Fe. Melkild et. al and Danielsen et al. found an increased risk of lung cancer with MS welding, but the presence of confounders which were not accounted for in these studies limits these findings [54, 76]. Simonato et al. observed an increased risk of lung cancer among both SS and MS welders but concluded the risk was greater with SS welders [56]. Other

studies found no increased risk of lung cancer among MS welders [83, 84]. In a study by Steenland et al., however, welders only had to have two years of exposure for inclusion in the study, which may not have been long enough to increase lung cancer risk [84]. Nevertheless, numerous studies did find a significantly increased risk of lung cancer in MS welders [58-62, 79, 85]. Hansen et al. actually found that there was a significant excess risk of lung cancer in MS only welders but a non-significant excess risk of lung cancer among SS only welders [60]. Siew et al. specifically observed an increased risk of lung cancer in workers exposed to both iron and welding fumes [85]. However, because metal workers often weld with multiple different processes throughout their lifetime, many welders have mixed fume exposures which can make investigating these associations difficult [69].

Worker studies from the last 50 years have been at times contradictory and controversial. While some studies show clear, increased risks of lung cancer among welders, others show increased risk only with certain types of welding fumes or find that confounders such as smoking and asbestos exposure obscure any potential relationship. The results from epidemiological and worker studies emphasize the need for controlled *in vivo* and *in vitro* studies of welding fume exposures.

***In vivo* studies**

Despite substantial human studies concerning lung cancer and welding, *in vivo* studies are comparatively lacking. Those studies which have been published have focused primarily on MMA and GMAW studies using mouse or rats. Table 1 summarizes *in vivo* studies directly investigating a tumorigenic effect of welding fumes. Some of the earliest *in vivo* studies were published in the 1980s with little to no further investigations for nearly a decade.

Ruezel et al. 1985 studied the effects of exposure to MMA-SS and GMAW-SS fumes in male Syrian golden hamsters [86]. Hamsters were exposed to 0.5 or 2.0 mg of GMAW-SS or

MMA-SS fume via intratracheal instillation once per week for 50 weeks. However, due to the high morbidity and mortality in the 2.0 mg MMA-SS group, dosing in this group was reduced to once every 4 weeks after week 26. Histopathological analysis showed just two malignant tumors in the lungs of MMA-SS-exposed hamsters and none in the GMAW-SS-exposed animals. The authors concluded that MMA-SS may induce malignant lung tumors.

Berg et al. 1987 investigated the carcinogenic property of MMA-SS by implanting pellets into the bronchi of 100 male and female Sprague-Dawley rats [87]. Pellets were prepared by rolling 5 x 10 mm rectangle sheets of fine stainless steel wire which were then dipped into cholesterol containing the welding fume or a control substance. An incision was made at the level of the clavicle between the cartilaginous rings of the trachea and the pellet was implanted into the left bronchus. Rats were euthanized by exsanguination 34 months post-implantation of the pellet and the pellet was removed. Serial sections were cut from the lung near where the pellet had been located. The pellet remained in position in the majority of rats and produced local fibrosis which was not different between control and MMA-SS exposed mice. At no point in the study did any rats show signs of respiratory disease. While many rats developed non-respiratory tumors such as mammary and skin tumors, few lung tumors were observed. A subpleural squamous cell carcinoma was observed in the right lung lobe of one rat exposed to the welding fume pellet, opposite the site of pellet implantation. The appearance was more similar to a peripheral metastasis to the lung rather than a primary lung tumor. The authors concluded that this Cr-containing welding fume did not increase the risk of lung cancer in Sprague Dawley rats.

As the epidemiological support for an association between welding and lung cancer continued to grow, further *in vivo* studies were performed. In the late 1990s, Antonini et al. began to investigate the pneumotoxic and inflammatory properties of different types of welding

fumes *in vivo*. When the pneumotoxic properties of GMAW-SS and GMAW-MS were investigated via intratracheal instillation into male CD/VA rats, it was observed that GMAW-SS induced greater lung injury and inflammation than GMAW-MS fume [88]. In a subsequent study, MMA-SS was compared to GMA-MS after intratracheal instillation into male CD/VAF rats and bronchoalveolar lavage was performed at 1, 14, and 35 days post-exposure. Both fumes caused lung damage at the earlier time point, but this lung damage had resolved by 14 days post-instillation in the GMAW-MS exposed rats. However, significant lung damage was still observed at 14 days post-instillation in the MMA-SS exposed rats which subsided at 35 days post-exposure. MMA-SS also caused a significantly greater release of TNF- α and IL-1 β in the lavage fluid [89]. Similarly, it was observed that GMA-SS, GMA-MS, and MMA-SS caused increased cytotoxicity in Sprague-Dawley rats after intratracheal instillation. However, MMA-SS treatment caused maximal cytotoxicity and greater cellularity of lavage compared to GMA-SS or GMA-MS fumes [90].

Solano-Lopez et al. investigated inflammatory and hyperplastic changes in the lungs of A/J mice following MMA-SS exposure via oropharyngeal aspiration [91]. They performed bronchoalveolar lavage at 1 day, 1 week, and 16 weeks post-exposure to assess lung injury and inflammation and 1, 8, 16, 24, and 48 weeks post-exposure to analyze histopathology. Lung injury and inflammation was increased at 1 day and 1 week post-exposure to MMA-SS but resolved by 16 weeks. Bronchiolar epithelial cellular atypia and alveolar bronchioloalveolar hyperplasia as well as a lymphogranulomatous response characterized by lymphocytes and epithelioid macrophages was observed 1 week post-exposure to MMA-SS. The normal architecture of the pulmonary tissue was effaced with accumulation of brown pigment presumed to be SMA-SS. By 8 weeks post-exposure, the pulmonary architecture was restored but the

inflammation, bronchiolar cellular atypia, and proliferation persisted. These results emphasized the need for ongoing animal studies exploring the tumorigenic potential of welding fumes.

Some studies have investigated potential mechanisms of welding fume toxicity and tumorigenic potential. Shoeb et al. investigated epigenetic changes following GMAW-MS and MMA-SS fume exposure [92]. Male Sprague-Dawley rats were exposed by intratracheal instillation to GMAW-MS or MMA-SS and bronchoalveolar lavage (BAL) was performed at 4 hours, 14 hours, 1 day, 3 days, 10 days, and 30 days post-exposure. Peripheral blood mononuclear cells were isolated from whole blood and dihydroethidium fluorescence and 4-hydroxynoneal protein adduct formation were assessed. DNA alterations including methylation and telomere changes were also investigated. It was observed that MMA-SS induced a greater, more persistent inflammatory response compared to GMA-MS or control. Markers of oxidative stress were only increased in mononuclear cells from MMA-SS-exposed rats. No significant differences were seen in DNA methylation between control and GMA-MS or MMA-SS at any time points. However, MMA-SS significantly increased telomere length 1 day and 30 days post-exposure compared to GMA-MS or control.

In 2006, Antonini et al. designed and constructed a robotic welding fume inhalation exposure system at the National Institute for Occupational Safety and Health which allowed for advancements in *in vivo* studies of welding fumes [10]. This robotic welder generates welding fumes behind closed glass doors and the fume is picked up by a flexible tube and carried to a separate room where animals can be exposed by whole-body inhalation exposure. In this exposure room, conditions such as temperature, humidity, and gas production can be closely monitored and controlled. The construction of this robotic welder allowed for future *in vivo* inhalation studies which would more closely mirror worker exposures.

One of the earlier welding fume inhalation studies investigated the pneumotoxic and inflammatory properties of GMAW-SS fume in male Sprague-Dawley rats [93]. Rats were exposed to 15 or 40 mg/m³ of GMAW-SS x 3 hours/day for 1, 3, or 10 days. Parameters of lung injury and inflammation were assessed at 1, 4, 6, 11, 14, and 30 days post-exposure. At all of the earlier time points, parameters of lung injury were significantly elevated but neutrophils were not increased until 6 days post-exposure. It was concluded that short-term inhalation of GMAW-SS causes significant lung damage and delayed pulmonary inflammation, but chronic inhalation studies were needed to further investigate the effect of welding fumes.

In 2008, Zeidler-Erdely et al. exposed male A/J and C57BL/6J mice to GMA-MS, GMA-SS, and MMA-SS via oropharyngeal aspiration in four separate bolus doses [94]. BAL was performed at 2, 7, and 28 days post-exposure and gross lung tumor counts and histopathological analysis were assessed at 48 and 78 weeks post-exposure. Results showed that GMAW-SS caused an acutely greater and more prolonged inflammatory response in the lungs of A/J mice. GMAW-SS also persisted in the lungs the longest and caused a trend towards increased tumor incidence. In a similar study, male A/J and C57BL/6J mice were exposed to MMA-SS fume by oropharyngeal aspiration once per month for four months [94]. At 78 weeks post-exposure, gross tumor counts and histopathology were assessed. MMA-SS-exposed A/J mice had significantly increased average tumor numbers per lung compared to air control, but this was only an average of about 1 more tumor per lung than control. There was no difference in tumor numbers among C57BL/6J mice exposed to air or MMA-SS. The authors concluded that MMA-SS fume on its own does not produce a significant tumorigenic response in an animal model. This study was accompanied by a short-term inhalation study of GMAW-SS fume in A/J and C57BL/6J mice [95]. Mice were exposed to GMAW-SS at 40 mg/m³ for 3 hours/day for 6 and 10 days.

Pneumotoxicity and inflammation was observed in BAL at 1, 4, 7, 10, 14, and 28 days post the 10 day exposure. Lung tumor counts and histopathology were analyzed in A/J mice at 78 weeks post the 6 and 10 day exposures. While GMAW-SS induced a significant inflammatory response that was not recovered by 28 days in both mouse strains, no significant lung tumor development occurred in A/J mice.

Given these findings and the strong epidemiological support for lung cancer in welders, more chronic *in vivo* exposure studies were needed. The first such study was conducted in 2013 by Zeidler-Erdely et al. in which the authors employed a two-stage initiation-promotion model to study potential lung tumor production in A/J mice following GMAW-SS exposure [96]. An initiation-promotion model was investigated as a potential mechanism of welding fume lung tumorigenesis given that the former studies showed that welding fumes were not significantly initiating lung tumor formation, despite the strong epidemiologic evidence of lung cancer in welders. In this study, male A/J mice were treated with the chemical initiator 3-methylcholanthrene (MCA) or a corn oil vehicle control and one week later were exposed to low or high doses of GMAW-SS via oropharyngeal aspiration once per week for 5 weeks. After 30 weeks post-initiation, lung tumors were enumerated. It was observed that MCA initiation followed by GMAW-SS promotion significantly increased lung tumor number compared to MCA/air controls (12.1 ± 1.5 tumors/mouse for low dose GMAW-SS and 14.0 ± 1.8 tumors/mouse for high dose GMAW-SS vs. 4.77 ± 0.7 tumors/mouse in MCA/air). This study provided support for the theory that welding fumes can act as lung tumor promoters *in vivo*. This study was followed by a chronic *in vivo* inhalation study [97]. Male A/J mice received intraperitoneal injections of corn oil or MCA and beginning one week later were exposed to air or GMAW-SS fume at a concentration of 40 mg/m^3 for 8 hours/day, 4 days/week, for 9 weeks.

After 30 weeks post-initiation, average tumors per mouse lung and histopathology were analyzed. Mice initiated with MCA and then promoted with GMAW-SS had significantly greater average lung tumor numbers compared to MCA/air controls (16.11 ± 1.18 vs. 7.93 ± 0.82). Taken together, the results of these studies provide strong support that welding fumes can act as lung tumor promoters *in vivo*.

***In vitro* studies**

Numerous *in vitro* studies have been performed investigating the toxicity of the individual metals that can be found in welding fumes. However, *in vitro* studies investigating the potential toxic and tumorigenic properties of the welding fumes themselves are scarcer.

Hedenstedt et al. 1977 investigated the mutagenicity of MMA-SS, MMA-MS, GMAW-MS, and GMAW-SS fumes in *Escherichia coli* [98]. They observed that MS fume did not cause mutagenicity while SS fume did cause a mutagenic effect, which they attributed to the Cr^{6+} in the SS. They also found that MMA was more mutagenic than GMAW. MMA is known to be more soluble than GMAW, and the authors concluded this solubility contributed to its mutagenicity. Maxild et al. agree with these results, demonstrating that SS and MMA were more mutagenic than MS and GMAW, respectively, using the Salmonella/microsome mutagenicity test [99]. In 1983, White et al. exposed bovine alveolar macrophages to MMA-SS and MS fumes *in vitro* for 17 to 20 hours [100]. The results indicated that both welding fumes were more cytotoxic than control, but SS had even greater cytotoxicity than MS. It was also observed that MS and SS fumes did not reduce alveolar macrophage number, suggesting they damage cell membranes without destroying the cells up to 20 hours. Additionally, MS fume had reduced toxicity when added with DPPC, the main component of surfactant, which may make it less cytotoxic *in vivo*.

More than a decade later, Antonini et al. investigated the effect of MMA-SS on free radical production and DNA damage *in vitro* [101]. Electron spin resonance demonstrated that

MMA-SS fume had the ability to produce reactive hydroxyl radical, likely as a result of reduction of Cr(VI) in the fume to Cr(V). Using a DNA strand break assay, they observed that MMA-SS fume caused a concentration-dependent increase in DNA damage. These responses may help to explain a potential carcinogenic process of welding fumes. A similar study by Leonard et al. investigated free radical and reactive oxygen species generation after exposing mouse peritoneal monocytes to GMA-SS and GMAW-MS fumes *in vitro* [102]. It was observed that the welding fumes generated free radicals from reactions with H₂O₂ and caused lipid peroxidation and DNA damage. While both MS and SS produced free radicals, GMAW-SS consistently generated more reactivity and free radicals. Similar to Antonini et al., this heightened toxicity was thought to be due to the presence of Cr and/or Ni in the SS but not MS fume. It was therefore hypothesized that perhaps a newer Cu-Ni welding fume would be a safer alternative to GMAW-SS or MMA-SS which contain Cr. Badding et al. exposed RAW 264.7 mouse macrophages to welding fumes and observed that GMA-MS and GMA-SS had greater ROS production than the Cu-Ni welding fume [103]. However, the Cu-Ni welding fume proved to be more cytotoxic as it induced cell death and mitochondrial dysfunction at a lower dose and impaired macrophage ability to phagocytose bacteria. Similarly, Antonini et al. observed that the Cu-Ni welding fume, unlike GMAW-MS and GMAW-SS, did not significantly increase free radical production *in vitro* yet did reduce lung macrophage viability even more than GMAW-MS or GMAW-SS.[104] This suggested the Cu-Ni fume may have a direct cytotoxic effect on the lung rather than cause toxicity by ROS production [104]. These findings support the notion that it is not just the presence of Cr in the fumes that may be dangerous to worker health. Nevertheless, future *in vitro* studies could help to better explore which welding fumes and their component metals are most toxic.

Conclusions

Significant evidence that welding fumes are carcinogenic led to their re-classification as a group 1 carcinogen by IARC in 2017. While epidemiological and worker studies have shown mixed results, this points to the difficulties of epidemiological studies given the potential for confounders like smoking and asbestos, the possibility of mixed welding fume exposures, personal safety habits, genetics, and other risk factors. *In vitro* and *in vivo* studies have demonstrated that many types of welding fumes have toxic and tumorigenic potential. Most notably, studies have demonstrated that some welding fumes have the ability to promote lung tumorigenesis *in vivo*. Nevertheless, little is known concerning the mechanisms by which welding fumes act as lung carcinogens. Continued research is needed to better elucidate potential mechanisms as well as continue to clarify which welding fumes and their metal constituents are most hazardous to worker health.

Bibliography

1. Antonini JM: **Health Effects Associated with Welding**. 2014:49-70.
2. Ferguson: *Careers in Focus Construction*. New York: Ferguson; 2010.
3. Guha N, Loomis D, Guyton KZ, Grosse Y, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, Vilahur N, Muller K, Straif K: **Carcinogenicity of welding, molybdenum trioxide, and indium tin oxide**. *Lancet Oncol* 2017, **18**:581-582.
4. *The Procedure Handbook of Arc Welding*. 14 edn. The James F. Lincoln Arc Welding Foundation; 2000.
5. Ferguson: *Careers in Focus Technicians*. New York: Infobase Publishing; 2010.
6. Antonini JM: **Health effects of welding**. *Crit Rev Toxicol* 2003, **33**:61-103.

7. Kalliomaki PL, Kalliomaki K, Korhonen O, Nordman H, Rahkonen E, Vaaranen V: **Respiratory status of stainless steel and mild steel welders.** *Scand J Work Environ Health* 1982, **8 Suppl 1**:117-121.
8. Beckett WS: **Welding.** In *Occupational and Environmental Respiratory Disease*. Edited by Harber, P., Schenker MB, Balmes JR. St. Louis, MO: Mosby-Year Book, Inc.; 1996: 704-717
9. Zimmer AT: **The influence of metallurgy on the formation of welding aerosols.** *J Environ Monit* 2002, **4**:628-632.
10. Antonini JM, Afshari AA, Stone S, Chen B, Schwegler-Berry D, Fletcher WG, Goldsmith WT, Vandestouwe KH, McKinney W, Castranova V, Frazer DG: **Design, construction, and characterization of a novel robotic welding fume generator and inhalation exposure system for laboratory animals.** *J Occup Environ Hyg* 2006, **3**:194-203; quiz D145.
11. Jenkins NT, Pierce WMG, Eagar T: *Particle size distribution of gas metal and flux cored arc welding fumes.* 2005.
12. Sowards J, Ramirez A, Dickinson DW, Lippold JC: *Characterization of Welding Fume from SMAW Electrodes - Part II.* 2010.
13. McClellan RO: **Particle Interactions with the Respiratory Tract.** In *Particle-Lung Interactions*. Edited by Lenfant C. New York: Marcel Dekker, Inc.; 2000: 3-56
14. Antonini JM, Santamaria AB, Jenkins NT, Albini E, Lucchini R: **Fate of manganese associated with the inhalation of welding fumes: potential neurological effects.** *Neurotoxicology* 2006, **27**:304-310.

15. G. O: **Kinestics of Inhaled Ultrafine Particles in the Organism.** In *Effects of Air Contaminants on the Respiratory Tract - Interpretations from Molecules to Meta Analysis*. Hannover, Germany; 2004: 53-68
16. Antonini JM, Lawryk NJ, Murthy GG, Brain JD: **Effect of welding fume solubility on lung macrophage viability and function in vitro.** *J Toxicol Environ Health A* 1999, **58**:343-363.
17. Kalliomaki PL, Kalliomaki K, Rahkonen E, Aittoniemi K: **Follow-up study on the lung retention of welding fumes among shipyard welders.** *Ann Occup Hyg* 1983, **27**:449-452.
18. Wild P, Bourgkard E, Paris C: **Lung cancer and exposure to metals: the epidemiological evidence.** *Methods Mol Biol* 2009, **472**:139-167.
19. Cohen MD, Kargacin B, Klein CB, Costa M: **Mechanisms of chromium carcinogenicity and toxicity.** *Crit Rev Toxicol* 1993, **23**:255-281.
20. **Chromium, nickel and welding.** *IARC Monogr Eval Carcinog Risks Hum* 1990, **49**:1-648.
21. **Occupational exposure to hexavalent chromium. Final rule.** *Fed Regist* 2006, **71**:10099-10385.
22. Harris MK, Ewing WM, Longo W, DePasquale C, Mount MD, Hatfield R, Stapleton R: **Manganese exposures during shielded metal arc welding (SMAW) in an enclosed space.** *J Occup Environ Hyg* 2005, **2**:375-382.
23. Laohaudomchok W, Lin X, Herrick RF, Fang SC, Cavallari JM, Shrairman R, Landau A, Christiani DC, Weisskopf MG: **Neuropsychological effects of low-level manganese exposure in welders.** *Neurotoxicology* 2011, **32**:171-179.

24. Mergler D, Baldwin M: **Early manifestations of manganese neurotoxicity in humans: an update.** *Environ Res* 1997, **73**:92-100.
25. Roels HA, Bowler RM, Kim Y, Claus Henn B, Mergler D, Hoet P, Gocheva VV, Bellinger DC, Wright RO, Harris MG, et al: **Manganese exposure and cognitive deficits: a growing concern for manganese neurotoxicity.** *Neurotoxicology* 2012, **33**:872-880.
26. Shukakidze A, Lazriev I, Mitagvariya N: **Behavioral impairments in acute and chronic manganese poisoning in white rats.** *Neurosci Behav Physiol* 2003, **33**:263-267.
27. Wennberg A, Iregren A, Struwe G, Cizinsky G, Hagman M, Johansson L: **Manganese exposure in steel smelters a health hazard to the nervous system.** *Scand J Work Environ Health* 1991, **17**:255-262.
28. *Ventilation Guide for Weld Fume.* Miami, FL: American Welding Society; 2001.
29. **Confined Spaces.** In *Safety and Health Fact Sheets.* Miami, FL: American Welding Society; 1998
30. Chen HL, Chung SH, Jhuo ML: **Efficiency of different respiratory protective devices for removal of particulate and gaseous reactive oxygen species from welding fumes.** *Arch Environ Occup Health* 2013, **68**:101-106.
31. Blanc PD, Boushey HA, Wong H, Wintermeyer SF, Bernstein MS: **Cytokines in metal fume fever.** *Am Rev Respir Dis* 1993, **147**:134-138.
32. Sferlazza SJ, Beckett WS: **The respiratory health of welders.** *Am Rev Respir Dis* 1991, **143**:1134-1148.
33. Al-Otaibi ST: **Respiratory health of a population of welders.** *J Family Community Med* 2014, **21**:162-165.

34. **Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society.** *Am J Respir Crit Care Med* 1995, **152**:S77-121.
35. Holm M, Kim JL, Lillienberg L, Storaas T, Jogi R, Svanes C, Schlunssen V, Forsberg B, Gislason T, Janson C, Toren K: **Incidence and prevalence of chronic bronchitis: impact of smoking and welding. The RHINE study.** *Int J Tuberc Lung Dis* 2012, **16**:553-557.
36. Cotes JE, Feinmann EL, Male VJ, Rennie FS, Wickham CA: **Respiratory symptoms and impairment in shipyard welders and caulker/burners.** *Br J Ind Med* 1989, **46**:292-301.
37. Flors L, Domingo ML, Leiva-Salinas C, Mazon M, Rosello-Sastre E, Vilar J: **Uncommon occupational lung diseases: high-resolution CT findings.** *AJR Am J Roentgenol* 2010, **194**:W20-26.
38. Buerke U, Schneider J, Rosler J, Woitowitz HJ: **Interstitial pulmonary fibrosis after severe exposure to welding fumes.** *Am J Ind Med* 2002, **41**:259-268.
39. McCormick LM, Goddard M, Mahadeva R: **Pulmonary fibrosis secondary to siderosis causing symptomatic respiratory disease: a case report.** *J Med Case Rep* 2008, **2**:257.
40. Morgan WK: **On welding, wheezing, and whimsy.** *Am Ind Hyg Assoc J* 1989, **50**:59-69.
41. Hannu T, Piipari R, Kasurinen H, Keskinen H, Tuppurainen M, Tuomi T: **Occupational asthma due to manual metal-arc welding of special stainless steels.** *Eur Respir J* 2005, **26**:736-739.
42. Lee HS, Chia SE, Yap JC, Wang YT, Lee CS: **Occupational asthma due to spot-welding.** *Singapore Med J* 1990, **31**:506-508.

43. Coggon D, Inskip H, Winter P, Pannett B: **Lobar pneumonia: an occupational disease in welders.** *Lancet* 1994, **344**:41-43.
44. Beaumont JJ, Weiss NS: **Mortality of welders, shipfitters, and other metal trades workers in boilermakers Local No. 104, AFL-CIO.** *Am J Epidemiol* 1980, **112**:775-786.
45. Palmer KT, Poole J, Ayres JG, Mann J, Burge PS, Coggon D: **Exposure to metal fume and infectious pneumonia.** *Am J Epidemiol* 2003, **157**:227-233.
46. Zeidler-Erdely PC, Erdely A, Antonini JM: **Immunotoxicology of arc welding fume: worker and experimental animal studies.** *J Immunotoxicol* 2012, **9**:411-425.
47. Miller JM, Hair JG, Hebert M, Hebert L, Roberts FJ, Jr., Weyant RS: **Fulminating bacteremia and pneumonia due to *Bacillus cereus*.** *J Clin Microbiol* 1997, **35**:504-507.
48. Vilaume JE WK, Liss-Suter D, Hsiao S.: *Effects of Welding on Health.* Miami, FL: American Welding Society; 1979.
49. Becker N, Claude J, Frentzel-Beyme R: **Cancer risk of arc welders exposed to fumes containing chromium and nickel.** *Scand J Work Environ Health* 1985, **11**:75-82.
50. Lerchen ML, Wiggins CL, Samet JM: **Lung cancer and occupation in New Mexico.** *J Natl Cancer Inst* 1987, **79**:639-645.
51. Oleru G, Ademiluyi SA: **Some acute and long-term effects of exposure in welding and thermal-cutting operations in Nigeria.** *Int Arch Occup Environ Health* 1987, **59**:605-612.
52. Sjogren B, Gustavsson A, Hedstrom L: **Mortality in two cohorts of welders exposed to high- and low-levels of hexavalent chromium.** *Scand J Work Environ Health* 1987, **13**:247-251.

53. Ronco G, Ciccone G, Mirabelli D, Troia B, Vineis P: **Occupation and lung cancer in two industrialized areas of northern Italy.** *Int J Cancer* 1988, **41**:354-358.
54. Melkild A, Langard S, Andersen A, Tonnessen JN: **Incidence of cancer among welders and other workers in a Norwegian shipyard.** *Scand J Work Environ Health* 1989, **15**:387-394.
55. Becker N, Chang-Claude J, Frentzel-Beyme R: **Risk of cancer for arc welders in the Federal Republic of Germany: results of a second follow up (1983-8).** *Br J Ind Med* 1991, **48**:675-683.
56. Simonato L, Fletcher AC, Andersen A, Anderson K, Becker N, Chang-Claude J, Ferro G, Gerin M, Gray CN, Hansen KS, et al.: **A historical prospective study of European stainless steel, mild steel, and shipyard welders.** *Br J Ind Med* 1991, **48**:145-154.
57. Keller JE, Howe HL: **Cancer in Illinois construction workers: a study.** *Am J Ind Med* 1993, **24**:223-230.
58. Moulin JJ, Wild P, Haguenoer JM, Faucon D, De Gaudemaris R, Mur JM, Mereau M, Gary Y, Toamain JP, Birembaut Y, et al.: **A mortality study among mild steel and stainless steel welders.** *Br J Ind Med* 1993, **50**:234-243.
59. Moulin JJ: **Assessment of risk of lung cancer among mild steel and stainless steel welders.** *Occup Environ Med* 1995, **52**:284-285.
60. Hansen KS, Lauritsen JM, Skytthe A: **Cancer incidence among mild steel and stainless steel welders and other metal workers.** *Am J Ind Med* 1996, **30**:373-382.
61. Lauritsen JM, Hansen KS: **Lung cancer mortality in stainless steel and mild steel welders: a nested case-referent study.** *Am J Ind Med* 1996, **30**:383-391.

62. Steenland K: **Ten-year update on mortality among mild-steel welders.** *Scand J Work Environ Health* 2002, **28**:163-167.
63. Richiardi L, Boffetta P, Simonato L, Forastiere F, Zambon P, Fortes C, Gaborieau V, Merletti F: **Occupational Risk Factors for Lung Cancer in Men and Women: A Population-Based Case–Control Study in Italy.** *Cancer Causes & Control* 2004, **15**:285-294.
64. Ambroise D, Wild P, Moulin JJ: **Update of a meta-analysis on lung cancer and welding.** *Scand J Work Environ Health* 2006, **32**:22-31.
65. Paris C, Clement-Duchene C, Vignaud JM, Gislard A, Stoufflet A, Bertrand O, Thiberville L, Grosdidier G, Martinet Y, Benichou J, Hainaut P: **Relationships between lung adenocarcinoma and gender, age, smoking and occupational risk factors: A case-case study.** *Lung Cancer* 2010, **68**:146-153.
66. Guida F, Papadopoulos A, Menvielle G, Matrat M, Fevotte J, Cenee S, Cyr D, Schmaus A, Carton M, Paget-Bailly S, et al: **Risk of lung cancer and occupational history: results of a French population-based case-control study, the ICARE study.** *J Occup Environ Med* 2011, **53**:1068-1077.
67. Tse LA, Yu IT, Qiu H, Au JS, Wang XR: **Occupational risks and lung cancer burden for Chinese men: a population-based case-referent study.** *Cancer Causes Control* 2012, **23**:121-131.
68. Barkhordari A, Zare Sakhvidi MJ, Zare Sakhvidi F, Halvani G, Firoozichahak A, Shirali G: **Cancer Risk Assessment in Welder's Under Different Exposure Scenarios.** *Iran J Public Health* 2014, **43**:666-673.

69. Matrat M, Guida F, Mattei F, Cenee S, Cyr D, Fevotte J, Sanchez M, Menvielle G, Radoi L, Schmaus A, et al: **Welding, a risk factor of lung cancer: the ICARE study.** *Occup Environ Med* 2016, **73**:254-261.
70. Kendzia B, Behrens T, Jockel KH, Siemiatycki J, Kromhout H, Vermeulen R, Peters S, Van Gelder R, Olsson A, Bruske I, et al: **Welding and lung cancer in a pooled analysis of case-control studies.** *Am J Epidemiol* 2013, **178**:1513-1525.
71. Wong JYY, Bassig BA, Seow WJ, Hu W, Ji BT, Blair A, Silverman DT, Lan Q: **Lung cancer risk in welders and foundry workers with a history of heavy smoking in the USA: The National Lung Screening Trial.** *Occup Environ Med* 2017, **74**:440-448.
72. Sjogren B, Hansen KS, Kjuus H, Persson PG: **Exposure to stainless steel welding fumes and lung cancer: a meta-analysis.** *Occup Environ Med* 1994, **51**:335-336.
73. Vallieres E, Pintos J, Lavoue J, Parent ME, Rachet B, Siemiatycki J: **Exposure to welding fumes increases lung cancer risk among light smokers but not among heavy smokers: evidence from two case-control studies in Montreal.** *Cancer Med* 2012, **1**:47-58.
74. Polednak AP: **Mortality among welders, including a group exposed to nickel oxides.** *Arch Environ Health* 1981, **36**:235-242.
75. Hull CJ, Doyle E, Peters JM, Garabrant DH, Bernstein L, Preston-Martin S: **Case-control study of lung cancer in Los Angeles county welders.** *Am J Ind Med* 1989, **16**:103-112.
76. Danielsen TE, Langard S, Andersen A, Knudsen O: **Incidence of cancer among welders of mild steel and other shipyard workers.** *Br J Ind Med* 1993, **50**:1097-1103.

77. Danielsen TE, Langard S, Andersen A: **Incidence of lung cancer among shipyard welders investigated for siderosis.** *Int J Occup Environ Health* 1998, **4**:85-88.
78. Rolland P, Gramond C, Lacourt A, Astoul P, Chamming's S, Ducamp S, Frenay C, Galateau-Salle F, Ilg AG, Imbernon E, et al: **Occupations and industries in France at high risk for pleural mesothelioma: A population-based case-control study (1998-2002).** *Am J Ind Med* 2010, **53**:1207-1219.
79. t Mannetje A, Brennan P, Zaridze D, Szeszenia-Dabrowska N, Rudnai P, Lissowska J, Fabianova E, Cassidy A, Mates D, Bencko V, et al: **Welding and lung cancer in Central and Eastern Europe and the United Kingdom.** *Am J Epidemiol* 2012, **175**:706-714.
80. Jockel KH, Ahrens W, Bolm-Audorff U: **Lung cancer risk and welding--preliminary results from an ongoing case-control study.** *Am J Ind Med* 1994, **25**:805-812.
81. Becker N: **Cancer mortality among arc welders exposed to fumes containing chromium and nickel. Results of a third follow-up: 1989-1995.** *J Occup Environ Med* 1999, **41**:294-303.
82. Danielsen TE, Langard S, Andersen A: **Incidence of cancer among welders and other shipyard workers with information on previous work history.** *J Occup Environ Med* 2000, **42**:101-109.
83. Tola S, Kalliomaki PL, Pukkala E, Asp S, Korkala ML: **Incidence of cancer among welders, platers, machinists, and pipe fitters in shipyards and machine shops.** *Br J Ind Med* 1988, **45**:209-218.
84. Steenland K, Beaumont J, Elliot L: **Lung cancer in mild steel welders.** *Am J Epidemiol* 1991, **133**:220-229.

85. Siew SS, Kauppinen T, Kyyronen P, Heikkilä P, Pukkala E: **Exposure to iron and welding fumes and the risk of lung cancer.** *Scand J Work Environ Health* 2008, **34**:444-450.
86. Reuzel PGJ BR, DeRaad WK, Lohman PHM. : **Carcinogenicity and in vitro genotoxicity of the particulate fraction of two stainless steel welding fumes.** In *Proceedings of the International Conference on Health Hazards and Biological Effects of Welding Fumes and Gases*. Edited by Stern RM BA, Fletcher AC, Jarvisalo J. New York: Excerpta Medica; 1985: 329-332
87. Berg NO, Berlin M, Bohgard M, Rudell B, Schutz A, Warvinge K: **Bronchocarcinogenic properties of welding and thermal spraying fumes containing chromium in the rat.** *Am J Ind Med* 1987, **11**:39-54.
88. Antonini JM, Krishna Murthy GG, Rogers RA, Albert R, Ulrich GD, Brain JD: **Pneumotoxicity and pulmonary clearance of different welding fumes after intratracheal instillation in the rat.** *Toxicol Appl Pharmacol* 1996, **140**:188-199.
89. Antonini JM, Krishna Murthy GG, Brain JD: **Responses to welding fumes: lung injury, inflammation, and the release of tumor necrosis factor-alpha and interleukin-1 beta.** *Exp Lung Res* 1997, **23**:205-227.
90. Taylor MD, Roberts JR, Leonard SS, Shi X, Antonini JM: **Effects of welding fumes of differing composition and solubility on free radical production and acute lung injury and inflammation in rats.** *Toxicol Sci* 2003, **75**:181-191.
91. Solano-Lopez C, Zeidler-Erdely PC, Hubbs AF, Reynolds SH, Roberts JR, Taylor MD, Young SH, Castranova V, Antonini JM: **Welding fume exposure and associated**

- inflammatory and hyperplastic changes in the lungs of tumor susceptible a/j mice.** *Toxicol Pathol* 2006, **34**:364-372.
92. Shoeb M, Kodali VK, Farris BY, Bishop LM, Meighan TG, Salmen R, Eye T, Friend S, Schwegler-Berry D, Roberts JR, et al: **Oxidative stress, DNA methylation, and telomere length changes in peripheral blood mononuclear cells after pulmonary exposure to metal-rich welding nanoparticles.** *NanoImpact* 2017, **5**:61-69.
 93. Antonini JM, Stone S, Roberts JR, Chen B, Schwegler-Berry D, Afshari AA, Frazer DG: **Effect of short-term stainless steel welding fume inhalation exposure on lung inflammation, injury, and defense responses in rats.** *Toxicol Appl Pharmacol* 2007, **223**:234-245.
 94. Zeidler-Erdely PC, Battelli LA, Salmen-Muniz R, Li Z, Erdely A, Kashon ML, Simeonova PP, Antonini JM: **Lung tumor production and tissue metal distribution after exposure to manual metal ARC-stainless steel welding fume in A/J and C57BL/6J mice.** *J Toxicol Environ Health A* 2011, **74**:728-736.
 95. Zeidler-Erdely PC, Battelli LA, Stone S, Chen BT, Frazer DG, Young SH, Erdely A, Kashon ML, Andrews R, Antonini JM: **Short-term inhalation of stainless steel welding fume causes sustained lung toxicity but no tumorigenesis in lung tumor susceptible A/J mice.** *Inhal Toxicol* 2011, **23**:112-120.
 96. Zeidler-Erdely PC, Meighan TG, Erdely A, Battelli LA, Kashon ML, Keane M, Antonini JM: **Lung tumor promotion by chromium-containing welding particulate matter in a mouse model.** *Part Fibre Toxicol* 2013, **10**:45.
 97. Falcone LM, Erdely A, Meighan TG, Battelli LA, Salmen R, McKinney W, Stone S, Cumpston A, Cumpston J, Andrews RN, et al: **Inhalation of gas metal arc-stainless**

- steel welding fume promotes lung tumorigenesis in A/J mice.** *Arch Toxicol* 2017, **91**:2953-2962.
98. Hedenstedt A, Jenssen D, Lidesteen BM, Ramel C, Rannug U, Stern RM: **Mutagenicity of fume particles from stainless steel welding.** *Scand J Work Environ Health* 1977, **3**:203-211.
 99. Maxild J, Andersen M, Kiel P: **Mutagenicity of fume particles from metal arc welding on stainless steel in the Salmonella/microsome test.** *Mutat Res* 1978, **56**:235-243.
 100. White LR, Marthinsen AB, Jakobsen K, Eik-Nes KB: **Response of bovine alveolar macrophages in vitro to welding fume particles.** *Environ Health Perspect* 1983, **51**:211-215.
 101. Antonini JM, Leonard SS, Roberts JR, Solano-Lopez C, Young SH, Shi X, Taylor MD: **Effect of stainless steel manual metal arc welding fume on free radical production, DNA damage, and apoptosis induction.** *Mol Cell Biochem* 2005, **279**:17-23.
 102. Leonard SS, Chen BT, Stone SG, Schwegler-Berry D, Kenyon AJ, Frazer D, Antonini JM: **Comparison of stainless and mild steel welding fumes in generation of reactive oxygen species.** *Part Fibre Toxicol* 2010, **7**:32.
 103. Badding MA, Fix NR, Antonini JM, Leonard SS: **A comparison of cytotoxicity and oxidative stress from welding fumes generated with a new nickel-, copper-based consumable versus mild and stainless steel-based welding in RAW 264.7 mouse macrophages.** *PLoS One* 2014, **9**:e101310.
 104. Antonini JM, Badding MA, Meighan TG, Keane M, Leonard SS, Roberts JR: **Evaluation of the Pulmonary Toxicity of a Fume Generated from a Nickel-, Copper-Based**

Electrode to be Used as a Substitute in Stainless Steel Welding. *Environ Health Insights* 2014, **8**:11-20.

Tables

Welding Fume Sample	Metal (weight %)	Soluble/Insoluble Ratio
GMA-MS	Fe (85%) Mn (14%)	0.020
GMA-SS	Fe (57%) Mn (13.8%) Cr (20.2%) Ni (8.8%) Cu (0.2%)	0.006

Table 1. Metal composition of SS and MS welding fumes based on metal analysis previously presented in Antonini et al. 2006.

Welding Fume	Exposure Route	Animal Model	Carcinogenic Effect	Article
MMA-SS	Intratracheal instillation	Syrian golden hamster	Yes	Ruezel et al. 1985
	Intrabronchial pellet implantation	Sprague-Dawley rat	No	Berg et al. 1987
	Oropharyngeal Aspiration	A/J mouse C57BL/6J mouse	Yes No	Zeidler-Erdely et al. 2011
GMAW-SS	Intratracheal instillation	Syrian golden hamster	No	Ruezel et al. 1985
	Oropharyngeal Aspiration	A/J mouse C57BL/6J mouse	No No	Zeidler-Erdely et al. 2008
	Oropharyngeal Aspiration	A/J mouse	Yes	Zeidler-Erdely et al. 2011
	Inhalation	A/J mouse C57BL/6J mouse	No No	Zeidler-Erdely et al. 2011
	Inhalation	A/J mouse	Yes	Zeidler-Erdely et al. 2013
	Inhalation	A/J mouse	Yes	Falcone et al. 2017

Table 2. Published *in vivo* studies investigating carcinogenic effects of welding fumes.

MMA-SS: Manual manual arc welding – stainless steel

GMAW – SS: Gas metal arc welding – stainless steel

Chapter 3: Gas Metal Arc – Stainless Steel Welding Fume Promotes Lung Tumorigenesis in A/J Mice

Lauryn M Falcone^{1,2}, Aaron Erdely², Terence G Meighan², Lori A Battelli², Rebecca Salmen², Walter McKinney², Samuel Stone², Amy Cumpston², Jared Cumpston², Ronnee N Andrews³, Michael Kashon², James M Antonini², Patti C Zeidler-Erdely²

¹West Virginia University, School of Medicine, Morgantown, WV; ²Health Effects Laboratory Division, National Institute for Occupational Safety and Health, Morgantown, WV; ³Division of Applied Research and Technology, National Institute for Occupational Safety and Health, Cincinnati, OH

Originally published in: Falcone LM, Erdely A, Meighan TG, et al. Inhalation of gas metal arc stainless steel welding fume promotes lung tumorigenesis in A/J mice. *Archives of Toxicology*. 2017;91(8):2953-2962.

Abstract

Epidemiologic studies suggest an increased risk of lung cancer with exposure to welding fumes, but controlled animal studies are needed to support this association. Oropharyngeal aspiration of collected “aged” gas metal arc-stainless steel (GMA-SS) welding fume has been shown by our laboratory to promote lung tumor formation *in vivo* using a two-stage initiation-promotion model. Our objective in this study was to determine if inhalation of freshly generated GMA-SS welding fume also acts as a lung tumor promoter in lung tumor susceptible mice. Male A/J mice received intraperitoneal (IP) injections of corn oil or the chemical initiator 3-methylcholanthrene (MCA; 10 μ g/g) and one week later were exposed by whole body inhalation to air or GMA-SS welding aerosols for 4 h/d x 4 d/w x 9 w at a target concentration of 40 mg/m³. Lung nodules were enumerated at 30 weeks post-initiation. GMA-SS fume significantly promoted lung tumor multiplicity in A/J mice initiated with MCA (16.11 ± 1.18) compared to MCA/air-exposed mice (7.93 ± 0.82). Histopathological analysis found that the increased number of lung nodules in the MCA/GMA-SS group were hyperplasias and adenomas, which was consistent with developing lung tumorigenesis. Metal deposition analysis in the lung revealed a lower deposited dose, approximately 5 fold compared to our previous aspiration study, still elicited a significant lung tumorigenic response. In conclusion, this study demonstrates that inhaling GMA-SS welding fume promotes lung tumorigenesis *in vivo* which is consistent with the epidemiologic studies that show welders may be at an increased risk for lung cancer.

Introduction

Welding, a process of joining metals, is a common industrial practice worldwide. It is estimated that there are nearly 400,000 full-time welding occupations in the United States alone as of 2014 [1]. Gas metal arc (GMA) welding is a type of electric arc welding where an electric arc is established between the work piece and a consumable wire electrode. High temperatures create a molten pool into which the electrode is continuously fed and the metals fuse together as they cool. This process utilizes an inert shielding gas to protect the weld from oxidative weakening and vaporizes metals, forming metal oxides which react with air to form welding fumes. The welding fumes are a complex mixture of gases and metal oxides that are derived primarily from the electrode. However, the shielding gas, electrode coating, base metal, and paint or other surface coatings may also contribute to the welding fume composition [2].

GMA-stainless steel (SS) welding fumes contain a metal-rich particulate matter that contains carcinogenic (hexavalent chromium [Cr VI] and nickel [Ni]) and non-carcinogenic (manganese [Mn] and iron [Fe]) metals. A number of well-documented, harmful effects have been associated with welding fume exposure. The most common acute health effect of welding fume inhalation is metal fume fever, characterized by flu-like symptoms, cough, and dyspnea, while the most common chronic health effect is bronchitis [2]. Along with complications such as infection or neurological effects, lung cancer from exposure to welding fumes is an area of concern, yet few controlled animal studies have investigated this association. Several epidemiological studies support the hypothesis that exposure to welding fume increases lung cancer risk [3-6]. The need for animal studies is critical, as worker exposure is not always well-documented. In addition, workers may be exposed to additional occupational agents or confounders (e.g. smoking) that complicate epidemiological studies [7]. The International Agency for Research on Cancer (IARC) advisory group on the Monograph priorities for 2008

listed welding fume as a high priority agent for further evaluation of lung cancer risk in humans. Welding fume is classified as a group 2B carcinogen (possibly carcinogenic to humans) and will be re-evaluated by an IARC working group in 2017 [8].

Previous research in our laboratory has shown that GMA-SS welding fume persists in the lung for 1.5 years and triggers mild, chronic inflammation, but does not initiate tumor formation in lung tumor-susceptible A/J mice [9]. In a two-stage initiation-promotion model of lung tumorigenesis, GMA-SS welding fume significantly increased lung tumor incidence and multiplicity at 30 weeks post-oropharyngeal aspiration [10]. This finding suggests stainless steel welding fume may act as a lung tumor promoter. Given these results, we aimed to determine if inhalation of GMA-SS welding fume also promotes lung tumor formation in A/J mice. Inhalation is the preferred route for welding fume-related toxicity studies in animals because it closely simulates the occupational exposure with respect to both particle size and surface properties of the fume and lung particle deposition. Furthermore, “fresh” GMA-SS welding fume as delivered via inhalation is more reactive than “aged” welding fume which is used for oropharyngeal aspiration studies [11].

Methods

Animals

Male A/J mice, 4 to 5 weeks of age, were purchased from Jackson Laboratories (Bar Harbor, ME) and housed in an Association for Assessment and Accreditation of Laboratory Animal Care-Accredited, specific pathogen-free, environmentally-controlled facility. All mice were free of endogenous viral pathogens, parasites, mycoplasmas, *Helicobacter*, and *CAR* bacillus. Mice were housed in groups of five in ventilated cages and provided high-efficiency particulate filtered air under a controlled light cycle (12 hour light/12 hour dark) at a standard

temperature (22-24°C) and 30-70% relative humidity. Animals were acclimated to the animal facility for one week and allowed access to a conventional diet (6% irradiated NIH-31 Diet, Envigo RMS, Inc., Madison, WI) and tap water *ad libitum*. All procedures were performed using protocols approved by the National Institute for Occupational Safety and Health (NIOSH) Institutional Animal Care and Use Committee.

Experimental protocols for animal exposure and welding fume generator

A/J mice, 120 in total, were organized into 4 groups using a block design for randomization (Figure 1). On day 1, mice aged 5 to 6 weeks were intraperitoneally (IP) injected with the chemical initiator, 3-methylcholanthrene (MCA) (Sigma, St. Louis, MO) dissolved in corn oil (CO) (Sigma, St. Louis, MO) at a dose of 10 µg/g of body weight or CO alone. MCA was chosen as the initiating agent based on the efficient response of the A/J mouse to this carcinogen in our oropharyngeal aspiration study [10]. One week post-initiation, mice were exposed in whole body inhalation chambers with individual steel mesh cages to aerosols generated during GMA-SS welding or air for 4 h/d and 4 d/w for 9 weeks at a target concentration of 40 mg/m³ (actual 32.3 ± 2.8 mg/m³). The welding wire used was 0.045 inch diameter Lincoln Electric Blue Max MIG 308LSI and the welding parameters were set to 25 volts DC, 300 inch per minute wire feed, 30 L/min of 95% Argon - 5% CO₂ shielding gas, and a typical welding current of 220 amps.

The design and construction of the welding fume aerosol generator were previously described [12]. This automated robotic welder continuously generated welding fumes by welding beads onto ¼ inch thick plates of mild steel. The resulting fume was carried into a whole body exposure chamber through a ¾ inch flexible tube by maintaining the chamber at a negative pressure (0.70 Inch H₂O). Particle concentrations within the exposure chamber were

continuously monitored with a Data RAM (DR-40000 Thermo Electron Co, Franklin, MA), and gravimetric determinations (37 mm cassettes with 0.45 μm pore-size Teflon filters) were used to calibrate and verify the Data RAM readings each day. Gas generation, including carbon monoxide (CO), carbon dioxide (CO₂), oxygen (O₂), and ozone (O₃), was continuously monitored. During the welding exposure, O₂ levels were maintained above the OSHA minimal acceptable level. O₃, CO, CO₂ were below OSHA permissible exposure limits and NIOSH recommended exposure limits (REL) during the entire exposure duration. In the exposure chamber, CO and O₃ levels were not significantly higher than background. The exposure system setup was slightly modified from that described previously [12] to reduce the travel time of the particulate fume from the welding torch to the exposure chamber. This was done to ensure delivery of fresher fumes to more closely mimic a worker's inhalation exposure.

Body weight determination

All mice were weight-matched prior to the inhalation exposure. Mice were weighed weekly throughout the experimental time course and at the 30-week sacrifice.

Whole lung metal analysis

Male A/J mice were exposed by inhalation to GMA-SS welding aerosols (40 mg/m³) (n = 25) or filtered air (n = 10) for 4 h. Immediately following exposure, whole lungs were excised, trimmed, and lyophilized. The freeze-dried tissue was weighed then acid digested. Inductively coupled argon plasma, atomic emission spectroscopy at NIOSH-Division of Applied Research and Technology (Cincinnati, OH) was used to determine the amount of Cr, Ni, Cu, Fe, and Mn present in the lung according to the draft NIOSH method 8200 modified to accommodate the sample matrix (NIOSH 2003).

Gross lung tumor counts and histopathology

At 30 weeks post-exposure, A/J mice were euthanized with Fatal Plus [100-300 mg/kg IP; 390 mg/ml pentobarbital sodium] (Vortech Pharmaceuticals, Dearborn, MI), weighed, and then the vena cava was cut to exsanguinate the animal. All internal organs were examined for the presence of tumors. The whole lung was then excised. All tumors were clearly defined with no apparent merged tumors. The lungs were inflated and fixed with 10% neutral buffered formalin for 24 h. Tumors were counted and measured 24 h after fixation. Lungs were embedded in paraffin, then a 5 μ m standardized section was cut. Slides were stained with hematoxylin and eosin and interpreted by two separate, contracted, board certified veterinary pathologists in a blinded fashion for evidence of hyperplasia and neoplasia, inflammation, lymphoid tissue response, and foreign materials by light microscopy. Diagnostic criteria for hyperplastic and neoplastic findings were according to *goRENI* (<http://www.goreni.org/>), the standard reference for nomenclature and diagnostic criteria in toxicologic pathology and at the same time the Internet discussion platform for the global initiative "**INHAND**" - the International Harmonization of Nomenclature and Diagnostic criteria [13, 14]. If abnormal changes were found, severity was scored using the following scale: 1=minimal, 2=mild, 3=moderate, 4=marked. The final severity score reflects the average of the right and left lung lobe scores and are presented as means $\pm$ standard error. Because bronchiolo-alveolar hyperplasia (BAH) and bronchiolo-alveolar adenomas (BAA) represent a continuum of the proliferative process and there is possible overlap between these diagnoses, the numbers of lesions were combined to compare the oncogenic potential of each treatment [14]. However, the gross tumor count at necropsy is more representative of the response because examination of a single histological section per lung underestimates the total number of lesions per lung [15].

Statistical comparisons and analysis

Statistical analyses were performed using JMP version 12. Factorial analysis of variance (ANOVA) was utilized on continuous variables to make comparisons between the treatment groups. For some variables a log transformation was performed on the data to reduce heterogeneous variance and meet the assumptions of an ANOVA. Gross tumor counts and histopathology counts from sections were analyzed similarly. Tumor incidence (presence or absence of tumors) was analyzed using a chi-square test in SAS 'Proc Freq', while tumor multiplicity (number of tumors per lung) was analyzed using Poisson regression in SAS 'Proc Genmod'. In cases where overdispersion existed, a negative binomial regression was performed. Analyses were performed independently on CO and MCA treated animals, and only utilized data from those animals surviving to the 30 week time point. For all analyses, a *p*-value of <0.05 was set as the criteria for significance

Results

Welding fume characteristics

A summary of the characteristics of GMA-SS welding fume and images of the fume are presented in Figure 2. Particle mass size distribution was measured for this newer configuration using a Micro-Orifice Uniform Deposit Impactor (MOUDI, model 110; MSP corp., Shoreview, Minn.) with additional Nano-MOUDI stages (MSP model 115). The mass median aerodynamic diameter (MMAD) was 350 nm. The count-based particle size distributions of the particles were measured using a Scanning Mobility Particle Sizer (SMPS model 3936, TSI Inc, Shoreview, MN). The SMPS estimated the count median aerodynamic diameter to be 230 nm. Particle imaging was achieved with a scanning electron microscope (SEM; JEOL 6400, JEOL Inc). Inspection of physical characteristics of the particles showed many small nano-spheres (10 to 50 nm) linked together into long chain like structures often with several branches. Elemental

analysis of the welding particles were previously measured [10]. The overall particulate fume was composed of 57% Fe, 20.2% Cr, 13.8% Mn, 8.8% Ni, 0.2% copper (Cu) and trace amounts of silicon (Si), aluminum (Al), and vanadium (V). Hexavalent chromium (Cr (VI)) levels were also measured and determined to be 2929 ppm. GMA-SS welding fume is largely water insoluble with a soluble: insoluble ratio of 0.006 [16].

Lung metal deposition after GMA-SS welding fume inhalation

Shown in Table 1 is the lung metal deposition in A/J mice after 4 h of inhalation of GMA-SS welding fume. The most abundant metal measured in the lung was Fe followed by Cr, Mn, Ni, and Cu, as predicted from the previous characterization of this fume [12]. The metal analysis by weight % of the whole lungs (60 % Fe, 17 % Cr, 14 % Mn, 8 % Ni, and 0.8 % Cu) agrees with the weight % of collected fume.

The analysis of the metals shows a cumulative increase of ~10.1 µg of total GMA-SS fume deposited in the lung from a single 4 h exposure. The alveolar deposition in the mice was equated to the human by the equations below using the previous threshold limit value-time weighted average (TLV-TWA) of 5 mg/m³ for total welding fume and the PEL of 5 µg/m³ for Cr(VI). Previously, we estimated that 70% of the total dose reached the alveolar space (10.1 µg/d x 0.70 = 7.07 µg/d) [17, 18]. The mice were exposed for 36 days (9 w at 4 d/w) for an approximate total alveolar deposition of 254.5 µg.

Factored for human dose using previous welding fume TLV of 5 mg/m³:

Fume concentration x min volume x exposure duration x deposition efficiency = deposited human dose

$5 \text{ mg/m}^3 \times (20 \text{ L/min})(10^{-3} \text{ m}^3/\text{L}) \times (8 \text{ h/day})(60 \text{ min/h}) \times 0.16 = \mathbf{7.7 \text{ mg deposited per 8 h day}}$
in humans

Human equivalent dose to mouse by alveolar surface area (SA) [19]

$$(SA_{\text{human}} \times \text{Deposition}_{\text{mouse}}) / SA_{\text{mouse}} = \text{Deposition}_{\text{human}}$$

$$(102 \text{ m}^2 \times 0.00707 \text{ mg}) / 0.05 \text{ m}^2 = \mathbf{14.4 \text{ mg} (\sim 2 \text{ fold greater: } 14.4 / 7.7)}$$

Factored for human dose using Cr(VI) PEL of 5 µg/m³:

Cr(VI) concentration x min volume x exposure duration x deposition efficiency) = deposited human dose

$$5 \text{ µg/m}^3 \times (20 \text{ L/min})(10^{-3} \text{ m}^3/\text{L}) \times (8 \text{ h/day})(60 \text{ min/h}) \times 0.16 = \mathbf{7.7 \text{ µg deposited per 8 h day in humans}}$$

In the GMA-SS fume, Cr(VI) was 0.29% of the total welding fume [10, 20]. Using our alveolar deposition dose of 7.07 µg roughly 0.0205 µg (7.07 x 0.0029) would be Cr(VI).

Human equivalent dose to mouse by SA:

$$(SA_{\text{human}} \times \text{Deposition}_{\text{mouse}}) / SA_{\text{mouse}} = \text{Deposition}_{\text{human}}$$

$$(102 \text{ m}^2 \times 0.0205 \text{ µg}) / 0.05 \text{ m}^2 = \mathbf{41.8 \text{ µg} (\sim 5 \text{ fold greater: } 41.8 / 7.7)}$$

Morbidity and mortality

A timeline of the experimental protocol for the two-stage (initiation-promotion) carcinogenesis model is shown in Figure 1. Initial body weights at week 0 (means ± standard error [SE]) were 18.56 ± 0.35, 19.1 ± 0.39, 18.25 ± 0.31, and 19.05 ± 0.36 for the CO/air, CO/GMA-SS, MCA/air, and MCA/GMA-SS groups, respectively. Body weights increased steadily and were not changed due to exposure from week 0 to 30 with 10.26 ± 0.58, 9.46 ± 0.56, 11.38 ± 0.65, 9.78 ± 0.61 for the CO/air, CO/GMA-SS, MCA/air, and MCA/GMA-SS groups, respectively. Morbidity and mortality throughout the study was low (~5 %) and no

abnormalities, such as other tumor types besides lung, were found at the terminal sacrifice at 30 weeks. In total, 6 mice died during the course of the study and were not included in the final analysis of the data. Necropsy determined that all 6 mice died from typical morbidities that included enlarged heart or otherwise undetermined.

Gross tumor multiplicity and incidence

GMA-SS welding fume significantly promoted lung tumors in the A/J mouse 30 weeks after initiation with MCA. The grossly observed tumor multiplicity (average tumor number/mouse lung $\pm$ SE) for all groups is shown in Figure 3. There was no effect of welding fume alone on tumor multiplicity (CO/air, 0.32 ± 0.10 ; CO/GMA-SS, 0.45 ± 0.13 ; $p = 0.44$). In animals initiated with MCA, tumor multiplicity was 7.93 ± 0.82 and 16.11 ± 1.18 for air and GMA-SS, respectively ($p < 0.0001$). Average tumor incidence (% of tumor-bearing mice) was 29% in CO/air and 38% in CO/GMA-SS-exposed animals. Reports in the literature indicate the background tumor frequency in A/J mice between 43 and 53 weeks to be 31-40% [21, 22]. The mice in this study were 35 or 36 weeks old upon sacrifice, indicating the observed tumor incidence is consistent with the literature. As expected, tumor incidence was >96% in all MCA-initiated groups ($n = 29$ for MCA/air and $n = 28$ for MCA/GMA-SS groups) which confirmed successful experimental administration as well as its carcinogenic effectiveness in A/J mice. Total and average tumor number per treatment group across each of the individual lung regions is described in Table 2. MCA/GMA-SS-exposed mice had significantly greater lung tumor multiplicity in every lung region compared to MCA/air ($p < 0.009$). There was no difference between CO/air and CO/GMA-SS groups ($p = 0.44$).

Gross lung morphology from a GMA-SS-exposed mouse initiated with MCA is shown in Figure 4. Welding fume deposition was visible in exposed mouse lungs and appeared black-

brown in color. Tumors appeared white in color and opaque on initial gross exam and became more well-defined after fixation which aided enumeration. At 30 weeks, tumors were between ~0.5 mm and ~3 mm, with most tumors ~1 mm.

Histopathological evaluation of lung lesions, inflammation, and welding fume presence

CO/air animals had no lymphoid infiltrate or foreign material (brown-black pigment, i.e., welding fume) and hyperplasia was unremarkable (0.09 ± 0.05). There were 5 total lesions reported in the CO/air group. The CO/GMA-SS-exposed group had minimal, but significant, lymphoid infiltrates (0.22 ± 0.063 ; $p < 0.03$) and foreign material (1.86 ± 0.07 ; $p < 0.03$) compared to CO/air. There were 2 total hyperplastic lesions reported in this group. Welding fume, indicated by black-brown foreign material presence in the lungs, was found in both GMA-SS-exposed groups (CO and MCA) in every lung section. Significant hyperplasia (1.20 ± 0.11 ; $p < 0.03$) and increased total preneoplastic/neoplastic lesions (BAH and BAA) were reported in the MCA/GMA-SS animals compared to MCA/air animals (114 versus 70; $p < 0.03$). Histopathological assessment of the lungs from a separate, second board certified veterinary pathologist confirmed these findings (Table 3). The total number of proliferative lesions for MCA/GMA-SS-exposed mice was 153 compared to 90 for MCA/air. Increased perivascular mononuclear infiltrate in the MCA/GMA-SS group consisting of small aggregates or cuffs of lymphocytes, sometimes mixed with a few plasma cells, adjacent to or around multiple scattered vessels was also reported. This infiltrate was not observed in any of the MCA/air lungs. Because there were no significant findings in the CO groups besides evidence of welding fume and minimal lymphoid infiltrates in GMA-SS-exposed mice, a second evaluation was not deemed necessary. Figure 5a demonstrates a BAA and two areas of BAH. Figure 5b shows the adenoma in panel a at 20x magnification adjacent to areas of welding fume deposition. Panels c and d demonstrate a BAA at 40x and BAH at 20x, respectively. The

BAA were more compact nodules composed of enlarged Type II cells that obscured the normal tissue morphology. These benign neoplasms had a smooth margin that frequently caused compression of surrounding tissue. The cells sometimes had prominent nucleoli and frequently formed radiating proliferations around blood vessels. BAH were round to irregular in shape with increased numbers of Type II cells lining alveolar septae. The cells were of normal size and normal tissue architecture was retained. The margins of these lesions were irregular and did not cause compression of surrounding tissues. Because BAH and BAA represent a continuum of the proliferative process and there is possible overlap between these diagnoses, the number of lesions were combined to compare the tumorigenic potential of each treatment [14]. In addition, the number of adenomas in the MCA/GMA-SS group was significantly greater than in the MCA/air group ($p < 0.05$; Table 3) [23].

Discussion

This study was the first to find that inhalation of GMA-SS welding fume can promote lung tumorigenesis *in vivo*. Tumor multiplicity increased two-fold after initiation with the chemical initiator MCA. Histopathology analysis confirmed the gross findings and showed a significant increase in lung adenomas and combined adenomas and hyperplastic lesions in welding fume-exposed animals. In addition, welding fume exposure increased inflammatory infiltrates. Interestingly, the tumorigenic potential of the inhaled welding fume was achieved at a significantly lower total-deposited dose compared to our previous oropharyngeal aspiration exposure in mice [10]. The results of this study further support the epidemiological findings of an association between lung cancer and welding.

The measured lung deposition following welding fume exposure in this study after a single (4 h) exposure was 10.1 μg , or a cumulative dose of 254.5 μg in the lung alveolar region (see calculation in results). This dose represents approximately two times the former TLV-TWA

of 5 mg/m³ for 8 h/d, a level commonly exceeded in the workplace [3]. This exposure in terms of the TLV is equivalent to 14 weeks (36 days of exposure x 2 = 72 days) of constant exposure to GMA-SS fume for 8 h/d. If a welder was exposed to GMA-SS fume for 5% (1/20) of their working time at the maximum concentration, then the exposure would be 280 weeks (14 weeks x 20), or 5.6 years. Therefore, the deposited dose in our study is occupationally relevant because epidemiologic research has demonstrated a 70% increase in the risk of lung cancer among workers who welded for at least 5% or more of their working time [5].

Our lab previously demonstrated that at 78 weeks post-oropharyngeal aspiration, lung tumor incidence in A/J mice approached significance ($p = 0.057$; $n=16$) and a trend for increased tumor multiplicity was found after exposure to GMA-SS welding PM alone [24]. In a follow up study, GMA-SS welding fume delivered via oropharyngeal aspiration significantly increased tumor multiplicity at 30 weeks post-initiation using a two-stage (initiation-promotion) model with the chemical initiator MCA [10]. These preliminary studies suggest that GMA-SS fume may be a weak carcinogen in A/J mice; however, oropharyngeal aspiration is considered to be less relevant to a real-world exposure because it delivers a bolus exposure to the lung, potentially overestimating the hazard. Inhalation studies are an important next step as they closely resemble the occupational route of exposure in welders and avoid this potential bolus effect. Inflammation is well-known to be a hallmark of cancer, and epidemiologic studies have indicated nearly a quarter of human cancers are associated with inflammation [25, 26]. Our lab demonstrated that inhalation and oropharyngeal aspiration induce different inflammatory responses in A/J mice, suggesting these exposure methods may also differ in their ability to promote lung tumor formation [9, 24]. Inhalation of GMA-SS welding fume causes a delayed rise in PMN compared to aspiration and also induces a more complex cytokine profile. A potential explanation for the

differing inflammatory responses between oropharyngeal and inhalation exposure is the dose rate at which fume is deposited [27, 28]. Former studies have indicated that the dose rate is an important determinant of the acute inflammatory response in the respiratory tract. Baisch et al. demonstrated a higher inflammatory response in F-344 rats following intratracheal instillation of TiO₂ compared with an equivalent dose delivered via inhalation. Our former aspiration protocol delivered five bolus doses of 340 µg or 680 µg (1.7 or 3.4 mg cumulative) of GMA-SS welding PM once a week for 5 weeks [10]. In this study, inhalation exposure deposited ~10 µg per day (or 360 µg estimated total) over 36 days. Despite this much lower calculated total lung burden and dose rate, we found a significant lung tumor promotion for inhalation of welding fume as was also observed with high dose rate delivery oropharyngeal aspiration in our previous study. The objective of the present study was to identify if GMA-SS fume at a reasonable exposure level is a tumor promoter. Limitations must be noted when comparing lung tumor multiplicity rates from this and our previous study published in 2013. Indeed, the present study reports results for only a single total inhaled dose, limiting its usefulness in determining thresholds and dose-response effects. Also, the particle deposition patterns may differ (e.g. upper airways) between the inhalation and oropharyngeal aspiration exposure routes.

Interestingly, “fresh” GMA-SS welding fume as delivered via inhalation is more reactive than “aged” welding fume which is used for oropharyngeal aspiration studies [11]. Aged fume has shown to be less inflammatory because it generates significantly less reactive oxygen species than freshly generated welding fume that is used for inhalation studies or generated in the workplace. As such, welding fume is 6 to 9 times more potent when delivered by inhalation rather than oropharyngeal aspiration [9, 24, 29]. Although the metals are deposited in a lower amount with inhalation, their increased potency may make them more available for DNA

damaging effects. Genomic mutations and instability are known enablers of carcinogenesis [30]. Cancer cells often increase their rates of mutation in order to acquire the hallmarks of inducing angiogenesis, resisting cell death, sustaining proliferative signaling, enabling replicative immortality, evading growth suppressors, and activating invasion and metastasis. The heightened free radicals and oxidative stress that occurs with welding fume inhalation exposure independent of dosing rate may also potentially contribute to tumorigenicity [31]. Therefore, it is likely that the amount of carcinogenic metals in the welding fume may not be the only factor contributing to the formation of lung cancer.

At 30 weeks post-initiation, adenomas and proliferative bronchiolo-alveolar epithelial lesions were the most commonly observed microscopic lung pathologies. This finding is consistent with the literature and our previous observations in A/J mice of this age [24, 32]. In humans, lung cancers are more diverse than in mice and adenocarcinoma is the most common diagnosis. The adenomas in A/J mice are relevant to the production of adenocarcinomas in humans as these lung adenomas are often the direct precursor to lung adenocarcinomas. Likewise, human and A/J mouse tumors both often arise in the context of atypical hyperplasia in the periphery of the lung [33-36]. Thus, the A/J mouse is a very useful and relevant model to study welding fume toxicity and lung tumorigenesis.

In conclusion, the current research suggests that SS welding fume may serve as a promoter of chemically-initiated lung tumors in the A/J mouse model. Future studies will be directed at investigating additional types of welding fumes. Nearly 90% of welding processes use mild steel (MS) while 10% or less use SS [1]. However, SS welding is still widely utilized as it offers increased protection from corrosion and rusting to which other metals are susceptible [20]. Unlike SS electrodes, MS electrodes are comprised mainly of the non-carcinogenic metals Fe

and various concentrations of Mn. Interestingly, both MS and SS fumes have been linked epidemiologically to lung cancer in welders. Future studies will focus on MS inhalation using a two stage initiation-promotion model in A/J mice as reported here.

Bibliography

1. **Welders, Cutters, Solderers, and Brazers** [<http://www.bls.gov/ooh/production/welders-cutters-solderers-and-brazers.htm>]
2. Antonini JM: **Health effects of welding.** *Crit Rev Toxicol* 2003, **33**:61-103.
3. Korczynski RE: **Occupational health concerns in the welding industry.** *Appl Occup Environ Hyg* 2000, **15**:936-945.
4. Lauritsen JM, Hansen KS: **Lung cancer mortality in stainless steel and mild steel welders: a nested case-referent study.** *Am J Ind Med* 1996, **30**:383-391.
5. Matrat M, Guida F, Mattei F, Cenee S, Cyr D, Fevotte J, Sanchez M, Menvielle G, Radoi L, Schmaus A, et al: **Welding, a risk factor of lung cancer: the ICARE study.** *Occup Environ Med* 2016, **73**:254-261.
6. Steenland K: **Ten-year update on mortality among mild-steel welders.** *Scand J Work Environ Health* 2002, **28**:163-167.
7. Antonini JM: **Health Effects Associated with Welding.** 2014:49-70.
8. IARC: **Report of the advisory group to recommend priorities for IARC Monographs during 2010-2014.** 08/001 edition; 2008.
9. Zeidler-Erdely PC, Battelli LA, Stone S, Chen BT, Frazer DG, Young SH, Erdely A, Kashon ML, Andrews R, Antonini JM: **Short-term inhalation of stainless steel welding fume causes sustained lung toxicity but no tumorigenesis in lung tumor susceptible A/J mice.** *Inhal Toxicol* 2011, **23**:112-120.

10. Zeidler-Erdely PC, Meighan TG, Erdely A, Battelli LA, Kashon ML, Keane M, Antonini JM: **Lung tumor promotion by chromium-containing welding particulate matter in a mouse model.** *Part Fibre Toxicol* 2013, **10**:45.
11. Antonini JM, Clarke RW, Krishna Murthy GG, Sreekanthan P, Jenkins N, Eagar TW, Brain JD: **Freshly generated stainless steel welding fume induces greater lung inflammation in rats as compared to aged fume.** *Toxicol Lett* 1998, **98**:77-86.
12. Antonini JM, Afshari AA, Stone S, Chen B, Schwegler-Berry D, Fletcher WG, Goldsmith WT, Vandestouwe KH, McKinney W, Castranova V, Frazer DG: **Design, construction, and characterization of a novel robotic welding fume generator and inhalation exposure system for laboratory animals.** *J Occup Environ Hyg* 2006, **3**:194-203; quiz D145.
13. Keenan CM, Baker J, Bradley A, Goodman DG, Harada T, Herbert R, Kaufmann W, Kellner R, Mahler B, Meseck E, et al: **International Harmonization of Nomenclature and Diagnostic Criteria (INHAND): Progress to Date and Future Plans.** *Toxicol Pathol* 2015, **43**:730-732.
14. Renne R, Brix A, Harkema J, Herbert R, Kittel B, Lewis D, March T, Nagano K, Pino M, Rittinghausen S, et al: **Proliferative and nonproliferative lesions of the rat and mouse respiratory tract.** *Toxicol Pathol* 2009, **37**:5s-73s.
15. Rehm S, Ward JM: **Quantitative analysis of alveolar type II cell tumors in mice by whole lung serial and step sections.** *Toxicol Pathol* 1989, **17**:737-742.
16. Antonini JM, Lawryk NJ, Murthy GG, Brain JD: **Effect of welding fume solubility on lung macrophage viability and function in vitro.** *J Toxicol Environ Health A* 1999, **58**:343-363.

17. Erdely A, Hulderman T, Salmen-Muniz R, Liston A, Zeidler-Erdely PC, Chen BT, Stone S, Frazer DG, Antonini JM, Simeonova PP: **Inhalation exposure of gas-metal arc stainless steel welding fume increased atherosclerotic lesions in apolipoprotein E knockout mice.** *Toxicol Lett* 2011, **204**:12-16.
18. Raabe OG, Al-Bayati, M.A., Teague, S.V., Rasolt, A., : **Regional deposition of inhaled monodisperse coarse and fine aerosol particles in small laboratory animals.** *Ann Occup Hyg* 1988, **32**:53-63.
19. Stone KC, Mercer RR, Gehr P, Stockstill B, Crapo JD: **Allometric relationships of cell numbers and size in the mammalian lung.** *Am J Respir Cell Mol Biol* 1992, **6**:235-243.
20. Keane M, Stone S, Chen B, Slaven J, Schwegler-Berry D, Antonini J: **Hexavalent chromium content in stainless steel welding fumes is dependent on the welding process and shield gas type.** *J Environ Monit* 2009, **11**:418-424.
21. Groch KM, Khan MA, Brooks AL, Saffer JD: **Lung cancer response following inhaled radon in the A/J and C57BL/6J mouse.** *Int J Radiat Biol* 1997, **71**:301-308.
22. Curtin GM, Higuchi MA, Ayres PH, Swauger JE, Mosberg AT: **Lung tumorigenicity in A/J and rasH2 transgenic mice following mainstream tobacco smoke inhalation.** *Toxicol Sci* 2004, **81**:26-34.
23. McConnell EE, Solleveld HA, Swenberg JA, Boorman GA: **Guidelines for combining neoplasms for evaluation of rodent carcinogenesis studies.** *J Natl Cancer Inst* 1986, **76**:283-289.
24. Zeidler-Erdely PC, Kashon ML, Battelli LA, Young SH, Erdely A, Roberts JR, Reynolds SH, Antonini JM: **Pulmonary inflammation and tumor induction in lung tumor**

- susceptible A/J and resistant C57BL/6J mice exposed to welding fume. *Part Fibre Toxicol* 2008, **5**:12.
25. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A: **Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability.** *Carcinogenesis* 2009, **30**:1073-1081.
 26. Punturieri A, Szabo E, Croxton TL, Shapiro SD, Dubinett SM: **Lung cancer and chronic obstructive pulmonary disease: needs and opportunities for integrated research.** *J Natl Cancer Inst* 2009, **101**:554-559.
 27. Baisch BL, Corson NM, Wade-Mercer P, Gelein R, Kennell AJ, Oberdorster G, Elder A: **Equivalent titanium dioxide nanoparticle deposition by intratracheal instillation and whole body inhalation: the effect of dose rate on acute respiratory tract inflammation.** *Part Fibre Toxicol* 2014, **11**:5.
 28. Bonner JC, Silva RM, Taylor AJ, Brown JM, Hilderbrand SC, Castranova V, Porter D, Elder A, Oberdorster G, Harkema JR, et al: **Interlaboratory evaluation of rodent pulmonary responses to engineered nanomaterials: the NIEHS Nano GO Consortium.** *Environ Health Perspect* 2013, **121**:676-682.
 29. Erdely A, Salmen-Muniz R, Liston A, Hulderman T, Zeidler-Erdely PC, Antonini JM, Simeonova PP: **Relationship between pulmonary and systemic markers of exposure to multiple types of welding particulate matter.** *Toxicology* 2011, **287**:153-159.
 30. Hanahan D, Weinberg RA: **Hallmarks of cancer: the next generation.** *Cell* 2011, **144**:646-674.
 31. Valavanidis A, Vlachogianni T, Fiotakis K, Loridas S: **Pulmonary oxidative stress, inflammation and cancer: respirable particulate matter, fibrous dusts and ozone as**

major causes of lung carcinogenesis through reactive oxygen species mechanisms.

Int J Environ Res Public Health 2013, **10**:3886-3907.

32. Gunning WT, Castonguay A, Goldblatt PJ, Stoner GD: **Strain A/J mouse lung adenoma growth patterns vary when induced by different carcinogens.** *Toxicol Pathol* 1991, **19**:168-175.
33. Belinsky SA, Devereux TR, Foley JF, Maronpot RR, Anderson MW: **Role of the alveolar type II cell in the development and progression of pulmonary tumors induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in the A/J mouse.** *Cancer Res* 1992, **52**:3164-3173.
34. Foley JF, Anderson MW, Stoner GD, Gaul BW, Hardisty JF, Maronpot RR: **Proliferative lesions of the mouse lung: progression studies in strain A mice.** *Exp Lung Res* 1991, **17**:157-168.
35. Westra WH: **Early glandular neoplasia of the lung.** *Respir Res* 2000, **1**:163-169.
36. Westra WH, Baas IO, Hruban RH, Askin FB, Wilson K, Offerhaus GJ, Slebos RJ: **K-ras oncogene activation in atypical alveolar hyperplasias of the human lung.** *Cancer Res* 1996, **56**:2224-2228.

Figure Legends

Figure. 1 Experimental protocol and block design for two-stage initiation-promotion lung tumorigenesis model in A/J mice. A/J mice, 120 in total, were randomized and separated into four blocks of $n = 7$ or 8 per exposure group. Mice received intraperitoneal (IP) injections of either MCA or corn oil and one week later were exposed to GMA-SS welding fume (40 mg/m^3) or air for 4 h/d, 4 d/w, for 9 w. Animal weights were recorded weekly. At 30 weeks, mice were sacrificed for tumor multiplicity and incidence and histopathological studies

Figure 2 GMA-SS welding fume characteristics. Panels a and b are SEM images depicting small nano-spheres (10 to 50 nm) linked together in long chain-like structures often with several branches. The bottom panels show the particle size distribution of the generated welding fume in terms of the mass median aerodynamic diameter (MMAD) (c) and estimated count median aerodynamic diameter (d)

Figure 3 Lung tumor multiplicity upon gross examination in A/J mice promoted with air or GMA-SS welding fume. At 30 weeks, MCA initiation followed by GMA-SS welding fume exposure increased lung tumor multiplicity (average tumor number/mouse lung) significantly above MCA/air exposed animals (7.93 ± 0.82 and 16.11 ± 1.18 , respectively). * $p < 0.0001$ – compared to CO/air, ** $p < 0.0001$ – compared to MCA/air

Figure 4 Gross images of lung tumors promoted by GMA-SS welding fume 30 weeks after initiation with MCA. Panel a shows lung tumor morphology before fixation and panel b represents tumors 24 h post-fixation. Asterisks (*) indicate areas of welding fume deposition and arrows indicate lung tumors. Most tumors were ~1 mm in diameter

Figure 5 Photomicrographs of lung tissue from MCA/GMA-SS exposed mice. Panel a shows a bronchiolo-alveolar adenoma and two areas of bronchiolo-alveolar hyperplasia in the lung at 2x magnification. Panel b demonstrates the adenoma in panel a at 20x magnification. Panel c shows a bronchiolo-alveolar adenoma at 40x magnification. Cells are enlarged and forming a compact mass that obscures normal architecture and causes compression of adjacent tissue. Panel d shows a bronchiolo-alveolar hyperplasia in the lung at 20x magnification. Arrows depict brown pigment (welding fume particles) within alveolar macrophages. H&E stain

Figures

Figure 1.

	Air		GMA-SS	
Block	Corn oil (n=)	MCA (n=)	Corn oil (n=)	MCA (n=)
1	7	7	7	7
2	7	7	7	7
3	8	8	8	8
4	8	8	8	8
n group	30	30	30	30

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Tables

Table 1. Lung metal deposition in A/J mice after stainless steel welding fume inhalation for 4 h at a target concentration of 40 mg/m³

Exposure	Cr (µg/lung)	Cu (µg/lung)	Fe (µg/lung)	Mn (µg/lung)	Ni (µg/lung)
Air	0.02 ± 0.01	0.22 ± 0.03	8.97 ± 0.36	0.02 ± 0.00	0.01 ± 0.00
GMA-SS	1.65 ± 0.05	0.32 ± 0.01	15.12 ± 0.39	1.48 ± 0.04	0.82 ± 0.02

Freeze-dried whole lung tissue was analyzed for aluminum (Al), chromium (Cr), copper (Cu), iron (Fe), manganese (Mn), nickel (Ni), titanium (Ti), and zinc (Zn) by Inductively Coupled Plasma-Atomic Emission Spectroscopy. Samples were prepared according to draft NIOSH Analytical Method 8200 for bulk tissue samples. Trace amounts of Al, Ti, and Zn were found. In cases in which no result was measured, the limit of quantification (LOQ) was used in calculating the average deposition. *Note:* Values are mean ± standard error of the mean (n=10 air; n=25 GMA-SS); GMA-SS – gas metal arc-stainless steel welding fume.

Table 2. Total and average (in parenthesis) tumor number across individual lung lobes following GMA-SS welding fume inhalation exposure 30 weeks post-initiation with MCA or corn oil

	n	Left	Apical	Cardiac	Diaphragmatic	Azygos
Corn oil/air	28	3 (0.11 ± 0.06)	3 (0.11 ± 0.06)	0	3 (0.11 ± 0.06)	0
Corn oil/GMA-SS	29	5 (0.17 ± 0.07)	1 (0.03 ± 0.03)	0	5 (0.17 ± 0.09)	2 (0.07 ± 0.05)
MCA/air	29	78 (2.69 ± 0.39)*	30 (1.03 ± 0.20)*	25 (0.86 ± 0.15)*	67 (2.31 ± 0.36)*	30 (1.03 ± 0.25)*
MCA/GMA-SS	28	150 (5.35 ± 0.54)**	68 (2.43 ± 0.42)**	63 (2.25 ± 0.35)**	110 (3.93 ± 0.37)**	60 (2.14 ± 0.32)**

GMA-SS: gas metal arc- stainless steel, MCA: 3-methylcholanthrene

* $p < 0.0001$ - compared to Corn oil/air

** $p < 0.009$ -compared to MCA/air

Table 3. Severity scores for abnormal morphological findings and numbers of adenomas and hyperplastic lesions observed in lung sections of A/J mice exposed to GMA-SS welding fume by inhalation at 30 weeks post-initiation with MCA

	Lymphoid Infiltrates*	Foreign material*	Hyperplasia Severity*	Hyperplasia	Adenoma	Total lesions
MCA/air	--	0.03 $\pm$ 0.03	1.41 $\pm$ 0.19	70	20	90
MCA/GMA-SS	0.34 $\pm$ 0.07**	1.5 $\pm$ 0.08**	1.86 $\pm$ 0.19	119 [‡]	34 [^]	153 [‡]

GMA-SS: gas metal arc-stainless steel, MCA: 3-methylcholanthrene.

* Severity scores are the averages of the left and right lung lobes and are presented as mean $\pm$ standard error. Lymphoid infiltrates represents perivascular and peribronchiolar mononuclear cells. Foreign material refers to the presence of brown pigment in the lungs. Severity was scored as 1 = minimal, 2 = mild, 3 = moderate, 4 = marked.

-- indicates no findings

** $p < 0.0002$ – compared to MCA/air

[‡] $p < 0.004$ – compared to MCA/air

[^] $p < 0.05$ – compared to MCA/air

Chapter 4: Inhalation of Iron-Abundant Gas Metal Arc – Mild Steel Welding Fume Promotes Lung Tumors in Mice

LM Falcone^{1,2}, A Erdely^{1,2}, V. Kodali¹, R Salmen¹, LA Battelli¹, T Dodd¹, W McKinney¹, S Stone¹, M Donlin¹, HD Leonard¹, JL Cumpston¹, JB Cumpston¹, RN Andrews³, M Kashon¹, JM Antonini¹, PC Zeidler-Erdely^{1,2}

¹Health Effects Laboratory Division, National Institute for Occupational Safety and Health, Morgantown, WV; ²West Virginia University, School of Medicine, Morgantown, WV; ³Division of Applied Research and Technology, National Institute for Occupational Safety and Health, Cincinnati, OH

Abstract

Welding fumes were reclassified as a Group 1 carcinogen by the International Agency for Research on Cancer (IARC) in 2017. Gas metal arc welding (GMAW) is a process widely used in industry. Fume generated from GMAW-mild steel (MS) is abundant in iron with some manganese, while GMAW-stainless steel (SS) fume also contains significant amounts of chromium and nickel, known carcinogenic metals. It has been shown that exposure to GMAW-SS fume in A/J mice promotes lung tumors. The objective was to determine if GMAW-MS fume, which lacks known carcinogenic metals, also promotes lung tumors in mice. Male A/J mice received a single intraperitoneal injection of corn oil or the initiator 3-methylcholanthrene (MCA; 10 $\mu\text{g/g}$) and, one week later, were exposed by whole-body inhalation to GMAW-MS aerosols for 4 hours/day x 4 days/week x 8 weeks at a mean concentration of 34.5 mg/m^3 . Lung nodules were enumerated by gross examination at 30 weeks post-initiation. GMAW-MS fumes significantly promoted lung tumor multiplicity in mice initiated with MCA (21.86 ± 1.50) compared to MCA/air-exposed mice (8.34 ± 0.59). Histopathological analysis confirmed these findings and revealed absence of inflammation. Bronchoalveolar lavage analysis also indicated a lack of lung inflammation and toxicity after short-term inhalation exposure to GMAW-MS fume. In conclusion, this study demonstrates that inhalation of GMAW-MS fume promotes lung tumors *in vivo* and aligns with epidemiologic evidence that shows MS welders, despite less exposure to carcinogenic metals, are at an increased risk for lung cancer.

Keywords: mild steel, welding, inhalation, iron, A/J mice

Introduction

Welding fumes were recently reclassified as *carcinogenic to humans* (Group 1) by the International Agency for Research on Cancer (IARC) based on strong epidemiological evidence and limited evidence in animals [1]. It is estimated that 11 million workers worldwide weld full-time and an additional 110 million have had some type of welding-related exposure [1]. Arc welding, including one type known as gas metal arc welding (GMAW), is the most common industrial welding process. In GMAW, an electric arc is established between a work piece and a consumable wire electrode [2, 3]. High temperatures create a molten pool into which the electrode is continuously fed and the work pieces are fused together as temperatures cool. While this process is the strongest method of joining metals, it creates a significant amount of welding fume. The composition of the fume largely depends on whether a stainless steel (SS) or mild steel (MS) electrode is used. GMAW-SS fume contains largely iron (Fe), chromium (Cr), nickel (Ni), copper (Cu), and manganese (Mn), whereas GMAW-MS contains primarily Fe and Mn. Most experimental studies have focused on the presumably more toxic Cr and Ni and largely overlooked Fe when examining pulmonary toxicity and/or carcinogenicity of welding fume. Importantly, many epidemiological studies suggest that both GMAW-SS and GMAW-MS are associated with increased risk of lung cancer, even though GMAW-MS exposure is predominantly limited to Fe and Mn [4, 5]. Some studies are conflicting, however [6]. Welding exposures are complex because of the diversity of welding modalities used in the workplace and the potential for confounders or additional occupational exposures [2, 7]. Welders often perform multiple types of welding processes throughout their working lifetime, further complicating epidemiological studies. Therefore, controlled animal studies are crucial to better understand which welding fumes and their component metals are the most toxic and have the greatest tumorigenic potential.

It was previously shown that GMAW-SS fume persists in the lung for 1.5 years and triggers mild, chronic inflammation in lung tumor-susceptible A/J mice compared to other welding fumes [8]. In a two-stage initiation-promotion model of lung tumorigenesis, GMAW-SS fume significantly increased lung tumor multiplicity after both an oropharyngeal aspiration and inhalation exposure in A/J mice [9, 10]. It was also demonstrated that GMAW-MS increased lung toxicity as measured by elevated lactate dehydrogenase (LDH) levels in mice 2 and 7 days after an oropharyngeal aspiration exposure [11]. However, GMAW-SS had a greater cytotoxic effect than GMAW-MS. Similarly, studies in rats have indicated that GMAW-MS seems to be less toxic than GMAW-SS [12-14]. Antonini et al. found that GMAW-MS caused no lung inflammation or lung injury in Sprague-Dawley rats 1, 4, or 11 days post-inhalation compared to GMAW-SS, which caused significant lung damage [12, 13].

It is well known that certain conditions associated with iron-overloaded states lead to an increased risk of cancer. While iron plays a vital role in redox reactions and as a cofactor for enzymatic reactions in the body, too much iron can increase cancer risk via the production of reactive oxygen species [15, 16]. Asbestosis, hemochromatosis, myelodysplastic syndromes, and endometriosis are all diseases in which there is iron excess and increased risk of cancer [17, 18]. Epidemiologic studies concerning iron oxide exposures and lung cancer are conflicting. An early study of iron ore miners found that these workers had a 70% greater mortality of lung cancer than the general population [19]. Yet, other reports suggest that iron oxide is not a human carcinogen [20, 21]. An early *in vivo* study by Campbell 1940 found an increase in lung carcinomas in mice exposed to iron oxide [22]. Regardless, *in vivo* studies investigating occupational exposures to iron oxides, as occurs with mild steel welding, are lacking. In this

study, we aimed to characterize the lung toxicity of GMAW-MS, which contains primarily Fe, and determine if it could promote lung tumors in mice following inhalation exposure.

Methods

Animals

Male A/J mice (age 4–5 week) were purchased from Jackson Laboratories (Bar Harbor, ME) and housed in an AAALAC International - specific pathogen-free, environmentally-controlled facility. All mice were free of endogenous pathogens including viruses, bacteria, mycoplasmas, and parasites. Mice were housed in groups of two in ventilated cages and provided high-efficiency particulate filtered air under a controlled light cycle (12 h light/12 h dark) at a standard temperature (22-24°C) and 30-70% relative humidity. Animals were acclimated to the animal facility for one week before beginning the experimental protocols and allowed access to a conventional diet (6% irradiated NIH-31 Diet, Envigo RMS, Inc.; Madison, WI) and tap water *ad libitum*. All procedures were performed using protocols approved by the National Institute for Occupational Safety and Health (NIOSH) Institutional Animal Care and Use Committee.

Welding fume inhalation exposure system

The design and construction of the welding fume aerosol generator were previously described [23]. This automated robotic welder continuously generated welding fumes by welding beads onto ¼ inch thick plates of mild steel. The welding wire used was 0.045 inch diameter Lincoln Electric Super Arc MIG L56 and the welding parameters were set to 25 volts DC, 300 inch per minute wire feed, 30 L/min of 95% argon – 5% CO₂ shielding gas, and a typical welding current of 220 amps. The resulting fume was carried into a whole body exposure chamber through a ¾ inch flexible tube by maintaining the chamber at a negative pressure (0.70 inch H₂O). Particle concentrations within the exposure chamber were continuously monitored

with a Data RAM (DR-40000 Thermo Electron Co; Franklin, MA), and gravimetric determinations (37 mm cassettes with 0.45 μm pore-size Teflon filters) were used to calibrate and verify the Data RAM readings each day. Gas generation, including carbon monoxide (CO), carbon dioxide (CO₂), oxygen (O₂), and ozone (O₃), was continuously monitored. During the welding exposure, O₂ levels were maintained above the OSHA minimal acceptable level. O₃, CO, CO₂ were below OSHA permissible exposure limits and NIOSH recommended exposure limits (REL) during the entire exposure duration. In the exposure chamber, CO and O₃ levels were not significantly higher than background. The exposure system was modified slightly from that described previously to reduce the travel time of the particulate fume from the welding torch to the exposure chamber [23].

Welding fume metal analysis

A small amount of welding fume was collected gravimetrically onto 47-mm Nucleopore polycarbonate filters (Whatman; Clinton, PA) for field emission scanning electron microscopy (FESEM) to assess particle size and morphology. The particles were imaged using a Hitachi S4800 Field Emission Scanning Electron Microscope (Hitachi; Tokyo, Japan). For elemental analysis of GMAW-MS fume, generated particles were collected inside the exposure chamber onto 5.0 μm polyvinyl chloride membrane filters in 37-mm cassettes during three 30 minute collections. The particle samples were digested and the metals were analyzed by inductively coupled plasma atomic emission spectroscopy according to the NIOSH method 7303 for hot block/HCL/HNO₃ digestion (NIOSH, 1994) as previously described [23]. Metal content of blank filters also were analyzed for control purposes.

Experimental protocol for whole lung metal analysis

Weight-matched A/J mice were exposed by whole-body inhalation in individual steel mesh cages to GMAW-MS welding aerosols (mean concentration 36.4 mg/m^3 over 4 hours) ($n = 10$) or filtered air ($n = 10$) (Figure 1A). Immediately following exposure (time zero), whole lungs were excised, trimmed, and lyophilized. The freeze-dried tissue was weighed then acid digested. Inductively coupled argon plasma atomic emission spectroscopy at NIOSH-Division of Applied Research and Technology (Cincinnati, OH) was used to determine the amount of Al, Cr, Cu, Fe, Mn, Ni, Zn present in the lung according to the NIOSH method 7300 modified to accommodate the sample matrix (NIOSH 2003).

Experimental protocol for two-stage lung carcinogenesis assay in A/J mice

For the two-stage initiation-promotion protocol, 120 mice were weight-matched and randomized into four exposure groups ($n = 30/\text{group}$). On day 1, mice were intraperitoneally (IP) injected with the chemical initiator, 3-methylcholanthrene (MCA) (Sigma-Aldrich; St. Louis, MO) dissolved in corn oil (CO) (Sigma-Aldrich; St. Louis, MO) at a dose of $10 \text{ } \mu\text{g/g}$ of body weight or CO alone (Figure 1B). MCA was chosen as the initiating agent based on the efficient response of the A/J mouse to this carcinogen in our previous oropharyngeal aspiration and inhalation studies [10, 24]. Beginning 1 week post-initiation, mice were exposed by whole-body inhalation to GMAW-MS aerosols or filtered air for 4 hours/day, 4 days/week, for 8 weeks at a target concentration of 40 mg/m^3 (actual mean concentration 34.5 mg/m^3 over 8 weeks). Throughout the study, mice were weighed biweekly including at the terminal sacrifice at 30-weeks post-initiation. Mice were euthanized with sodium pentobarbital [$100\text{-}300 \text{ mg/kg}$ IP] (Vortech Pharmaceuticals; Dearborn, MI), weighed, and exsanguinated via the vena cava. All internal organs were examined for the presence of tumors. Then, the whole lung was excised and inflated with 10% neutral buffered formalin. Twenty-four hours post-fixation, lung tumors were

counted. Lung tumor incidence was recorded as the percent of tumor-bearing mice out of the total. Lung tumor multiplicity was determined as the average tumor number per mouse lung including mice with no tumors. Any apparent merged tumors were counted as one tumor. Lungs were embedded in paraffin before a 5 μ m standardized section was cut and slides were made.

Slides were stained with hematoxylin and eosin, and a contracted, board-certified veterinary pathologist observed the slides in a blinded fashion for evidence of hyperplasia or neoplasia, inflammation, lymphoid tissue response, and foreign materials by light microscopy. The diagnosis of alveolar hyperplasia, adenoma, and adenocarcinoma was based upon well-established criteria [25]. If abnormal changes were found, severity was scored as: 1 = minimal, 2 = mild, 3 = moderate, 4 = marked. Severity of hyperplasia was graded based upon the overall size of the lesion, and ranged from small foci, which were graded as minimal, to large foci, which were graded as marked. The severity of the hyperplasia was recorded as the severity of the most severe lesion seen in each lung. The final severity score reflects the average of the right and left lung lobe scores and is presented as means $\pm$ standard error. Because bronchioloalveolar hyperplasia (BAH), bronchioloalveolar adenomas (BAA), and bronchioloalveolar adenocarcinomas (BAC) represent a continuum of the proliferative process, and there is possible overlap between these diagnoses, the numbers of lesions were combined to compare the tumorigenic potential of each treatment [25]. However, examination of a single histological section per lung underestimates the total number of lesions per lung, making the gross tumor count at time of sacrifice more indicative of the actual response [26].

Experimental protocol for bronchoalveolar lavage (BAL) and biochemical measurements of lung toxicity

For the BAL and lung toxicity protocol, 64 male A/J mice were exposed to filtered air or GMAW-MS fume at a target concentration of 40 mg/m³ (actual mean concentration 36.28 mg/m³) for 4 hours/day for 10 days (Figure 1C). Whole-lung BAL was used to assess lung injury and inflammation at 1, 7, 28, and 84 days post-exposure (n = 8 per treatment group per time point). Mice were anesthetized with sodium pentobarbital (100-300 mg/kg IP; Vortech Pharmaceuticals) then weighed. Once unresponsive, blood was drawn from the vena cava and serum was frozen at -80 °C. The mouse was then exsanguinated. For BAL, the trachea was cannulated with a blunted 22 gauge needle, and the thorax was massaged as 0.6 ml of cold calcium and magnesium-free phosphate buffered saline (PBS) was instilled into the lungs. The thorax was massaged for 10 seconds before the fluid was withdrawn and placed in a 15 ml conical tube. This consisted of the first lavage fraction. BAL was repeated 3 times using 1 ml of PBS per instillate and this second fraction was collected in a separate 15 ml conical tube. The BAL fluid was preserved on ice then centrifuged at 500 x g, 10 min, and 4°C. The acellular supernatant of the first lavage fraction was used to measure lactate dehydrogenase (LDH) activity, indicative of lung cytotoxicity. LDH activity was analyzed using a COBAS MIRA Plus auto-analyzer (Roche Diagnostic Systems; Montclair, NJ) which measured the oxidation of lactate to pyruvate coupled with the formation of NADH at 340 nm. The supernatant from the second lavage fraction was discarded. The cell pellets of both fractions were combined and resuspended in 800 µl of PBS. This final cell pellet was used for cell enumeration and differentials. For cell enumeration, cells were gently vortexed then combined in a 1:2 dilution with trypan blue (Sigma-Aldrich). The suspension was slowly mixed with a pipette and 10 µl was loaded onto the hemocytometer. The number of live cells in the four outer squares were recorded and cell concentration was calculated as: total cell count in 4 squares x 2500 x 2

(dilution factor). For cell differentials, cells were plated onto glass slides using a Cytospin 3 centrifuge (Shandon Life Sciences International; Cheshire, England) set at 800 rpm for 5 minutes. Slides were stained with Hema 3 Fixative and Solutions (Fisher Scientific; Pittsburgh, PA) then cover slipped. A minimum of 300 cells/slide were identified using light microscopy.

Statistical comparisons and analysis

Statistical analyses were performed using either JMP version 13, or SAS version 9.4 for Windows. Continuous variables were analyzed using treatment by day factorial analyses of variance (ANOVA), followed by Fishers LSD for pairwise comparisons. For some variables, a natural log transformation was performed on the data to reduce heterogeneous variance and meet the assumptions of an ANOVA. Score variables such as hyperplasia severity were analyzed using nonparametric Kruskal-Wallis tests and followed by pair-wise comparisons using the Wilcoxon Rank Sums test. Gross tumor counts and histopathology count data from sections were analyzed similarly. Tumor incidence was analyzed using a Chi-square test in SAS 'Proc Freq,' while tumor multiplicity was analyzed using Poisson regression in SAS 'Proc Genmod.' In cases where over dispersion existed, a negative binomial regression was performed. Analyses were performed independently on CO and MCA-treated animals, and only utilized data from those animals surviving to the 30-week time point. For all analyses, a p value of <0.05 was set as the criteria for significance.

Results

Welding fume characteristics

Scanning electron microscope (SEM) images of GMAW-MS fume are presented in Figure 2 and show the particles forming chain-like aggregates. GMAW-MS fume ranged in size from nanoparticles to larger, coarse particles with most particles between 0.1 to 1 μm in size.

The mass median aerodynamic diameter (MMAD) was 0.31 μm . Elemental analysis indicated that GMAW-MS was primarily Fe and Mn (Table 1). Fe content by weight percent averaged 83.67% and Mn was 14.33%. Approximately 2% of fume consisted of other trace metals.

Whole lung metal deposition after GMAW-MS fume inhalation

The lung metal deposition in A/J mice measured at time 0 after 4 hours of inhalation of GMAW-MS fume is shown in Table 2 and was calculated as done previously [24]. The most abundant metals measured were Fe (5.17 μg Fe/6.1 μg total metal deposition = 84.75%) and Mn (0.87 μg Mn/6.1 μg total metal deposition = 14.26%), which equates to the elemental analysis of the GMAW-MS fume shown in Table 1.

Human relevance deposition calculation:

The analysis of the metals showed a cumulative increase of 6.1 μg of total GMAW-MS fume deposited in the lung from a single 4 hour exposure (Table 2). The alveolar deposition in the mice was equated to the human by the equations below using the previous threshold limit value-time weighted average (TLV-TWA) of 5 mg/m^3 for total welding fume. Previously, we estimated that 70% of the total dose reached the alveolar space (6.1 $\mu\text{g}/\text{d}$ x 0.70 = 4.27 $\mu\text{g}/\text{d}$) [27, 28]. The mice were exposed for 32 days (8 weeks at 4 days/week) for an approximate total alveolar deposition of 136.64 μg .

Estimated human daily deposition using previous welding fume TLV-TWA of 5 mg/m^3 :

Fume concentration x min volume x exposure duration x deposition efficiency = deposited human dose

5 mg/m^3 x (20 l/min)(10⁻³ m³/l) x (8 hours/day)(60 minutes/hour) x 0.16 = 7.7 mg deposited per 8 hour day in humans

Estimated human equivalent deposition from quantified deposition in mouse using alveolar surface area (SA)[29]

$$(SA_{\text{human}} \times \text{deposition}_{\text{mouse}}) / SA_{\text{mouse}} = \text{deposition}_{\text{human}}$$

$$(102 \text{ m}^2 \times 0.13664 \text{ mg}) / 0.05 \text{ m}^2 = 278.75 \text{ mg}$$

278.75 mg / 7.7 mg/day = approximately 36 working days for a human working at 5 mg/m³ for 8 hours/day. While it is understood that welding is usually not done for 8 hours/day, and the exposure levels are likely not to consistently reach 5 mg/m³ as a TWA, the deposition in this study model was representative of cumulative exposure in a human.

Morbidity and mortality

Initial body weights at week 0 (means ± standard error [SE]) were 19.24 ± 0.30, 19.10 ± 0.28, 19.41 ± 0.27, and 19.18 ± 0.28 g for the CO/air, CO/GMAW-MS, MCA/air, and MCA/GMAW-MS groups, respectively. Body weights were not significantly changed due to exposure and increased steadily from week 0 to 30 with average net weight gains of 10.82, 10.28, 10.25, and 10.91 g for the CO/air, CO/GMAW-MS, MCA/air, and MCA/GMAW-MS groups, respectively. Morbidity and mortality throughout the study was low (~5 %) and no abnormalities, such as other tumor types besides lung, were found at the terminal sacrifice at 30 weeks. In total, 6 mice died during the course of the study and were not included in the final analysis of the data. The deaths were distributed equally among treatment groups. Necropsy determined that all 6 mice died from morbidities that included groin-associated skin lesions or a cause of death otherwise undetermined but not associated with the experimental protocol.

Gross tumor incidence and multiplicity

The total tumor number per mouse lung for each exposure group (lines indicate average gross-observed tumor multiplicity) is shown in Figure 3. GMAW-MS fume significantly promoted lung tumors in mice at 30 weeks after initiation with MCA. Lung tumor multiplicity was 8.34 ± 0.59 and 21.86 ± 1.50 for MCA/air and MCA/GMAW-MS, respectively ($p < 0.0001$). There was no effect of welding fume alone on tumor multiplicity (CO/air, 0.28 ± 0.11 ; CO/GMAW-MS, 0.18 ± 0.07 ; $p = 0.44$). Average tumor incidence (% of tumor-bearing mice) was 21% in CO/air and 17% in CO/GMAW-MS-exposed animals. Reports in the literature indicate the background tumor frequency in A/J mice between 43 and 53 weeks to be 31-40% [30, 31]. The mice in this study were 35 or 36 weeks old upon sacrifice, indicating the observed tumor incidence is consistent with reported findings. As expected, tumor incidence was 100% in all MCA-initiated groups ($n = 29$ for MCA/air and $n = 28$ MCA/GMAW-MS groups), which confirmed the successful administration as well as its carcinogenic effectiveness in A/J mice. Total and average tumor number per treatment group across each of the individual lung lobes are reported in Table 3. MCA/GMAW-MS-exposed mice had significantly greater lung tumor multiplicity in every lung region compared to MCA/air ($p < 0.05$).

Gross lung morphology from a GMAW-MS-exposed mouse initiated with MCA is shown in Figure 4. Welding fume deposition was visible in all exposed mouse lungs and appeared reddish to black-brown in color. Tumors appeared white in color and opaque on initial gross exam and became more well-defined after fixation which aided enumeration. At 30 weeks, tumors were between ~0.5 mm and ~4 mm in diameter, with most tumors ~1 mm. Mean tumor sizes were 1.14 ± 0.12 , 0.98 ± 0.20 , 1.14 ± 0.02 , and 1.19 ± 0.02 mm for CO/air, CO/GMAW-MS, MCA/air, and MCA/GMAW-MS, respectively.

Histopathological evaluation of lung lesions, inflammation, and welding fume presence

Severity scores for abnormal morphological findings and numbers of lung lesions observed in lung sections from A/J mice are shown in Table 4. Histopathology analysis confirmed the gross findings, with significantly greater lung tumor multiplicity in the MCA/GMAW-MS animals (9.86 ± 0.88) compared to MCA/air (3.34 ± 0.34), CO/GMAW-MS (0.14 ± 0.07), or CO/air animals (0.27 ± 0.12). In addition, two bronchioloalveolar adenocarcinomas were present in the MCA/GMAW-MS-exposed mice. None were observed in other treatment groups. Bronchiolo-alveolar adenomas and adenocarcinomas can arise from foci of alveolar hyperplasia [25]. Some of the adenomas in this study were solid discrete nodular masses, typical of adenoma, but the majority of the lesions diagnosed as adenomas arose within hyperplasias. Hyperplasias generally had irregular borders and consisted of alveoli lined by plump, round to ovoid to cuboidal epithelial cells that formed a single layer and, occasionally, small foci of hypercellularity, but still maintained the normal alveolar architecture (Figure 5A and 5B). Lesions were distinguished by focal nodular areas characterized by abnormal growth structure characteristic of adenoma, such as solid hypercellular areas and hypercellular papillary structures sometimes containing slightly atypical cells, that were clearly different from the adjacent areas of hyperplasia, resulting in disruption of the normal alveolar architecture (Figure 5C and 5D). This represented transition from hyperplasia to neoplasia and these lesions were diagnosed simply as bronchioloalveolar adenoma.

Foreign material, (i.e., GMAW-MS fume), was observed in the right and left lobes of nearly all MCA/GMAW-MS and CO/GMAW-MS-exposed lungs. The foreign material ranged in appearance from multiple, scattered small clusters of minute discrete focal aggregates of histiocytes to a few widely scattered individual histiocytes containing black intracytoplasmic granules. Foreign material was graded based upon the amount of accumulated material present

and was considered minimal in all cases. Unremarkable inflammation was observed in any of the treatment groups. No significant monocytic or lymphoid infiltrate was observed in any mouse lungs, indicating a lack of inflammation from GMAW-MS inhalation exposure.

BAL findings 1 day, 7 days, 28 days, and 84 days post-exposure to GMAW-MS fume

At 1 day post-exposure, cytotoxicity as measured by LDH levels was not significantly increased in GMAW-MS-exposed compared to air-exposed mice (111.10 ± 7.08 and 101.90 ± 4.65 U/L, respectively). The same result was found at 7, 28, and 84 days post-exposure (Table 5). In both the GMAW-MS fume and air-exposed groups, cell populations were $> 99\%$ AM. Similarly, slides from control animals typically contained $>99\%$ AM. A significant increase in macrophage cell number was seen in GMAW-MS-exposed mice at 28 and 84 days post-exposure ($p < 0.05$). No significant neutrophils, eosinophils, or lymphocytes were observed at any time point post-exposure (data not shown).

Discussion

This study demonstrated that GMAW-MS fume is a lung tumor promoter in A/J mice, despite a lack of significant chronic lung inflammation or the presence of known carcinogenic metals in the fume. Gross and histopathological examination revealed significantly increased lung tumor multiplicity in MCA/GMAW-MS-exposed mice compared to MCA/air controls. This tumor promotion effect was achieved at a lower fume deposition than our previous GMAW-SS oropharyngeal aspiration or inhalation studies [9, 10]. The results of this study support epidemiological findings that MS welders are still at increased risk of lung cancer despite absence of known carcinogens in the MS fume [4, 5].

Whole lung metal analysis revealed $6.1 \mu\text{g}$ of GMAW-MS fume was deposited after a single 4 hour exposure, which equates to an approximate total deposition of $136.64 \mu\text{g}$ in the alveolar region of the lung throughout the course of the exposure. In comparison, a previous

GMAW-SS inhalation study by Falcone et al. found a lung metal deposition of $\sim 10.1 \mu\text{g}$, or an approximate total deposition of $254.4 \mu\text{g}$ in the alveolar region [24]. This GMAW-MS deposition is approximately 46% lower than the GMAW-SS study, yet the tumor multiplicity after exposure to GMAW-MS was similar (21.86 ± 1.50 compared to 16.11 ± 1.18 , respectively).

GMAW-SS has been shown to induce a mild, chronic inflammation in the lung [11]. Histopathological analysis of mouse lung sections after GMAW-SS fume exposure revealed significantly increased perivascular and peribronchiolar mononuclear cell infiltrates [11]. In contrast, no significant lung inflammation or cytotoxicity was found in this study after a short-term GMAW-MS fume exposure. Histopathological analysis of lung sections showed no evidence of chronic inflammation. These findings agree with earlier occupational and rat MS welding fume studies [12, 32]. Despite the lack of overt inflammation following this exposure, substantial evidence indicates that tumor promotion and inflammation are often connected, and inflammation is considered an enabling hallmark of carcinogenesis [33-35]. Many carcinogens are now thought to cause both genetic and/or epigenetic changes that may lead to cancer. It is possible there may be an epigenetic effect occurring with welding fume exposures [36]. A number of metals such as nickel, cadmium, and arsenic, as well as exposure to substances like alcohol and cigarette smoke, are known to cause epigenetic changes such as DNA methylation and histone modification which can lead to the development of cancer [36, 37]. Totsuka et al. observed DNA damage and increased formation of DNA adducts in mice after exposure to iron oxide [38]. Epigenetic changes are now considered an important contributor to carcinogenesis and this may be an important area to investigate with welding fumes in the future. Indeed, stainless steel welding fume exposure has been shown to cause epigenetic changes (e.g., increased telomere length) in circulating peripheral blood monocytes of rats [39]. Similar studies

that examine these epigenetic effects in lung epithelial cells isolated from A/J mice after inhalation exposure to GMAW-MS fume are needed.

Although there was a lack of overt inflammation following *in vivo* exposure to GMAW-MS fume in this study, worker studies have indicated that welders are at increased risk of lobar pneumonia from *Streptococcus pneumoniae* infection as well as other lung infections [40-43]. A cross-sectional study of shipyard workers in the Middle East found that those exposed to welding fumes had a higher prevalence of respiratory symptoms and were more likely to report to healthcare professionals concerning respiratory infections [44]. Epidemiological studies have found that welders are at increased risk of developing and dying from pneumococcal and lobar pneumonia, suggesting a need for pneumococcal vaccination among welders [45]. According to prevailing hypotheses, the reasons for increased risk of infection in welders include the ability of Fe to act as a micronutrient for bacteria, inhibition of the immune system, and enhanced binding of *Streptococcus pneumoniae* to lung epithelial cells [41]. Recent research most strongly supports enhanced bacterial binding to lung epithelial cells as the primary mechanism for the increased *Streptococcal* infection risk [40, 42, 46]. Research concerning inhibition of the immune system is less consistent. A study investigating inflammatory markers in welders saw no inflammatory response nor a change in inflammatory markers that would be expected with an inhibited immune response [47]. Antonini et al. 2014 observed that pre-treatment of RAW 264.7 macrophages with GMA-MS had no effect on phagocytic function at 3 and 6 hours [48]. However, a later study by Antonini et al. found that inhalation of GMAW-MS fume suppressed lung defense responses following bacterial challenge in rats [12]. If GMAW-MS suppressed mouse lung defenses in this study, it is possible this represents a potential mechanism by which tumor promotion is occurring.

Even though GMAW-MS fume is composed of both Mn and Fe, the majority of studies in the literature suggest Mn as having primarily neurotoxic effects. These can potentially include Manganism and a Parkinson disease-like disorder in welders [2, 49, 50]. Studies have also indicated impairment in learning and memory in rats exposed to Mn [51, 52]. In contrast, it is widely accepted that Fe overload increases cancer risk, with evidence from Fe over-load diseases like hemochromatosis, mylodysplastic syndromes, and endometriosis in which Fe excess can contribute to the development of cancer [15, 18, 53, 54]. Fe overload has also been shown to be a contributory cause of pathogenesis in asbestos-induced mesothelioma [54]. Although Fe is a crucial micronutrient for the body, too much Fe can increase cancer risk via the production of reactive oxygen species. The Fe in welding fume is present as various forms of iron oxides, including Fe_2O_3 . Once inhaled, this Fe^{3+} could be reduced and then oxidized by the Fenton reaction to create hydroxyl radical. This radical can damage lipids and DNA leading to mutations that can cause cancer. Hydroxyl radical has also been shown to accelerate migratory and invasive capabilities of lung cancer cells and modulate signals that regulate cell transformation, increase apoptosis, and alter gene expression, although it is unclear if this is occurring in this study given the lack of overt inflammation [18, 55]. Fe homeostasis has also been shown to be associated with airway obstruction, with elevated serum ferritin corresponding to lower FEV_1/FVC ratios [56]. As Fe accumulates, it may progressively damage the airway and lungs, leading to obstructive disease as well as lead to accompanying diseases such as cancer and infections. In this study, we observed increased macrophages in the GMAW-MS-exposed mice at 28 and 84 days post-exposure which likely infiltrated into the lungs to clear the welding fume particles. Epidemiological evidence from numerous worker studies involving industrial exposures to iron oxides, such as iron ore mining, iron and steel founding, and welding, reveal increased cancer

risks in these populations [19, 57]. However, the results are conflicting, with some reports suggesting no increased cancer risk [21]. Iron oxide exposures are difficult to study in isolation, however, as many of these occupations also involve exposures to other cancer-causing materials such as radon, cigarette smoke, or known carcinogenic metals. Furthermore, *in vivo* inhalation studies of iron oxide exposures are scarce [58]. Because of limited evidence from “pure” human iron oxide exposures, iron oxide is currently not classified as carcinogenic to humans according to the IARC [57].

In conclusion, this study is the first to demonstrate that GMAW-MS fume, despite containing no metals currently classified as carcinogens, promotes lung tumors in A/J mice. Future studies in our laboratory will investigate the toxicity and tumorigenic potential of the individual metal components of GMAW-SS and GMAW-MS fumes. Results of these studies may help to identify the metal components that are most toxic and tumorigenic. Ultimately, a more complete understanding of the toxicity and tumorigenic potential of the welding fume components can lead to a safer work environment for welders.

Bibliography

1. Guha N, Loomis D, Guyton KZ, Grosse Y, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, Vilahur N, Muller K, Straif K: **Carcinogenicity of welding, molybdenum trioxide, and indium tin oxide.** *Lancet Oncol* 2017, **18**:581-582.
2. Antonini JM: **Health Effects Associated with Welding.** 2014:49-70.
3. *The Procedure Handbook of Arc Welding.* 14 edn. The James F. Lincoln Arc Welding Foundation; 2000.
4. Hansen KS, Lauritsen JM, Skytthe A: **Cancer incidence among mild steel and stainless steel welders and other metal workers.** *Am J Ind Med* 1996, **30**:373-382.

5. Lauritsen JM, Hansen KS: **Lung cancer mortality in stainless steel and mild steel welders: a nested case-referent study.** *Am J Ind Med* 1996, **30**:383-391.
6. Sorensen AR, Thulstrup AM, Hansen J, Ramlau-Hansen CH, Meersohn A, Skytthe A, Bonde JP: **Risk of lung cancer according to mild steel and stainless steel welding.** *Scand J Work Environ Health* 2007, **33**:379-386.
7. Matrat M, Guida F, Mattei F, Cenee S, Cyr D, Fevotte J, Sanchez M, Menvielle G, Radoi L, Schmaus A, et al: **Welding, a risk factor of lung cancer: the ICARE study.** *Occup Environ Med* 2016, **73**:254-261.
8. Zeidler-Erdely PC, Battelli LA, Stone S, Chen BT, Frazer DG, Young SH, Erdely A, Kashon ML, Andrews R, Antonini JM: **Short-term inhalation of stainless steel welding fume causes sustained lung toxicity but no tumorigenesis in lung tumor susceptible A/J mice.** *Inhal Toxicol* 2011, **23**:112-120.
9. Falcone LM, Erdely A, Meighan TG, Battelli LA, Salmen R, McKinney W, Stone S, Cumpston A, Cumpston J, Andrews RN, et al: **Inhalation of gas metal arc-stainless steel welding fume promotes lung tumorigenesis in A/J mice.** *Arch Toxicol* 2017, **91**:2953-2962.
10. Zeidler-Erdely PC, Meighan TG, Erdely A, Battelli LA, Kashon ML, Keane M, Antonini JM: **Lung tumor promotion by chromium-containing welding particulate matter in a mouse model.** *Part Fibre Toxicol* 2013, **10**:45.
11. Zeidler-Erdely PC, Kashon ML, Battelli LA, Young SH, Erdely A, Roberts JR, Reynolds SH, Antonini JM: **Pulmonary inflammation and tumor induction in lung tumor susceptible A/J and resistant C57BL/6J mice exposed to welding fume.** *Part Fibre Toxicol* 2008, **5**:12.

12. Antonini JM, Roberts JR, Stone S, Chen BT, Schwegler-Berry D, Frazer DG: **Short-term inhalation exposure to mild steel welding fume had no effect on lung inflammation and injury but did alter defense responses to bacteria in rats.** *Inhal Toxicol* 2009, **21**:182-192.
13. Antonini JM, Stone S, Roberts JR, Chen B, Schwegler-Berry D, Afshari AA, Frazer DG: **Effect of short-term stainless steel welding fume inhalation exposure on lung inflammation, injury, and defense responses in rats.** *Toxicol Appl Pharmacol* 2007, **223**:234-245.
14. Taylor MD, Roberts JR, Leonard SS, Shi X, Antonini JM: **Effects of welding fumes of differing composition and solubility on free radical production and acute lung injury and inflammation in rats.** *Toxicol Sci* 2003, **75**:181-191.
15. Manz DH, Blanchette NL, Paul BT, Torti FM, Torti SV: **Iron and cancer: recent insights.** *Ann N Y Acad Sci* 2016, **1368**:149-161.
16. Andrews NC: **Iron homeostasis: insights from genetics and animal models.** *Nat Rev Genet* 2000, **1**:208-217.
17. Akatsuka S, Toyokuni S: **[Iron function and carcinogenesis].** *Nihon Rinsho* 2016, **74**:1168-1175.
18. Steegmann-Olmedillas JL: **The role of iron in tumour cell proliferation.** *Clin Transl Oncol* 2011, **13**:71-76.
19. Boyd JT, Doll R, Faulds JS, Leiper J: **Cancer of the lung in iron ore (haematite) miners.** *Br J Ind Med* 1970, **27**:97-105.

20. Pease C, Rucker T, Birk T: **Review of the Evidence from Epidemiology, Toxicology, and Lung Bioavailability on the Carcinogenicity of Inhaled Iron Oxide Particulates.** *Chem Res Toxicol* 2016, **29**:237-254.
21. Bourgkard E, Wild P, Courcot B, Diss M, Ettlinger J, Goutet P, Hemon D, Marquis N, Mur JM, Rigal C, et al: **Lung cancer mortality and iron oxide exposure in a French steel-producing factory.** *Occup Environ Med* 2009, **66**:175-181.
22. Campbell JA: **Effects of Precipitated Silica and of Iron Oxide on the Incidence of Primary Lung Tumours in Mice.** *Br Med J* 1940, **2**:275-280.
23. Antonini JM, Afshari AA, Stone S, Chen B, Schwegler-Berry D, Fletcher WG, Goldsmith WT, Vandestouwe KH, McKinney W, Castranova V, Frazer DG: **Design, construction, and characterization of a novel robotic welding fume generator and inhalation exposure system for laboratory animals.** *J Occup Environ Hyg* 2006, **3**:194-203; quiz D145.
24. Falcone LM, Erdely A, Meighan TG, Battelli LA, Salmen R, McKinney W, Stone S, Cumpston A, Cumpston J, Andrews RN, et al: **Inhalation of gas metal arc-stainless steel welding fume promotes lung tumorigenesis in A/J mice.** *Arch Toxicol* 2017.
25. Renne R, Brix A, Harkema J, Herbert R, Kittel B, Lewis D, March T, Nagano K, Pino M, Rittinghausen S, et al: **Proliferative and nonproliferative lesions of the rat and mouse respiratory tract.** *Toxicol Pathol* 2009, **37**:5s-73s.
26. Rehm S, Ward JM: **Quantitative analysis of alveolar type II cell tumors in mice by whole lung serial and step sections.** *Toxicol Pathol* 1989, **17**:737-742.
27. Erdely A, Hulderman T, Salmen-Muniz R, Liston A, Zeidler-Erdely PC, Chen BT, Stone S, Frazer DG, Antonini JM, Simeonova PP: **Inhalation exposure of gas-metal arc**

- stainless steel welding fume increased atherosclerotic lesions in apolipoprotein E knockout mice.** *Toxicol Lett* 2011, **204**:12-16.
28. Raabe OG, Al-Bayati, M.A., Teague, S.V., Rasolt, A., : **Regional deposition of inhaled monodisperse coarse and fine aerosol particles in small laboratory animals.** *Ann Occup Hyg* 1988, **32**:53-63.
 29. Stone KC, Mercer RR, Gehr P, Stockstill B, Crapo JD: **Allometric relationships of cell numbers and size in the mammalian lung.** *Am J Respir Cell Mol Biol* 1992, **6**:235-243.
 30. Groch KM, Khan MA, Brooks AL, Saffer JD: **Lung cancer response following inhaled radon in the A/J and C57BL/6J mouse.** *Int J Radiat Biol* 1997, **71**:301-308.
 31. Curtin GM, Higuchi MA, Ayres PH, Swauger JE, Mosberg AT: **Lung tumorigenicity in A/J and rasH2 transgenic mice following mainstream tobacco smoke inhalation.** *Toxicol Sci* 2004, **81**:26-34.
 32. Antonini JM: **Health effects of welding.** *Crit Rev Toxicol* 2003, **33**:61-103.
 33. Hanahan D, Weinberg RA: **Hallmarks of cancer: the next generation.** *Cell* 2011, **144**:646-674.
 34. Fujiki H, Sueoka E, Suganuma M: **Tumor promoters: from chemicals to inflammatory proteins.** *J Cancer Res Clin Oncol* 2013, **139**:1603-1614.
 35. Fujiki H, Suganuma M, Okabe S, Sueoka E, Suga K, Imai K, Nakachi K: **A new concept of tumor promotion by tumor necrosis factor-alpha, and cancer preventive agents (-)-epigallocatechin gallate and green tea--a review.** *Cancer Detect Prev* 2000, **24**:91-99.

36. Herceg Z, Lambert MP, van Veldhoven K, Demetriou C, Vineis P, Smith MT, Straif K, Wild CP: **Towards incorporating epigenetic mechanisms into carcinogen identification and evaluation.** *Carcinogenesis* 2013, **34**:1955-1967.
37. Chappell G, Pogribny IP, Guyton KZ, Rusyn I: **Epigenetic alterations induced by genotoxic occupational and environmental human chemical carcinogens: A systematic literature review.** *Mutat Res Rev Mutat Res* 2016, **768**:27-45.
38. Totsuka Y, Ishino K, Kato T, Goto S, Tada Y, Nakae D, Watanabe M, Wakabayashi K: **Magnetite Nanoparticles Induce Genotoxicity in the Lungs of Mice via Inflammatory Response.** *Nanomaterials (Basel)* 2014, **4**:175-188.
39. Shoeb M, Kodali VK, Farris BY, Bishop LM, Meighan TG, Salmen R, Eye T, Friend S, Schwegler-Berry D, Roberts JR, et al: **Oxidative stress, DNA methylation, and telomere length changes in peripheral blood mononuclear cells after pulmonary exposure to metal-rich welding nanoparticles.** *NanoImpact* 2017, **5**:61-69.
40. Coggon D, Inskip H, Winter P, Pannett B: **Lobar pneumonia: an occupational disease in welders.** *Lancet* 1994, **344**:41-43.
41. Coggon D, Palmer KT: **Are welders more at risk of respiratory infections?** *Thorax* 2016, **71**:581-582.
42. Suri R, Periselneris J, Lanone S, Zeidler-Erdely PC, Melton G, Palmer KT, Andujar P, Antonini JM, Cohignac V, Erdely A, et al: **Exposure to welding fumes and lower airway infection with *Streptococcus pneumoniae*.** *J Allergy Clin Immunol* 2016, **137**:527-534.e527.
43. Zeidler-Erdely PC, Erdely A, Antonini JM: **Immunotoxicology of arc welding fume: worker and experimental animal studies.** *J Immunotoxicol* 2012, **9**:411-425.

44. Marongiu A, Hasan O, Ali A, Bakhsh S, George B, Irfan N, Minelli C, Canova C, Schofield S, De Matteis S, Cullinan P: **Are welders more at risk of respiratory infections? Findings from a cross-sectional survey and analysis of medical records in shipyard workers: the WELSHIP project.** *Thorax* 2016, **71**:601-606.
45. Coggon D, Harris EC, Cox V, Palmer KT: **Pneumococcal vaccination for welders.** *Thorax* 2015, **70**:198-199.
46. Wong A, Marrie TJ, Garg S, Kellner JD, Tyrrell GJ: **Welders are at increased risk for invasive pneumococcal disease.** *Int J Infect Dis* 2010, **14**:e796-799.
47. Palmer KT, McNeill Love RM, Poole JR, Coggon D, Frew AJ, Linaker CH, Shute JK: **Inflammatory responses to the occupational inhalation of metal fume.** *Eur Respir J* 2006, **27**:366-373.
48. Antonini JM, Badding MA, Meighan TG, Keane M, Leonard SS, Roberts JR: **Evaluation of the Pulmonary Toxicity of a Fume Generated from a Nickel-, Copper-Based Electrode to be Used as a Substitute in Stainless Steel Welding.** *Environ Health Insights* 2014, **8**:11-20.
49. Laohaudomchok W, Lin X, Herrick RF, Fang SC, Cavallari JM, Shrairman R, Landau A, Christiani DC, Weisskopf MG: **Neuropsychological effects of low-level manganese exposure in welders.** *Neurotoxicology* 2011, **32**:171-179.
50. Roels HA, Bowler RM, Kim Y, Claus Henn B, Mergler D, Hoet P, Gocheva VV, Bellinger DC, Wright RO, Harris MG, et al: **Manganese exposure and cognitive deficits: a growing concern for manganese neurotoxicity.** *Neurotoxicology* 2012, **33**:872-880.

51. Liang G, Qin H, Zhang L, Ma S, Huang X, Lv Y, Qing L, Li Q, Xiong Y, Huang Y, et al: **Effects of chronic manganese exposure on the learning and memory of rats by observing the changes in the hippocampal cAMP signaling pathway.** *Food Chem Toxicol* 2015, **83**:261-267.
52. Shukakidze A, Lazriev I, Mitagvariya N: **Behavioral impairments in acute and chronic manganese poisoning in white rats.** *Neurosci Behav Physiol* 2003, **33**:263-267.
53. Zhang C, Zhang F: **Iron homeostasis and tumorigenesis: molecular mechanisms and therapeutic opportunities.** *Protein Cell* 2015, **6**:88-100.
54. Jiang L, Chew SH, Nakamura K, Ohara Y, Akatsuka S, Toyokuni S: **Dual preventive benefits of iron elimination by desferal in asbestos-induced mesothelial carcinogenesis.** *Cancer Sci* 2016, **107**:908-915.
55. Luanpitpong S, Talbott SJ, Rojanasakul Y, Nimmannit U, Pongrakhananon V, Wang L, Chanvorachote P: **Regulation of lung cancer cell migration and invasion by reactive oxygen species and caveolin-1.** *J Biol Chem* 2010, **285**:38832-38840.
56. Ghio AJ, Hilborn ED: **Indices of iron homeostasis correlate with airway obstruction in an NHANES III cohort.** *Int J Chron Obstruct Pulmon Dis* 2017, **12**:2075-2084.
57. Wild P, Bourgkard E, Paris C: **Lung cancer and exposure to metals: the epidemiological evidence.** *Methods Mol Biol* 2009, **472**:139-167.
58. Kornberg TG, Stueckle TA, Antonini JA, Rojanasakul Y, Castranova V, Yang Y, Wang L: **Potential Toxicity and Underlying Mechanisms Associated with Pulmonary Exposure to Iron Oxide Nanoparticles: Conflicting Literature and Unclear Risk.** *Nanomaterials (Basel)* 2017, **7**.

Figure 1. Timelines of experimental protocols. Panel A – Experimental protocol for whole lung metal analysis. Mice were exposed by whole-body inhalation to filtered air (n = 10) or GMAW-MS fume (n = 10) for 4 hours/day for 10 days. Inductively coupled argon plasma, atomic emission spectroscopy was used to analyze metal content of lungs. Panel B - Experimental protocol for two-stage (initiation-promotion) bioassay. Mice received MCA (n = 60) or corn oil (n = 60) injections and beginning 1 week later were exposed to GMAW-MS or air inhalation 4 hours/day x 4 day/week x 8 weeks before terminal sacrifice at 30 weeks. Panel C - Experimental protocol for whole lung bronchoalveolar lavage (BAL). Sixty-four mice were exposed to GMAW-MS or air for 4 hours/day for 10 days. Whole lung BAL was used to assess lung injury and inflammation at 1 day, 7 days, 28 days, and 84 days post-exposure (n = 8 per treatment group per time point).

Figure 2. SEM images of GMAW-MS fume. Particles form small clustered aggregates ranging in size from less than 0.01 μm to over 1 μm , with a mass median aerodynamic diameter of 0.31 μm . [12] Primary particles were mainly in the nanometer size range and primarily composed of iron (83.67%) and manganese (14.33%).

Figure 3. Average tumor number per mouse lung (tumor multiplicity) upon gross examination in A/J mice following initiation-promotion study at 30 week sacrifice.

MCA/GMAW-MS significantly increased lung tumor number compared to air controls (21.86 ± 1.50 vs 8.34 ± 0.59 , respectively). As expected, mice not initiated with MCA had low tumor number. Horizontal bars represent mean tumor numbers per group. Circles = CO/Air, squares = MCA/air, upward triangles = MCA/air, downward triangles = MCA/GMAW-MS. $*p < 0.0001$ – compared to CO/air; $**p < 0.0001$ – compared to MCA/air

Figure 4. Gross images of A/J mouse lung promoted by GMAW-MS 30 weeks post-initiation with MCA. Panel A – Lung tumor morphology before fixation. Panel B – Lung tumors 24 hours after fixation. Fixation allows for more accurate enumeration of tumors. Tumors (arrows) were on average ~1 mm in diameter and opaque in color.

Figure 5. Photomicrographs of lung tissue from MCA/GMAW-MS exposed mice. Panel A- moderate bronchioloalveolar hyperplasia, 4x magnification. Panel B – moderate bronchioloalveolar hyperplasia, 10x magnification. Panel C – bronchioloalveolar adenoma as a solid discrete mass, 10x magnification. Panel D - bronchioloalveolar adenoma, 20x magnification.

Tables

Table 1. Metal composition of GMAW-MS fume

Metals Analyzed	Weight % of Metals
Fe	83.67 ± 0.47
Mn	14.33 ± 0.37
Cu	0.13 ± 0.03

GMAW-MS fume was analyzed for aluminum (Al), chromium (Cr), copper (Cu), iron (Fe), manganese (Mn), nickel (Ni), silicon (Si), titanium (Ti), vanadium (V), and zinc (Zn) by Inductively Coupled Plasma-Atomic Emission Spectroscopy. Samples were prepared according to the NIOSH method 7303 modified for microwave digestion. Trace amounts of Al, Cr, Ni, Si, Ti, and V were found. *Note:* Values are mean $\pm$ standard error of the mean (n = 3 welding fume collection periods of 30 minutes). Weight % is relative to all metals analyzed. GMAW-MS – gas metal arc welding-mild steel.

Table 2. Lung metal deposition in A/J mice after air or GMAW-MS fume inhalation for 4 hours at a concentration of 36.4 mg/m³

Exposure	Fe (µg/lung)	Mn (µg/lung)	Cu (µg/lung)
Air	9.45 ± 0.29	0.01 ± 0.00	0.23 ± 0.01
GMAW-MS	14.62 ± 0.45	0.88 ± 0.05	0.29 ± 0.01

Freeze-dried whole lung tissue was analyzed for aluminum (Al), chromium (Cr), copper (Cu), iron (Fe), manganese (Mn), nickel (Ni), titanium (Ti), and zinc (Zn) by Inductively Coupled Plasma-Atomic Emission Spectroscopy. Samples were prepared according to the NIOSH method 7300 for bulk tissue samples. Levels of Al, Cr, Ni, Ti, and Zn were not significantly increased in exposed animals or not detected. *Note:* Values are mean ± standard error of the mean (n=10 air; n=10 GMAW-MS); GMAW-MS – gas metal arc welding-mild steel.

Table 3. Total and average (in parenthesis) tumor number in A/J mice across each of the individual lung lobes following GMAW-MS or air exposure 30 weeks post-initiation with MCA or corn oil.

	n	Left	Apical	Cardiac	Diaphragmatic	Azygos
CO/air	29	4 (0.14 ± 0.07)	2 (0.07 ± 0.05)	0	1 (0.03 ± 0.03)	1 (0.03 ± 0.03)
CO/GMA-MS	28	3 (0.12 ± 0.06)	0	0	1 (0.04 ± 0.04)	1 (0.04 ± 0.04)
MCA/air	29	81 (2.79 ± 0.32)**	28 (0.97 ± 0.16)**	37 (1.28 ± 0.24)**	67 (2.31 ± 0.29)**	29 (1.00 ± 0.16)**
MCA/GMA-MS	28	226 (8.07 ± 0.74)*	77 (2.75 ± 0.31)*	77 (2.75 ± 0.36)*	187 (6.68 ± 0.48)*	45 (1.61 ± 0.28)^

CO – corn oil, GMAW-MS – gas metal arc welding – mild steel, MCA – 3-methylchloanthrene

*p < 0.0001 - compared to MCA/air, ** p < 0.0001 - compared to CO/air, ^ p < 0.05 - compared to MCA/air

Table 4. Lung histopathological findings including number of microscopically observed lung lesions at 30 weeks post-initiation with MCA or CO in A/J mice exposed to GMAW-MS fume or filtered air by inhalation

	n	Foreign Material [^]	Hyperplasia Severity [^]	Hyperplasia [#]	Adenoma [#]	Adenocarcinoma [#]	Total Lesions [#]
CO/air	15	--	0.1 ± 0.05	0.2 ± 0.11 (3)	0.07 ± 0.07 (1)	--	0.27 ± 0.12 (4)
CO/GMAW-MS	28	0.91 ± 0.05**	0.02 ± 0.02	0.07 ± 0.05 (2)	0.07 ± 0.05 (2)	--	0.14 ± 0.07 (4)
MCA/air	29	0.02 ± 0.02	1.79 ± 0.18**	2.93 ± 0.34 (85)**	0.41 ± 0.13 (12) [‡]	--	3.34 ± 0.34 (97)**
MCA/GMAW-MS	28	0.96 ± 0.02*	2.55 ± 0.16*	7.11 ± 0.64 (199)*	2.67 ± 0.36 (75)*	0.07 ± 0.05 (2)	9.86 ± 0.86 (276)*

GMAW-MS – gas metal arc welding – mild steel, MCA – 3 – methylcholanthrene, CO – corn oil

[^]Severity scores are the averages of the left and right lung lobes and are presented as mean ± standard error. Foreign material refers to presence of presumptive GMAW-MS fume (brown-black pigment) in the lungs. Severity was scored as 1 = minimal, 2 = mild, 3 = moderate, 4 = marked.

[#]Hyperplasias, adenomas, and adenocarcinomas are presented as mean ± standard error with total lesion number in parenthesis.

-- indicates no findings

* p < 0.0001 compared to MCA/air, **p < 0.0001 compared to CO/air, ‡p < 0.02 compared to CO/air

Table 5. Bronchoalveolar lavage parameters after exposure to air or GMAW-MS fume at a concentration 36.28 mg/m^3 for 4 hours/day for 10 days

Exposure	Time Point (days)	n	LDH (U/L)	Macrophages (BAL cell #/ml)
Air	1	8	101.90 ± 4.65	414286 ± 23234
GMAW-MS		8	111.10 ± 7.08	442500 ± 40820
Air	7	8	91.80 ± 4.06	452500 ± 28800
GMAW-MS		8	100.50 ± 2.86	411021 ± 33726
Air	28	8	84.30 ± 4.42	282500 ± 54052
GMAW-MS		8	85.10 ± 6.00	$491250 \pm 67445^*$
Air	84	8	103.70 ± 6.57	327143 ± 47193
GMAW-MS		8	84.50 ± 2.41	$520000 \pm 56901^*$

Total bronchoalveolar (BAL) lavage differential based on cell count of >300 cells.

Lymphocytes, neutrophils, and eosinophils were absent from BAL and excluded from the table.

Data are means $\pm$ SE. – indicates no findings. Abbreviations: GMAW-SS - gas metal arc welding - mild steel. LDH – lactate dehydrogenase. $*p < 0.05$.

Figures.

Figure 1.

Figure 2.

Figure 4.

Figure 5.

Chapter 5: Pulmonary Toxicity and Lung Tumorigenic Potential of Metal Oxides in Gas Metal Arc – Stainless Steel Welding Fume: Iron Oxide as a Lung Tumor Promoter

Lauryn M Falcone^{1,2}, Aaron Erdely^{1,2}, Rebecca Salmen¹, Lori Battelli¹, Michael Keane¹, Vamsi Kodali¹, Lauren Bowers³, Aleksandr B Stefaniak³, Michael L Kashon¹, James M Antonini¹, Patti C Zeidler-Erdely^{1,2}

¹Health Effects Laboratory Division, National Institute for Occupational Safety and Health, Morgantown, WV; ²West Virginia University, School of Medicine, Morgantown, WV;

³Respiratory Health Division, National Institute for Occupational Safety and Health, Morgantown, WV

Abstract

In 2017, the International Agency for Research on Cancer classified welding fumes as “carcinogenic to humans” (Group 1). Only some of the metals found in welding fume are considered pneumotoxic or carcinogenic, however. The objectives of this study were (1) to compare the pulmonary toxicity of chromium (as chromium [III] oxide or Cr_2O_3 and calcium chromate [Cr VI] as CaCrO_4), nickel [II] oxide (NiO), iron [III] oxide (Fe_2O_3), and gas metal arc welding-stainless steel (GMAW-SS) fume; and (2) determine if these metal oxides can promote lung tumors in A/J mice, a lung tumor susceptible strain. Male A/J mice (4–5 weeks) were exposed by oropharyngeal aspiration to a suspension of GMAW-SS fume at a cumulative dose (1.7 mg) that was previously found to promote lung tumors or a low or high dose of metal oxides based on the respective weight percent of each metal in the fume: $\text{Cr}_2\text{O}_3/\text{CaCrO}_4$ (366/5 μg and 731/11 μg), NiO (141 and 281 μg), or Fe_2O_3 (1 and 2 mg). Shams were exposed to 50 μl PBS (vehicle). Bronchoalveolar lavage, histopathology, and lung/liver qPCR were done at 1, 7, 28, and 84 days post-aspiration. In a separate study of two-stage lung carcinogenesis, mice received corn oil or 3-methylcholanthrene (10 $\mu\text{g/g}$; IP) and then were exposed by oropharyngeal aspiration to metal oxides or PBS (1 x/week for 5 weeks; cumulative dose for each metal equaled high dose from toxicity study). Lung tumor incidence and multiplicity were evaluated at 30 weeks post-initiation. GMAW-SS-induced lung cytotoxicity and inflammatory cell influx was significantly greater than any individual metals through 84 days post-exposure. The metals, therefore, may have a synergistic effect on lung toxicity and inflammation. Among the metal oxides, Fe_2O_3 was the most pneumotoxic and the only metal that significantly promoted lung tumors in mice.

Introduction

Nearly half of all U.S. products require welding for their production and there are millions of welders worldwide[1]. Welding, the strongest method of joining metals, is therefore a common industrial practice, with gas metal arc welding (GMAW) being among the most popular modalities. In GMAW, an electric arc is established between the work piece and a consumable electrode, often mild or stainless steel (MS or SS). High temperatures create a molten pool into which the electrode is fed and the work pieces fuse as the weld cools. Arc welding processes can generate a significant amount of welding fume- vaporized metals that react with air to form metal oxides particles that are respirable. The fume may contain particles from the base metal, wire/electrode, and coatings on the base metal or electrode.

Welding fumes have known adverse human health effects [2-4]. In 2017, the International Agency for Research on Cancer (IARC) classified welding fumes as a Group 1 (*carcinogenic to humans*) [1]. This classification was based on sufficient epidemiological evidence for an increased risk of lung cancer in welders even after adjustment for smoking and/or asbestos that potentially confound these studies. Positive associations were found for welding on SS which generate fumes that contains carcinogenic metals [i.e., chromium (Cr), nickel (Ni)] and MS welding where the fume is primarily oxides of iron (Fe) and manganese (Mn) [5-8]. Animal evidence for the carcinogenicity of welding fumes is limited, however. In a two-stage (initiation-promotion) model of lung carcinogenesis, inhalation and oropharyngeal aspiration of GMAW-SS fume promoted lung tumors in mice. Previous experimental evidence in mice showed that GMAW-SS persists in the lungs and causes a chronic, mild inflammatory response compared to GMAW-MS or manual metal arc (MMA)-SS fumes [9]. It is unknown which metal components of the fume are responsible for its toxic and tumorigenic effects.

Welding fume currently has no occupational exposure limit as the former Threshold Limit Value® of 5 mg/m³ as an 8-hour time-weighted average was retracted [10]. In the workplace, more emphasis is placed on regulating the exposure to the most toxic metals contained in the fume (i.e., Cr or Ni). The first aim of this study was to compare the pulmonary toxicity of metal oxides found in GMAW-SS fume. The second aim was to investigate the potential of those metals to promote lung tumors in A/J mice to gain an understanding of the metals that drive the carcinogenicity of SS fume. Minimizing the hazardous components of the welding fume could offer a better approach for maintaining welder health and safety as sustained inflammation and oxidative stress along with persistence of toxic components are likely key to lung tumorigenesis.

Methods

Animals

Male A/J mice, 4 to 5 weeks of age, were housed in an AAALAC International, specific pathogen-free, environmentally-controlled facility in groups of 2 as previously described [11]. All procedures were performed using protocols approved by the National Institute for Occupational Safety and Health (NIOSH) Institutional Animal Care and Use Committee.

GMAW-SS fume generation and metal oxide characterization

The welding fume used in this study was generated by the NIOSH robotic welder [12]. The individual metal oxides utilized were Cr₂O₃ (product number 393703; 151.99 g/mol), CaCrO₄ (product number CDS001277; 156.07 g/mol), NiO (product number 203882; 74.69 g/mol), and Fe₂O₃ (product number 310050; 159.69 g/mol) and were purchased from Sigma-Aldrich (St. Louis, MO). Specific surface area (m²/g) of the powders was determined using nitrogen gas adsorption (ASAP 2020, Micromeritics Instrument Corporation, Norcross, GA).

Cr₂O₃, NiO, GMAW-SS, or Fe₂O₃ powder was added to separate sample tubes and degassed under light vacuum at 300 °C for 2 hours then allowed to cool. CaCrO₄ was degassed using the same procedure, but was held at 80 °C for 6 hrs. A value of $1.62 \times 10^{-19} \text{ m}^2$ was used for the molecular cross-sectional area of N₂ at 77 K and surface area was calculated from at least five adsorption points in the range $p/p^0 = 0.01$ to 0.3. Measurements were repeated 4 times for each sample except GMAW-SS, which was repeated twice. Hydrodynamic diameter and zeta potential of each study material were determined using dynamic light scattering (DLS) and laser Doppler electrophoresis, respectively (Zetasizer ZS90, Malvern Instruments, Worcestershire, UK) following dispersion in the PBS dosing medium. The pH of each sample was measured before each run using a SevenMulti calibrated electrode (Mettler-Toledo, LLC, Columbus, OH). All measurements were made at 25 °C. Parameters of the dispersant were as follows: refractive index = 1.334, viscosity = 0.9110 cP, dielectric constant = 80.2, and Henry function approximation of 1.5. Material-specific refractive index and absorbance values were used for each metal oxide. Certain metal oxides were too polydisperse for size measurement via DLS and were instead analyzed using nanoparticle tracking analysis (NTA) (NanoSight NS300, Malvern Instruments, Worcestershire, UK) to characterize mean hydrodynamic particle size (nm). For NTA analysis, the samples were injected through a Low Volume Flow Cell (LVFC) and measured at room temperature. Camera levels in the NTA instrument varied with each sample to insure accurate particle characterization. Each sample was captured 5 times for 60 seconds.

GMAW-SS fume and metal oxide preparation

Previous metal analyses of GMAW-SS have shown that the metal content of the fume is 57% Fe, 20.2% Cr, 13.8% Mn, 8.8% Ni, and 0.2% Cu [12, 13]. These metals are present in the fume as metal oxides which were volatilized from the electrode/rod during welding and then

reacted with air to form particles. However, the Cr component of the fume consists of both Cr^{3+} and Cr^{6+} , with approximately 0.29% as Cr^{6+} [13]. Therefore, for this study, mice were exposed to a low or high dose of Ni as NiO, Fe as Fe_2O_3 , and Cr as a mixture of $\text{Cr}_2\text{O}_3/\text{CaCrO}_4$. Mn and Cu were not investigated as they are not known to be carcinogenic to humans or cause lung disease. To calculate the doses in this study, the following formula was used:

$$\text{Mass of metal oxide}_i (\text{g}) = \frac{\sum \text{mass of metals (g)}}{\text{mass of fume (g)}} \times \left(\frac{\text{mass of metal oxide}_i (\text{g})}{\sum \text{mass of metals (g)}} \times 100 \right) \times \text{fume dose (g)} \times \frac{\text{Molecular weight of metal oxide}_i (\frac{\text{g}}{\text{mol}})}{\text{Atomic weight of metal}_i (\frac{\text{g}}{\text{mol}})}$$

The first value in this equation represents that the metal content is 74% of the fume mass, with the remaining fume mass contributed by gases including O_2 . The second value in the equation represents the percentage of each metal (listed above) that contributed to that 74% of the fume mass. The third value in the equation uses the cumulative low dose (1.7 mg) or high dose (3.4 mg) of GMAW-SS which resulted in lung tumorigenesis in our previous study [13]. Lastly, the fourth value in the equation represents the atomic weight ratio of the metal oxide to metal. For example, mass (g) of NiO (low dose) = $0.74 \times 0.088 \times 1.7 \times (74.7/58.7) = 141 \mu\text{g}$.

The respective low and high doses of each metal oxide are shown in Figure 1A and scanning electron microscopy images are presented in Figure 1B, C, and D. The fume and each component metal were suspended in USP-grade calcium and magnesium-free phosphate buffered saline (PBS; vehicle) in a sterile conical tube. Fe_2O_3 was vortexed then sonicated at 40 amps for 15 seconds using a GE 130PB ultrasonic processor (Cole Parmer). GMAW-SS and NiO were vortexed then sonicated twice at 40 amps for 15 seconds with a 1 minute rest period in between. $\text{Cr}_2\text{O}_3/\text{CaCrO}_4$ was not sonicated.

Mouse oropharyngeal aspiration exposure

A/J mice were exposed to the metal oxides or the GMAW-SS fume by oropharyngeal aspiration as previously described [9, 14]. In brief, each mouse was placed in a glass jar with

gauze containing a histology cassette moistened with isoflurane (Abbott Laboratories, North Chicago, IL). Once slow breathing was observed, the mouse was suspended by its front incisors on a slanted board in a supine position. Forceps were used to extend the tongue and 50 μ l of metal oxide suspension was placed by pipette at the back of the throat. Shams received an equal volume of vehicle (PBS). The suspension was aspirated into the lungs by normal breathing and the tongue was released after three deep breaths were observed. All solutions were thoroughly vortexed immediately prior to dosing. This technique loses little solution to the gastrointestinal tract when performed properly. The mouse returned to normal activity in its cage within 10 to 20 seconds.

Experimental Protocol 1: biochemical measurements of lung toxicity, histopathology, and gene expression

In two parallel studies, 256 male A/J mice were organized into 4 blocks of 64 mice and then separated into 8 treatment groups within each block ($n = 8/\text{group}$) consisting of a single low or high bolus dose of $\text{Cr}_2\text{O}_3 + \text{CaCrO}_4$ mixture, NiO, Fe_2O_3 , GMAW-SS fume (low dose only) or PBS (sham control). Doses are shown in Figure 1A and a timeline of the exposure and the block design are shown in Figure 2. Animals were euthanized at 1, 7, 28, and 84 days post-oropharyngeal aspiration exposure. Mice were weighed after an acclimation period, throughout the dosing, and at the 1, 7, 28, and 84 days sacrifices. Mice were anesthetized with Fatal Plus ([100-300 mg/kg IP; 390 mg/ml pentobarbital sodium] (Henry Schein, Dublin, Ohio) then weighed. Once unresponsive to a toe pinch, the abdomen was the mouse was exsanguinated.

Whole lung bronchoalveolar lavage (BAL) toxicity profile

A blunted cannula was placed in the trachea through a small incision and the thorax was massaged as 0.6 mL of cold PBS was instilled into the lungs. After 10 seconds, the BAL fluid

was withdrawn and placed in a 15 mL conical tube. This consisted of the first lavage fraction. This process was then repeated 3 times using 1 mL of PBS per instillate and this second fraction was collected in a separate 15 mL conical tube. The BAL fluid was kept on ice until all the mice were sacrificed and then the samples were centrifuged (500 x g, 10 minutes, 4° C).

Bronchoalveolar lavage fluid cytokine analysis

Cytokine concentrations from the first fraction of BAL supernatant at 1 day and 28 days post-exposure were quantified simultaneously by using a Discovery Assay® called the Mouse Cytokine Array / Chemokine Array 32-Plex (Eve Technologies Corp, Calgary, AB, Canada). The multiplex assay was performed at Eve Technologies by using the Bio-Plex™ 200 system (Bio-Rad Laboratories, Inc., Hercules, CA, USA), and a Milliplex Mouse Cytokine / Chemokine kit (Millipore, St. Charles, MO, USA) according to their protocol. The 32-plex consisted of Eotaxin, granulocyte-colony stimulating factor (G-CSF), granulocyte monocyte- colony stimulating factor (GM-CSF), interferon gamma (IFN γ), interleukin-1 α (IL-1 α), IL-1 β , IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17, interferon-gamma-inducible protein 10 (IP-10), keratinocyte chemoattractant (KC), leukemia inhibitory factor (LIF), C-X-C motif chemokine 5 (CXCL5), monocyte chemotactic protein 1 (MCP-10), macrophage- colony stimulating factor (M-CSF), monokine induced by gamma interferon (MIG), macrophage inflammatory protein 1 α (MIP-1 α), MIP-1 β , MIP-2, regulated on activation, normal T-cell expressed and secreted (RANTES), tumor necrosis factor α (TNF α), and vascular endothelial growth factor (VEGF). Standard curves with a range of 0 to >25,000 pg/mL were determined for each cytokine. The lowest concentration in the group was used for any value that was out of range. The assay sensitivities of these markers range from 0.1 – 33.3

pg/mL. Individual analyte values and other assay details are available on Eve Technologies' website or in the Milliplex protocol.

Lactate dehydrogenase (LDH) activity and BAL cell profile.

The acellular supernatant of the first lavage fraction was used to measure LDH activity, indicative of lung cytotoxicity. LDH activity was analyzed using a COBAS MIRA Plus auto-analyzer (Roche Diagnostic Systems, Montclair, NJ) which measured the oxidation of lactate to pyruvate coupled with the formation of NADH at 340 nm.

For analysis of the BAL cells, the supernatant from the second lavage fraction was discarded and the cell pellets of both fractions were combined. The final cell pellet suspended in 800 μ L of PBS was used for cell counts and differential staining. Total cell numbers were determined using a hemocytometer. For cell differentials, cells were plated onto glass slides using a Cytospin 3 centrifuge (Shandon Life Sciences International, Cheshire, England) set at 800 rpm for 5 minutes. Slides were stained with Hema 3 Fixative and Solutions (Fisher Scientific, Pittsburgh, Pa) then coverslipped. A minimum of 300 cells/slide consisting of alveolar macrophages, lymphocytes, neutrophils, or eosinophils were identified using light microscopy. Slides from shams typically contained >99% alveolar macrophages.

Alveolar macrophage functional assay

To study the impact of the metal oxides on innate immune function, alveolar macrophages from the suspended cell pellet at 1, 7, and 28 days post-exposure to sham, SS, or the metal oxides were challenged with *Escherichia coli* (*E.coli*) GFP for 2 hours at 1:25 MOI (multiplicity of infection). The *E.coli* uptake by alveolar macrophages was quantified by flow cytometry.

Quantitative real-time polymerase chain reaction (qPCR) and lung histopathology.

The left lung lobe was ligated and flash frozen and then stored at -80 C for RNA isolation while the right lung lobes were fixed in 10% neutral buffered formalin for histopathology. Liver was cut (~ 30 mg piece) and flash frozen before storage. RNA was isolated from the lung and liver tissue using RNeasy Mini Kits (Qiagen, Hilden, Germany) and 1 µg was reverse transcribed using random hexamers, dNTP mix and SuperScript™ III Reverse Transcriptase (Invitrogen, ThermoFisher Scientific, Waltham, MA). Diluted cDNA (1:10) was combined with Taqman® Gene Expression Mastermix (ThermoFisher Scientific, Waltham, Ma) and one of the following genes of interest for the lung: nuclear receptor subfamily 1, group D, member 1 (*Nr1d1*; Mm00520708_m1), nuclear receptor subfamily 1, group D, member 2 (*Nr1d2*; Mm01310356_g1), heme oxygenase 1 (*Hmox1*; Mm00516005_m1), transferrin receptor (*Tfcr*; Mm00441941_m1), solute carrier family 40 (iron-regulated transporter), member 1 (*Slc40a1*; Mm01254822_m1), cyclin dependent kinase 4 (CDK4; Hs00364847_m1), cyclin-dependent kinase inhibitor 1A (p21; Mm04205640_g1), and SRY (sex determining region Y)-box 9 (*Sox9*; Mm00448840_m1). For the liver, the following genes of interest were analyzed: metallothionein 1 (*Mt1*; Mm00496660_g1), metallothionein 2 (*Mt2*; Mm00809556_s1), haptoglobin (*Hp*; Mm00516884_m1), and serum amyloid A1 (*Saa1*; Mm00656927_g1). Hypoxanthine phosphoribosyltransferase (*HPRT*) was used as the reference gene (Mm03024075_m1, ThermoFisher Scientific, Waltham, MA). Amplification parameters included 10 minutes at 95°C, 1 second at 95°C and 20 seconds at 60°C. Relative mRNA levels were calculated using the comparative threshold method ($2^{-\Delta\Delta Ct}$).

For histopathology studies, the right lung (consisting of apical, cardiac, azygos, and diaphragmatic lobes) was embedded in paraffin then a 5 µm standardized section was cut. Slides were stained with hematoxylin and eosin and interpreted by a contracted board certified

veterinary pathologist in a blinded fashion. Any type or degree of lung injury and inflammation in the airways and alveolar region and evidence of changes in lung structure related to allergy including thickening around airways (epithelium and/or smooth muscle), eosinophil and lymphocyte influx, and development of bronchus-associated lymphoid tissue was evaluated. If abnormal changes were found, severity was scored as follows: 1 = minimal, 2 = mild, 3 = moderate, 4 = marked.

Experimental Protocol 2: Two-stage (initiation-promotion) lung tumor bioassay

Male A/J mice (200) were organized into 5 groups (n = 40 per group) for a two stage initiation-promotion study. Mice were initiated with 3-methylcholanthrene (MCA) or corn oil (vehicle control) by intraperitoneal (IP) injection. Beginning one week later, mice were exposed once per week to a mixture of $\text{Cr}_2\text{O}_3 + \text{CaCrO}_4$ (146.2 μg /2.2 μg), NiO (56.2 μg), Fe_2O_3 (400 μg), or PBS (sham control) for 5 weeks via oropharyngeal aspiration (Figure 3A). The cumulative dose $\text{Cr}_2\text{O}_3 + \text{CaCrO}_4$ (731 μg /11 μg), NiO (281 μg), Fe_2O_3 (2 mg) was equivalent to the bolus high dose for each metal oxide as described in experimental protocol 1 (Figure 3B). Mice were weighed after a short acclimation period, throughout the dosing, and at sacrifice.

At 30 weeks post-initiation, A/J mice were euthanized as described above. All internal organs were examined for the presence of tumors. The whole lung was then excised. The lungs were inflated and fixed with 10% neutral buffered formalin for 24 hours. Tumors were counted and measured 24 hours after fixation. Any apparent merged tumors were counted as one. Lungs were embedded in paraffin, and then a 5- μm standardized section was cut. Slides were stained with hematoxylin and eosin and interpreted by a contracted, board-certified veterinary pathologist in a blinded fashion for evidence of hyperplasia and neoplasia, inflammation, lymphoid tissue response, and foreign materials by light microscopy. Diagnostic criteria for

hyperplastic and neoplastic findings were according to *goRENI* (<http://www.goreni.org/>), the standard reference for nomenclature and diagnostic criteria in toxicologic pathology and “INHAND”—the International Harmonization of Nomenclature and Diagnostic criteria [15, 16]. If abnormal changes were found, severity was scored using the following scale: 1 = minimal, 2 = mild, 3 = moderate, 4 = marked. The final severity score reflects the average of the right and left lung lobe scores and are presented as means $\pm$ standard error. Because bronchiolo-alveolar hyperplasia (BAH) and bronchiolo-alveolar adenomas (BAA) represent a continuum of the proliferative process, and there is possible overlap between these diagnoses, the numbers of lesions were combined to compare the tumorigenic potential of each treatment [16]. However, the gross tumor count at necropsy is more representative of the response because examination of a single histological section per lung underestimates the total number of lesions per lung [17].

Statistical comparisons and analysis

Statistical analyses were done using JMP version 12 and SAS version 9.4 for Windows (SAS Institute, Cary NC, USA). Factorial analysis of variance (ANOVA) was performed on continuous variables from the BAL fluid and the log fold changes from the PCR analytes to make comparisons between the treatment groups. For some variables, data were log transformed to reduce heterogeneous variance and meet the assumptions of an ANOVA. Histopathological findings using the graded scale were analyzed using nonparametric Kruskal Wallis tests followed by Wilcoxon Rank Sum tests for pairwise comparisons. Gross tumor counts and histopathology counts from sections were analyzed similarly. Tumor incidence (presence or absence of tumors) was analyzed using a Chi-square test in SAS ‘Proc Freq,’ while tumor multiplicity (number of tumors per lung) was analyzed using Poisson regression in SAS ‘Proc Genmod’. In cases where overdispersion existed, a negative binomial regression was performed using data from those

animals surviving to the 30-week time point. For all analyses, a p value of <0.05 was set as the criteria for significance.

Results

Metal oxide characterization

Table 1 summarizes results of the material characterization. Specific surface area (SSA) of the study materials ranged from about 1 to 6 m²/g, consistent with their smooth micronscale compact particle morphology (Figure 1), whereas the welding fume had SSA that was at least a factor of eight higher. The higher SSA of the welding fume is consistent with its nanoscale cluster particle agglomerates [18]. Among study materials, hydrodynamic diameter ranged from about 150 nm (chromium-containing particles) to 1000 nm (GMAW-SS). For a given study material, values of hydrodynamic diameter were similar for both the high and low dose concentration suspensions, indicating that particles did not agglomerate at the higher concentration. Values of zeta potential, which is a measure of colloidal stability, were similar among materials and for a given material did not differ between dosing concentrations.

Lung Cytotoxicity after exposure to GMAW-SS fume or metal oxides

At 1 day post-exposure, LDH activity in the BAL was significantly increased in all exposed groups compared to sham except for the low and high dose NiO groups (Figure 4). At 7 days, lung cytotoxicity remained significantly increased in the GMAW-SS fume (~ 5 fold), Fe₂O₃ low and high (>2 and 3 fold, respectively), and the Cr₂O₃/CaCrO₄ high dose groups. Cr₂O₃/CaCrO₄ low and NiO groups were not significantly different from sham. At 28 days post-exposure, only GMAW-SS fume- and Fe₂O₃ high-exposed groups had significant lung cytotoxicity. Cytotoxicity had decreased by 84 days, but remained significantly increased in the Fe₂O₃ high and GMAW-SS exposed groups.

BAL cell profile after exposure to GMAW-SS or metal oxides

Total BAL cells were significantly increased compared to sham in all groups except for low and high dose NiO at 1 day post-exposure (Figure 5A). The greatest increase in total BAL cells at 1 day, 7 days, and 28 days post exposure was observed in GMAW-SS fume-exposed mice. The Fe₂O₃ high group also had significantly increased BAL cells at every time point. The BAL cell increases at 1 day post-exposure were mostly due to neutrophil influx, as few changes in macrophages were observed at this time point (Figure 5B and 5C). However, significant neutrophil and macrophage influx was observed in GMAW-SS-exposed mice at 7 and 28 days post-exposure, but the macrophage influx was greater. Some eosinophil influx was observed in GMAW-SS, Cr low and high dose, and Fe₂O₃ high dose exposed mice 1 day post-exposure but this was minor compared to neutrophil and macrophage changes (data not shown). By 28 days post-exposure, no eosinophils were present. At 84 days post-exposure, only GMAW-SS and Fe₂O₃ high groups had slightly increased total BAL cells compared to control mice which were largely due to increased macrophages. Neutrophils were not significantly increased in any treatment group at 84 days post-exposure. No lymphocytes were observed in the BAL fluid in any treatment group at any time point. Macrophages had a decreased ability to phagocytose *E. Coli* 1 day and 7 days post-exposure to all component metals but returned to control levels by 28 days post-exposure (Figure 6).

BAL cytokine analysis at 1 and 28 days post-exposure

At 1 day post-exposure increases in G-CSF, GM-CSF, IL-5, IL-6, IP-10, KC, LIF, MIG, MIP-1 α , MIP-1 β , MIP-2, TNF α , and VEGF were noted in the exposed groups compared to sham (Table 2A). Most cytokine protein levels were highest in GMAW-SS-exposed groups and closest to sham in the NiO-exposed groups. GM-CSF levels were increased two to three-fold in only

GMAW-SS and Fe₂O₃ exposed animals at 1 day post-exposure but were increased almost six-fold in GMAW-SS at 28 days post-exposure (Table 2B). Most other cytokines were not significantly increased above sham levels at 28 days post-exposure.

Lung and liver gene expression analysis

Relative lung and liver mRNA levels are shown for selected genes at 1 day post-exposure to GMAW-SS fume, Fe₂O₃ low, and Fe₂O₃ high in Table 3 and Figure 7. By 7 days post-exposure, most liver and lung genes had returned to control levels in these treatment groups. However, metallothionein 1 (*MtI*) was still increased ~3 to 4 fold in all three groups, and serum amyloid A1 (*SAA-I*) was increased ~3 fold and ~2 fold in GMAW-SS and Fe₂O₃ low dose groups, respectively, at 7 days post-exposure (data not shown).

Fewer changes in lung and liver relative mRNA levels were observed in NiO or Cr₂O₃/CaCrO₄ groups compared to the GMAW-SS and Fe₂O₃ exposed groups (data not shown). No changes in relative mRNA levels were seen in NiO low or high exposed groups in any genes at any time points. At 1 day post-exposure to Cr₂O₃/CaCrO₄ low and high dose, levels of liver *MtI* and *SAA-I* were significantly increased above sham (~5 and ~12 fold for low dose and ~8 and ~17 fold for high dose *MtI* and *SAA-I* levels, respectively; $p < 0.05$). At 7 days post-exposure, *MtI* and *SAA-I* levels were still significantly elevated ~ 2 and ~3 fold in the Cr₂O₃/CaCrO₄ high dose exposed group, respectively ($p < 0.05$). Among relative lung mRNA levels, only heme oxygenase 1 (*HMOX1*) levels were significantly elevated in Cr₂O₃/CaCrO₄ high dose animals compared to sham (~2 fold; $p < 0.05$).

Effects on body weight and survival post-welding fume or component metal exposure

Mice for experimental protocol 1 weighed on average 18.33 ± 0.13 g at the start of dosing. Mice for experimental protocol 2 weighed on average 18.94 ± 0.13 g at the start of

dosing. All groups gained weight throughout the study and there were no significant differences found among the exposure groups versus sham for either protocol.

Histopathological evaluation of lung toxicity in A/J mice

Abnormal morphological findings and inflammation are presented in Table 1 with images in Figure 8. The response to NiO exposure was characterized by the presence of black foreign bodies and pigmented macrophages in terminal bronchioles and adjacent alveoli. At 1 and 7 days post-exposure, there was minimal to mild infiltration of neutrophils around terminal bronchioles and/or vessels in some instances. The response to the high dose was not notably different from the low dose, with the exception that black pigment and pigmented macrophages were more often detected 84 days post-exposure.

The response to Cr₂O₃/CaCrO₄ exposure was characterized by the presence of black foreign bodies and pigmented macrophages in terminal bronchioles and adjacent alveoli. At 1 and 7 days post-exposure, there was minimal infiltration of neutrophils around terminal bronchioles and/or vessels and neutrophil exudate in bronchiolar and alveolar lumens in many animals, especially in the high dose exposure animals.

Exposure to Fe₂O₃ was characterized by the presence of black foreign bodies and pigmented macrophages in terminal bronchioles and adjacent alveoli. At 1 and 7 days, there was minimal or mild infiltration of neutrophils around terminal bronchioles and/or vessels and neutrophil/macrophage exudate in alveolar lumens in many animals, especially in the high dose group. Hyperplasia of bronchiolar epithelium was rarely present. At 84 days, black foreign bodies and pigmented macrophages were consistently present in terminal bronchioles and adjacent alveolar lumens. Also, at 84 days the incidence and severity of lymphoid nodules was slightly increased.

The response to GMAW-SS fume was greater than any of the metal oxides alone and characterized by the presence of brown foreign bodies and pigmented macrophages in terminal bronchioles and adjacent alveoli. At 1 and 7 days post-exposure there was a prominent neutrophil response often filling both terminal bronchioles and adjacent alveoli. Also, the alveolar walls are often thickened due to mononuclear cell infiltration and hyperplasia of bronchial epithelium was also sometimes present at 1 and 7 days. Amorphous brown foreign bodies were occasionally present in bronchial lumens, particularly at 1 and 7 days post-exposure. At 28 and 84 days post-exposure, the response tended to transition from neutrophilic to mononuclear cell (macrophage and lymphocyte), including formation of lymphocytic nodules around vessels in affected regions. Notable lesions were still present on day 84, including pigment in terminal bronchioles that is surrounded by spindle shaped mononuclear cell that appeared to be walling off a focal accumulation of brown pigment.

Gross tumor multiplicity and incidence

Among the component metals, only Fe_2O_3 significantly promoted lung tumors in the A/J mouse after initiation with MCA compared to MCA/sham (15.18 ± 0.83 and 9.78 ± 0.80 , respectively; $p < 0.0001$). The grossly observed lung tumor multiplicity (average tumor number/mouse lung $\pm$ SE including mice with no tumors) after exposure to MCA or a metal oxide is shown in Figure 9. There was no effect of the other metal oxides or sham on lung tumor multiplicity (MCA/NiO, 8.62 ± 0.69 ; MCA/ $\text{Cr}_2\text{O}_3/\text{CaCrO}_4$, 10.57 ± 0.72 ; MCA/sham, 9.78 ± 0.80 ; CO/sham, 0.14 ± 0.07). As expected, average tumor incidence (% of tumor-bearing mice out of the total) was low in animals initiated with CO (CO/sham, 13.79%) and at or near 100% in animals initiated with MCA (MCA/sham, 100%; MCA/ $\text{Cr}_2\text{O}_3/\text{CaCrO}_4$, 97.22%; MCA/NiO, 100%; MCA/ Fe_2O_3 , 100%). Gross lung morphology 1 day post-fixation in sham, $\text{Cr}_2\text{O}_3/\text{CaCrO}_4$,

NiO, and Fe₂O₃ exposed mice is presented in Figure 10. Fe₂O₃ and Cr₂O₃/CaCrO₄ deposition were visible in mouse lungs and appeared red and green in color, respectively. Tumors appeared white in color and opaque on initial gross exam and became well-defined after fixation which aided enumeration. At 30 weeks, tumors were between ~0.5 and ~3 mm. Average tumor size was 1.00 mm, 1.30 mm, 1.17 mm, 1.18 mm, and 1.11 mm for CO/Sham, MCA/sham, MCA/NiO, MCA/Cr₂O₃/CaCrO₄, and MCA/Fe₂O₃, respectively. No significant difference in sizes among groups was found.

Histopathological evaluation of lung lesions, inflammation, and presence of metals

Microscopic findings of the lungs of mice exposed to MCA and one of the metal oxides or sham are presented in Table 2. The most common findings were one or more bronchiolo-alveolar adenomas, and one or more foci of alveolar epithelial hyperplasia. Adenoma and hyperplasia were observed in the right and/or left lungs in all animals in all treatment groups. No carcinomas were observed. A few of the adenomas in this study were well demarcated and formed solid hypercellular masses and/or hypercellular papillary structures that had replaced the normal alveolar architecture. The adenomas were composed primarily of cells that appeared similar to those of hyperplasias, although some slightly enlarged, somewhat atypical appearing cells with enlarged nuclei were sometimes present. Mitotic figures were rare. Maintenance of the normal alveolar structure versus replacement by an abnormal growth pattern, is the single most important characteristic distinguishing hyperplasia from adenoma. Alveoli within larger hyperplasias generally were collapsed and appeared hypercellular, but close examination of the lesion demonstrated that the normal alveolar structure was still intact and that the lesion was a hyperplasia and not an adenoma. Alveolar epithelial hyperplasia was greatest and most severe in MCA/Fe₂O₃ exposed mice. Foreign material, presumably the metal, was observed in MCA/NiO,

MCA/Fe₂O₃, and MCA/Cr₂O₃/CaCrO₄ treatment groups. The foreign material appeared as multiple, widely scattered individual or small clusters of minute discrete focal aggregates of black granules. In some cases the granules clearly were present within an alveolar histiocyte. In other cases the granules appeared to be within an alveolar histiocyte but the histiocyte was obscured by the granules. Occasionally, granules were scattered within an alveolus and not within a histiocyte. Mild lymphocytic infiltrate was observed in a few MCA/ Fe₂O₃ and MCA/Cr₂O₃/CaCrO₄ exposed animals but was not significantly different than control. Total lung lesions, recorded as the average of hyperplasias and adenomas per mouse lung, were significantly increased in MCA/ Fe₂O₃ exposed animals only compared to controls (6.91 ± 0.52 versus 4.33 ± 0.64 , respectively; $p < 0.0001$).

Discussion

The results of this study show that the total GMAW-SS fume is more pneumotoxic than any of the individual component metal oxides. These findings are consistent with other studies which have shown that components of the fume are less toxic than the total fume [9, 19]. Among the metals present in GMAW-SS fume, Fe₂O₃ was the most toxic and the only metal oxide to significantly promote lung tumors at a dose equivalent to the weight percentage found in the fume.

Numerous worker and animal studies have implicated chromium as contributing to lung cancer development, and Cr⁶⁺ is classified as *carcinogenic to humans* (Group 1) by the IARC [20-24]. While Cr⁶⁺ has been linked to cancer, research concerning Cr³⁺ is more conflicting and Cr³⁺ is not currently classified by the IARC [22]. It has been reported that Cr³⁺ cannot enter cells as readily as Cr⁶⁺ and is therefore less harmful [3, 21]. However, Cr⁶⁺ is reduced to Cr³⁺ once inside cells and in the process can generate reactive oxygen species which damage DNA [21]. In

the present study, $\text{Cr}_2\text{O}_3/\text{CaCrO}_4$ exposure did not promote lung tumors in the two-stage mouse model but did cause mild cytotoxicity and inflammation at 1 day and 7 day post-exposure. However, Cr exposure resulted in smaller BAL cytokine, gene expression, and lung histopathology changes compared to Fe and GMAW-SS fume. The mild cytotoxicity and lack of tumorigenic effect may be due to the low doses used in this study. Nettesheim et al. 1971 performed one of the first *in vivo* Cr^{6+} exposure studies, exposing C57BL/6 mice to calcium chromate via inhalation for 5 hours per day, 5 days per week for the lifetime of the animals [25]. They observed a fourfold increase in adenoma incidence in mice chronically exposed to calcium chromate [26]. Although the inhalation dose used in Nettesheim et al. was not reported, the authors performed a subsequent study in hamsters exposed intratracheally to 15 weekly calcium chromate injections of 0.5 or 0.1 mg for a total dose of 7.5 and 1.5 mg, respectively, and they also observed increased lung lesions in these animals [26]. Steinhoff et al. performed intratracheal instillation of Cr^{6+} once per week for up to 30 months in rats and saw no lung tumor incidence at doses of 0.05 or 0.25 mg/kg Cr^{6+} [27]. Instead, they observed that 17.5% of rats that received a single 1.25 mg/kg dose developed tumors in the lung. This suggests that a single, higher dose is more tumorigenic than multiple smaller doses of Cr^{6+} . Similarly, Glaser et al. exposed rats to Cr^{6+} via inhalation and found zero incidence of lung cancer (adenomas and adenocarcinomas) at 25 and 50 $\mu\text{m}/\text{m}^3$ while at concentrations of 63 $\mu\text{m}/\text{m}^3$ and 100 $\mu\text{m}/\text{m}^3$, rats had 5% and 15% incidences of lung cancer, respectively [28]. Therefore, these studies suggest that higher doses of Cr^{6+} are needed to observe its carcinogenic effects *in vivo* [25]. In contrast, while the dose of Cr^{6+} utilized in this study (cumulative 11 μg) reflected the percentage found in the GMAW-SS fume, it may have been too small to cause a tumorigenic effect. Interestingly,

both Steinhoff et al. and Glaser et al. also concluded that inflammation was essential for tumorigenesis, and in this study Cr caused only mild inflammation and cytotoxicity.

Like Cr^{6+} , Ni is classified as *carcinogenic to humans* by the IARC, with support from many worker and animal studies [24, 29-32]. In particular, Ni (II) seems to be the most carcinogenic Ni species, damaging DNA directly as well as through reactive oxygen species production, epigenetic effects, and chromosomal aberrations [24, 30, 31, 33-39]. In 2012, the IARC concluded that high cytotoxic concentrations as well as the presence of inflammation may be needed to see some of these potentially carcinogenic effects [24, 34, 37, 40, 41]. In the present study, Ni was not cytotoxic or inflammatory, which may explain its lack of tumor promotion. Few *in vivo* studies have specifically investigated the tumorigenic potential of NiO, which is the main form of Ni found in welding fumes [24]. Most notably, the National Toxicology Program performed studies which demonstrated that NiO caused inflammation and tumorigenesis in F344 rats and B6C3F1 mice; however, these were all inhalation studies utilizing higher doses [42]. NiO concentrations of 1.25, 2.5, or 5 mg/m^3 by inhalation for 6 hours/day, 5 day/week for 104 weeks in mice increased the incidence of alveolar and bronchiolar adenomas and/or carcinomas. Additionally, inhalation exposures may be more toxic than oropharyngeal aspiration exposures, as Antonini et al. demonstrated that welding fume, when freshly generated, caused more lung inflammation than aged fume dosed via intratracheal instillation due to higher production of free radicals [43]. Thus, the exposure route and low doses used in this study could partially explain the lack of lung tumor promotion by NiO that we observed. Nevertheless, the doses used in this study were calculated to represent the actual percentages of these metals in the GMAW-SS fume, and the objective of this study was not to evaluate if NiO could act as a lung tumor promoter.

Rather, we sought to determine what metal oxides(s) may be responsible for the carcinogenic properties of SS fume. This study suggests it may not be just Cr or Ni.

An Interesting finding in this study was that among the metal oxides, Fe_2O_3 was the only metal to significantly promote lung tumors *in vivo*. While it is well known that iron overload can contribute to the development of a variety of cancers, Fe is currently not classified as to its carcinogenicity by the IARC [44, 45]. This is largely due to the fact that most occupational exposures to Fe are mixed exposures to Fe as well as other metals or potential carcinogens, making epidemiologic studies of worker exposures difficult to associate a carcinogenic effect [22]. The results of this study support the epidemiology that mild steel welders, despite exposure to mainly Mn and Fe, are at increased risk of lung cancer [7, 8, 46]. Fe_2O_3 was also the most pneumotoxic of the component metals, as the Fe high dose group still had significant lung cytotoxicity and macrophages at 28 days post-exposure. Similarly, among the component metals, Fe had the greatest effects on increased BAL cytokine levels, liver relative mRNA abundance, and histopathological lung findings.

Interestingly, GMAW-SS fume was more cytotoxic than any of the individual metals. While this study demonstrated that none of the metals besides Fe could individually promote lung tumors, previous studies in our lab have demonstrated that GMAW-SS fume promotes lung tumor in A/J mice after both oropharyngeal aspiration and inhalation exposure [11, 13]. Results from previous studies have also suggested that the total fume may be more cytotoxic than any of its individual components. Earlier studies in our laboratory have shown that SS fume is more pneumotoxic than Cr after four bolus doses in mice, causing a greater increase in LDH, lymphocyte and neutrophil levels [9]. Antonini et al. observed that the lung toxicity and inflammation of SS fume from manual metal arc welding was due to both the soluble and

insoluble fraction of the fume, with neither fraction individually having as much toxicity as the total SS fume. They observed that the toxicity of the soluble and insoluble fractions were equal and added together to equal the toxicity of the total fume [19]. The results of these studies along with our findings suggest that the metal oxides may have a synergistic or additive effect when combined in the fume to create a greater toxicity than any individual component can have alone.

Abnormal morphological lung histopathological changes were also found in mice exposed to GMAW-SS fume, including both a mononuclear and neutrophilic infiltration that was not observed with the individual metals. Changes in BAL cytokine levels as well as liver mRNA abundance were also greatest in GMAW-SS fume-exposed groups. Most notably, GMAW-SS fume increased G-CSF and IP-10 protein levels, which promote neutrophil survival and function and act as a chemoattractant for macrophages, respectively. These cytokine changes mirror the neutrophil and macrophage influx that was observed in the BAL at the early time points. The greatest changes in gene expression were observed in liver of GMAW-SS WF exposed mice at 1 day post-exposure, with increased expression of Mt1, Mt2, and SAA-a in Fe and GMAW-SS exposed mice compared to controls, indicating a potential acute phase protein response.

There are a number of limitations to this study. First, the metal oxides which the mice were exposed to are pure oxides and not isolated directly from the fume. The metals in the freshly generated fume are likely more complex and may consist of different chemical compositions of these oxides; therefore, the oxides in the fume may also differ in morphology and reactivity compared to those used in this study. For this reason, we characterized the metal oxides used in this study and noted that each oxide had much smaller SSA and different hydrodynamic diameters than the GMAW-SS. A second limitation to this study was that the exposures were done by oropharyngeal aspiration. Although this is a well-established method, it

is a bolus dose and less representative of actual worker inhalation exposures. A further limitation of this study is that we only dosed metals individually and did not combine different metals in doses which eliminated the ability to observe any specific potential additive or synergistic effects among two metal oxides.

In summary, the results of this study provide new insight into the toxicity and tumorigenic potential of the metal oxide components of welding fumes. In particular, it was shown that Fe_2O_3 is a lung tumor promoter *in vivo* and may be the main metal oxide responsible for the carcinogenic effect of SS fume. Additional studies can be focused on further investigating these metal components *in vivo* and *in vitro* and exploring potential mechanisms of tumorigenesis of welding fumes and their component metal oxides.

Bibliography

1. Guha N, Loomis D, Guyton KZ, Grosse Y, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, Vilahur N, Muller K, Straif K: **Carcinogenicity of welding, molybdenum trioxide, and indium tin oxide.** *Lancet Oncol* 2017, **18**:581-582.
2. Antonini JM: **Health effects of welding.** *Crit Rev Toxicol* 2003, **33**:61-103.
3. Antonini JM: **Health Effects Associated with Welding.** 2014:49-70.
4. Zeidler-Erdely PC, Erdely A, Antonini JM: **Immunotoxicology of arc welding fume: worker and experimental animal studies.** *J Immunotoxicol* 2012, **9**:411-425.
5. Kendzia B, Behrens T, Jockel KH, Siemiatycki J, Kromhout H, Vermeulen R, Peters S, Van Gelder R, Olsson A, Bruske I, et al: **Welding and lung cancer in a pooled analysis of case-control studies.** *Am J Epidemiol* 2013, **178**:1513-1525.

6. Matrat M, Guida F, Mattei F, Cenee S, Cyr D, Fevotte J, Sanchez M, Menvielle G, Radoi L, Schmaus A, et al: **Welding, a risk factor of lung cancer: the ICARE study.** *Occup Environ Med* 2016, **73**:254-261.
7. Hansen KS, Lauritsen JM, Skytthe A: **Cancer incidence among mild steel and stainless steel welders and other metal workers.** *Am J Ind Med* 1996, **30**:373-382.
8. Lauritsen JM, Hansen KS: **Lung cancer mortality in stainless steel and mild steel welders: a nested case-referent study.** *Am J Ind Med* 1996, **30**:383-391.
9. Zeidler-Erdely PC, Kashon ML, Battelli LA, Young SH, Erdely A, Roberts JR, Reynolds SH, Antonini JM: **Pulmonary inflammation and tumor induction in lung tumor susceptible A/J and resistant C57BL/6J mice exposed to welding fume. Part Fibre Toxicol** 2008, **5**:12.
10. *2004 TLVs and BEIs.* Cincinnati, Ohio: American Conference of Governmental Industrial Hygienists; 2004.
11. Falcone LM, Erdely A, Meighan TG, Battelli LA, Salmen R, McKinney W, Stone S, Cumpston A, Cumpston J, Andrews RN, et al: **Inhalation of gas metal arc-stainless steel welding fume promotes lung tumorigenesis in A/J mice.** *Arch Toxicol* 2017.
12. Antonini JM, Afshari AA, Stone S, Chen B, Schwegler-Berry D, Fletcher WG, Goldsmith WT, Vandestouwe KH, McKinney W, Castranova V, Frazer DG: **Design, construction, and characterization of a novel robotic welding fume generator and inhalation exposure system for laboratory animals.** *J Occup Environ Hyg* 2006, **3**:194-203; quiz D145.

13. Zeidler-Erdely PC, Meighan TG, Erdely A, Battelli LA, Kashon ML, Keane M, Antonini JM: **Lung tumor promotion by chromium-containing welding particulate matter in a mouse model.** *Part Fibre Toxicol* 2013, **10**:45.
14. Rao GV, Tinkle S, Weissman DN, Antonini JM, Kashon ML, Salmen R, Battelli LA, Willard PA, Hoover MD, Hubbs AF: **Efficacy of a technique for exposing the mouse lung to particles aspirated from the pharynx.** *J Toxicol Environ Health A* 2003, **66**:1441-1452.
15. Keenan CM, Baker J, Bradley A, Goodman DG, Harada T, Herbert R, Kaufmann W, Kellner R, Mahler B, Meseck E, et al: **International Harmonization of Nomenclature and Diagnostic Criteria (INHAND): Progress to Date and Future Plans.** *Toxicol Pathol* 2015, **43**:730-732.
16. Renne R, Brix A, Harkema J, Herbert R, Kittel B, Lewis D, March T, Nagano K, Pino M, Rittinghausen S, et al: **Proliferative and nonproliferative lesions of the rat and mouse respiratory tract.** *Toxicol Pathol* 2009, **37**:5s-73s.
17. Rehm S, Ward JM: **Quantitative analysis of alveolar type II cell tumors in mice by whole lung serial and step sections.** *Toxicol Pathol* 1989, **17**:737-742.
18. Falcone LM, Erdely A, Meighan TG, Battelli LA, Salmen R, McKinney W, Stone S, Cumpston A, Cumpston J, Andrews RN, et al: **Inhalation of gas metal arc-stainless steel welding fume promotes lung tumorigenesis in A/J mice.** *Arch Toxicol* 2017, **91**:2953-2962.
19. Antonini JM, Taylor MD, Zimmer AT, Roberts JR: **Pulmonary responses to welding fumes: role of metal constituents.** *J Toxicol Environ Health A* 2004, **67**:233-249.

20. Barkhordari A, Zare Sakhvidi MJ, Zare Sakhvidi F, Halvani G, Firoozichahak A, Shirali G: **Cancer Risk Assessment in Welder's Under Different Exposure Scenarios.** *Iran J Public Health* 2014, **43**:666-673.
21. Cohen MD, Kargacin B, Klein CB, Costa M: **Mechanisms of chromium carcinogenicity and toxicity.** *Crit Rev Toxicol* 1993, **23**:255-281.
22. Wild P, Bourgkard E, Paris C: **Lung cancer and exposure to metals: the epidemiological evidence.** *Methods Mol Biol* 2009, **472**:139-167.
23. **Occupational exposure to hexavalent chromium. Final rule.** *Fed Regist* 2006, **71**:10099-10385.
24. **Arsenic, metals, fibres, and dusts.** *IARC Monogr Eval Carcinog Risks Hum* 2012, **100**:11-465.
25. Proctor DM, Suh M, Campleman SL, Thompson CM: **Assessment of the mode of action for hexavalent chromium-induced lung cancer following inhalation exposures.** *Toxicology* 2014, **325**:160-179.
26. Nettesheim P, Hanna MG, Jr., Doherty DG, Newell RF, Hellman A: **Effect of calcium chromate dust, influenza virus, and 100 R whole-body x radiation on lung tumor incidence in mice.** *J Natl Cancer Inst* 1971, **47**:1129-1144.
27. Steinhoff D, Gad SC, Hatfield GK, Mohr U: **Carcinogenicity study with sodium dichromate in rats.** *Exp Pathol* 1986, **30**:129-141.
28. Glaser U, Hochrainer D, Kloppel H, Oldiges H: **Carcinogenicity of sodium dichromate and chromium (VI/III) oxide aerosols inhaled by male Wistar rats.** *Toxicology* 1986, **42**:219-232.

29. **Chromium, nickel and welding.** *IARC Monogr Eval Carcinog Risks Hum* 1990, **49**:1-648.
30. Costa M: **Molecular mechanisms of nickel carcinogenesis.** *Annu Rev Pharmacol Toxicol* 1991, **31**:321-337.
31. Kasprzak KS, Sunderman FW, Jr., Salnikow K: **Nickel carcinogenesis.** *Mutat Res* 2003, **533**:67-97.
32. Shen HM, Zhang QF: **Risk assessment of nickel carcinogenicity and occupational lung cancer.** *Environ Health Perspect* 1994, **102 Suppl 1**:275-282.
33. **Nickel compounds and metallic nickel.** *Rep Carcinog* 2011, **12**:280-283.
34. Cai Y, Zhuang Z: **[DNA damage in human peripheral blood lymphocyte caused by nickel and cadmium].** *Zhonghua Yu Fang Yi Xue Za Zhi* 1999, **33**:75-77.
35. Chiou YH, Wong RH, Chao MR, Chen CY, Liou SH, Lee H: **Nickel accumulation in lung tissues is associated with increased risk of p53 mutation in lung cancer patients.** *Environ Mol Mutagen* 2014, **55**:624-632.
36. Dumala N, Mangalampalli B, Chinde S, Kumari SI, Mahoob M, Rahman MF, Grover P: **Genotoxicity study of nickel oxide nanoparticles in female Wistar rats after acute oral exposure.** *Mutagenesis* 2017, **32**:417-427.
37. M'Bemba-Meka P, Lemieux N, Chakrabarti SK: **Nickel compound-induced DNA single-strand breaks in chromosomal and nuclear chromatin in human blood lymphocytes in vitro: role of oxidative stress and intracellular calcium.** *Mutat Res* 2005, **586**:124-137.
38. Tessier DM, Pascal LE: **Activation of MAP kinases by hexavalent chromium, manganese and nickel in human lung epithelial cells.** *Toxicol Lett* 2006, **167**:114-121.

39. Zhao J, Shi X, Castranova V, Ding M: **Occupational toxicology of nickel and nickel compounds.** *J Environ Pathol Toxicol Oncol* 2009, **28**:177-208.
40. Pool-Zobel BL, Lotzmann N, Knoll M, Kuchenmeister F, Lambertz R, Leucht U, Schroder HG, Schmezer P: **Detection of genotoxic effects in human gastric and nasal mucosa cells isolated from biopsy samples.** *Environ Mol Mutagen* 1994, **24**:23-45.
41. Dally H, Hartwig A: **Induction and repair inhibition of oxidative DNA damage by nickel(II) and cadmium(II) in mammalian cells.** *Carcinogenesis* 1997, **18**:1021-1026.
42. **NTP Toxicology and Carcinogenesis Studies of Nickel Oxide (CAS No. 1313-99-1) in F344 Rats and B6C3F1 Mice (Inhalation Studies).** *Natl Toxicol Program Tech Rep Ser* 1996, **451**:1-381.
43. Antonini JM, Clarke RW, Krishna Murthy GG, Sreekanthan P, Jenkins N, Eagar TW, Brain JD: **Freshly generated stainless steel welding fume induces greater lung inflammation in rats as compared to aged fume.** *Toxicol Lett* 1998, **98**:77-86.
44. Manz DH, Blanchette NL, Paul BT, Torti FM, Torti SV: **Iron and cancer: recent insights.** *Ann N Y Acad Sci* 2016, **1368**:149-161.
45. Toyokuni S: **Iron overload as a major targetable pathogenesis of asbestos-induced mesothelial carcinogenesis.** *Redox Rep* 2014, **19**:1-7.
46. Siew SS, Kauppinen T, Kyyronen P, Heikkila P, Pukkala E: **Exposure to iron and welding fumes and the risk of lung cancer.** *Scand J Work Environ Health* 2008, **34**:444-450.

Figure legends

Figure 1A, B, C, D. Panel A - Low and high doses of the metal oxides or GMAW-SS fume. Panel B- Scanning electron microscopy images of NiO (panel B), Fe₂O₃ (panel C), and Cr₂O₃/CaCrO₄ (panel D).

Figure 2. Experimental timeline and block design for Experimental protocol 1: BAL and histopathology/gene expression studies. The experimental timeline shows 4 time points for sacrifice post-exposure. Two groups of 256 mice were used for parallel BAL and histopathology/gene expression studies. Each group of 256 mice was separated into 4 blocks with 8 treatment groups corresponding to the low or high doses of metal oxides, sham or GMAW-SS fume (8 groups * 8 mice/group * 4 blocks = 256 mice).

Figure 3. Experimental protocol 2: Two-stage initiation-promotion lung tumor bioassay. 200 male A/J mice were organized into 5 groups: MCA/NiO, MCA/Cr₂O₃ + CaCrO₄, MCA/Fe₂O₃, MCA/sham, or CO/sham. Beginning one week post-initiation with MCA or CO, mice were exposed to the metal oxide or sham by oropharyngeal aspiration once per week for 5 weeks (panel a). Doses of metal oxides were the cumulative high doses from experimental protocol 1 (panel b).

Figure 4. LDH activity after exposure to GMAW-SS fume or metal oxides. Data are presented as percent control compared to sham (dashed line). * $p < 0.0001$ compared to control, ** $p < 0.0001$ compared to control and all other low dose groups, # $p < 0.0001$ compared to low and high dose metals within a group.

Figure 5. Total BAL cells (panel a), neutrophils (panel b), and macrophages (panel c) after exposure to GMAW-SS fume or metal oxides. * $p < 0.0001$ compared to control, ** $p < 0.0001$ compared to sham and all other low dose groups, # $p < 0.0001$ compared to low and high dose metals within a group.

Figure 6. Ability of macrophages to phagocytose *E. Coli* green fluorescent protein after exposure to metal oxides. *E. Coli* uptake by macrophages was quantified by flow cytometry. * $p < 0.05$ – compared to sham

Figure 7. Relative mRNA levels at 1 day post-exposure to GMAW-SS, Fe₂O₃ low, or Fe₂O₃ high in the lung (panel A) or liver (panel B). Data presented as fold change respective to relative sham ** $p < 0.001$ compared to sham, * $p < 0.05$ compared to sham.

Figure 8. Lung histopathological findings following exposure to GMAW-SS or metal oxides. Exudate and brown material (arrow) in the bronchial lumen of a mouse exposed to GMAW-SS fume and sacrificed 1 day post-exposure (panel A; 10x magnification). Mononuclear cell infiltrate of alveolar wall in a mouse exposed to GMAW-SS fume (panel B; 20x magnification) or low dose Fe₂O₃ (panel C; 40x magnification) and sacrificed 7 days post-exposure. A bronchiolo-alveolar adenoma in an Fe₂O₃ - exposed mouse 30 weeks post-initiation with MCA at 10x magnification (panel D) and 20x magnification(panel E).

Figure 9. Total tumor number per mouse lung following exposure to CO or MCA and a metal oxide or sham. Bars represent lung tumor multiplicity (average tumor number per mouse lung) for each group. * $p < 0.0001$ compared to CO/Sham, ** $p < 0.0001$ compared to MCA/sham

Figure 10. Grossly observed lung tumors pre-fixation (left) and 24 h post-fixation (right) following exposure to $\text{Cr}_2\text{O}_3/\text{CaCrO}_4$ (panel A), Fe_2O_3 (panel B), and NiO (panel C).

Tumors (arrows) were on average ~1mm and opaque in color.

Figures

Figure 1.

Figure 2.

[illegible]

Figure 3.

A.

B.

Exposure	Weekly Dose	Cumulative Dose
NiO	56.2 µg	281 µg
Cr ₂ O ₃ /CaCrO ₄	146.2 µg/2.2 µg	731 µg/11 µg
Fe ₂ O ₃	400 µg	2 mg

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

Figure 9.

Figure 10.

Tables

Table 1

Sample	Dose	SSA (m ² /g)	Hydrodynamic Diameter (nm)	Zeta Potential (mV)**
Cr ₂ O ₃ /CaCrO ₄	High	2.7 ± 0.01 / 0.78 ± 0.01	147 ± 0.3*	-28.7 ± 2.1
	Low		142 ± 2.0*	-28.4 ± 2.3
Fe ₂ O ₃	High	6.0 ± 0.01	699 ± 200	-31.4 ± 0.9
	Low		639 ± 32	-32.0 ± 0.8
NiO	High	2.0 ± 0.01	124 ± 0.6*	-25.8 ± 2.0
	Low		126 ± 1.1	-28.1 ± 1.7
GMAW-SS	--	53.1 ± 0.26	1068 ± 197	-27.1 ± 0.8

Table 1.

*Value determined using NTA, all other values determined using DLS

**pH of study materials: Cr₂O₃/CaCrO₄ high (7.2), low (7.3); Fe₂O high (7.4), low (7.4); NiO high (7.4), low (7.4); GMAW-SS (6.9)

Table 2

A.

	G-CSF	GM-CSF	IL-5	IL-6	IP-10	KC	LIF	MIG	MIP-1a	MIP-1B	MIP-2	TNFa	VEGF
PBS	1	1	1	1	1	1	1	1	1	1	1	1	1
Ni low	7.08	1.05	2.71	2.52	1.42	2.08	1.74	2.44	3.28	7.53	1.32	4.1	1.56
Ni high	12.35	1.25	3.58	6.24	1.75	2.26	6.38	3.1	3.59	7.64	1.2	3.14	1.66
Cr low	64.05	1.5	5.7	24.99	10.08	7.36	25.63	22.17	16.36	48.1	1.18	9.13	4.88
Cr high	128.74	1.92	15.75	74.61	10.09	16.54	130.58	16.26	24.01	85.9	1.36	10.44	8.06
GMA-SS	854.8	2.84	18.56	1152.63	93.39	35.28	903.43	25.72	10.3	67.77	5.51	70.11	21.06
Fe low	303.29	2.22	12.1	261.51	85.35	13.51	345.98	63.91	19.39	221.71	5.73	132.77	9.76
Fe high	507.46	3.45	23.32	253.73	11.58	8.64	1002.59	16.64	8.97	41.97	1.61	15.93	9.9

B.

	G-CSF	GM-CSF	IL-6	IP-10	KC	MIP-1a	MIP-1B	MIP-2	TNFa	VEGF
PBS	1	1	1	1	1	1	1	1	1	1
Ni low	1.2	6.9	0.98	1.16	0.99	1.23	1.03	0.93	0.92	0.97
Ni high	0.89	1.13	1.9	4.67	1.98	3.43	1.4	0.78	0.68	0.82
Cr low	1.09	6.27	0.66	0.82	0.96	3.4	1.23	0.96	0.97	1.01
Cr high	1.14	3.58	0.95	1.18	1.46	6.44	2.91	0.73	0.9	1.03
GMA-SS	8.58	5.68	11.13	48.44	11.68	15.38	7.27	2.42	2.94	1.84
Fe low	1.15	0.81	0.84	5.62	2	4.75	2.3	0.77	0.61	1.12
Fe high	1.12	2.06	3	9.03	3.57	6.99	4.04	1.27	1.18	1.61

Table 2. BAL cytokine analysis at 1 d (panel a) and 28 d (panel b) post-exposure to component metals or sham.

Table 3

		GMAW-SS	Fe ₂ O ₃ low	Fe ₂ O ₃ high
Liver genes	<i>HAMP</i>	1.58 ± 0.25	1.3 ± 0.30	1.23 ± 0.24
	<i>MT1</i>	74.64 ± 9.02*	29.89 ± 18.16*	42.26 ± 13.46*
	<i>MT2</i>	9.65 ± 2.58*	7.41 ± 5.03**	8.59 ± 3.23*
	<i>HP</i>	3.93 ± 0.64*	3.24 ± 1.48*	2.31 ± 0.48*
	<i>SAA-1</i>	136.57 ± 38.32*	72.02 ± 51.83*	84.34 ± 31.52*
Lung genes	<i>p21</i>	2.29 ± 0.28 *	1.05 ± 0.08	1.05 ± 0.08
	<i>CDK4</i>	1.19 ± 0.16	0.89 ± 0.09	0.86 ± 0.06
	<i>Nr1d1</i>	1 ± 0.17	1.37 ± 0.19	1.07 ± 0.28
	<i>Nr1d2</i>	1.34 ± 0.21	1.95 ± 0.31**	1.67 ± 0.47
	<i>Hmox1</i>	2.69 ± 0.23*	1.54 ± 0.15**	1.92 ± 0.37**
	<i>Tfrc</i>	1.37 ± 0.15	1.13 ± 0.10	1.37 ± 0.28
	<i>Slc40a1</i>	1.32 ± 0.12**	1.05 ± 0.06	1.15 ± 0.13
	<i>Sox 9</i>	1.63 ± 0.23	2.76 ± 0.55**	4.36 ± 1.24**

Table 3. Relative mRNA levels as mean fold change compared to sham (mean fold change of 1) in the lungs and liver at 1 day post-exposure to GMAW-SS or Fe₂O₃ low or high dose. No changes were seen for NiO treated animals for any gene at any time point. GMAW-SS – gas metal arc welding – stainless steel, HAMP - hepcidin, Mt1 – metallothionein 1, Mt2 - metallothionein 2, HP – haptoglobin, SAA1 - serum amyloid A1, p21 – cyclin-dependent kinase inhibitor 1, CDK4 – cyclin-dependent kinase 4, NR1D1 – nuclear receptor subfamily 1 group D member 1, NR1D2 - nuclear receptor subfamily 1 group D member 2, HMOX1 – heme oxygenase 1, TFRC – transferrin receptor, SLC40A1 – solute carrier family 40 member 1, SOX 9 – SRY – box 9

* $p < 0.0001$, ** $p < 0.05$

Table 4

	n	Infiltration, mononuclear	Infiltration, neutrophils	Pigmented macrophages	Foreign bodies, black	hyperplasia	phagocytes with cell debris	Neutrophilic exudates
Sham	6	--	--	--	--	--	--	--
NiO low	6	--	1.33 ± 0.42	1 ± 0.26	1 ± 0.26	--	--	--
NiO high	6	--	1.67 ± 0.21*	1.17 ± 0.17	1.17 ± 0.17	0.67 ± 0.33	0.33 ± 0.33	--
Cr ₂ O ₃ /CaCrO ₄ low	6	1 ± 0.45	1.67 ± 0.21*	2	2	0.17 ± 0.17	1.33 ± 0.42	--
Cr ₂ O ₃ /CaCrO ₄ high	6	0.83 ± 0.40	1.33 ± 0.33	2.67 ± 0.21**	2.67 ± 0.21*	0.17 ± 0.17	1.67 ± 0.76	1 ± 0.52
GMA-SS	6	2.17 ± 0.17**	1.67 ± 0.21*	2.83 ± 0.17 [^]	3**	0.67 ± 0.42	3.17 ± 0.17**	1.83 ± 0.60
Fe ₂ O ₃ low	6	1.17 ± 0.17	1	2.5 ± 0.22*	--	--	1.67 ± 0.42	--
Fe ₂ O ₃ high	6	1 ± 0.37	1.83 ± 0.17**	3 [^]	4 ± 0.26 [^]	0.33 ± 0.33	1.5 ± 0.5	0.5 ± 0.5

Table 4. Abnormal morphological findings in lungs of mice 1 day post-exposure to GMAW-SS

fume, low and high dose metal oxides, or sham. Severity scores are the averages of the right lung lobes and presented as mean ± standard error. Severity was scored as 1 = minimal, 2 = mild, 3 = moderate, 4 = marked. * $p < 0.03$, ** $p < 0.003$, [^] $p < 0.0007$ - compared to sham.

GMAW-SS: gas metal arc welding – stainless steel; MCA: 3-methylcholanthrene.

Table 5

	n	Lymphocytic infiltrate*	Foreign material*	Hyperplasia severity*	Alveolar epithelial Hyperplasia**	Bronchiolo-alveolar adenoma**	Total lesions**
MCA/sham	24	--	--	1.69 ± 0.30	3.00 ± 0.60 (75)	1.33 ± 0.25 (32)	4.33 ± 0.64 (107)
MCA/NiO	26	--	0.77 ± 0.17 [^]	1.77 ± 0.42	2.77 ± 0.68 (72)	1.62 ± 0.48 (42)	4.38 ± 0.86 (114)
MCA/ Fe ₂ O ₃	33	0.45 ± 0.08	1.83 ± 0.05 [^]	2.33 ± 0.16 ⁺	4.96 ± 0.44 (164)	1.94 ± 0.24 (64)	6.91 ± 0.52 (228) [^]
MCA/ Cr ₂ O ₃ /CaCrO ₄	32	0.06 ± 0.06	0.97 ± 0.05 [^]	2.19 ± 0.38	3.91 ± 0.90 (125)	1.50 ± 0.43 (48)	5.41 ± 1.02 (173)

Table 5. Two stage (initiation-promotion) lung cancer bioassay: Lung histopathology severity scores for abnormal morphological findings and number of lesions in A/J mice at 30 weeks

*Severity scores are the averages of the left and right lung lobes and presented as mean ± standard error. Severity was scored as 1 = minimal, 2 = mild, 3 = moderate, 4 = marked.

**hyperplasia and adenoma were the only two lung lesions present and represented as count data presented as average or total lesions (in parenthesis).

-- indicates no findings

[^]p < 0.0001 - compared to MCA/sham

⁺p < 0.003 - compared to MCA/sham

GMAW-SS: gas metal arc welding – stainless steel

MCA: 3-methylcholanthrene

Chapter 6: Lack of Lung Tumor Promotion after Inhalation of a Copper-Nickel Welding Fume in A/J Mice

LM Falcone^{1,2}, A Erdely^{1,2}, R Salmen¹, LA Battelli¹, T Dodd¹, M Keane¹, W McKinney¹, S Stone¹, M Donlin¹, HD Leonard¹, JL Cumpston¹, JB Cumpston¹, R Mercer¹, TB Chen¹, RN Andrews³, M Kashon¹, JM Antonini¹, PC Zeidler-Erdely^{1,2}

¹Health Effects Laboratory Division, National Institute for Occupational Safety and Health, Morgantown, WV; ²West Virginia University, School of Medicine, Morgantown, WV; ³Division of Applied Research and Technology, National Institute for Occupational Safety and Health, Cincinnati, OH

Abstract

The International Agency for Research on Cancer classified welding fumes as a Group 1 (*carcinogenic to humans*) in 2017. The process of stainless steel welding creates fumes rich in carcinogenic metals such as chromium (Cr). Our lab has previously demonstrated that stainless steel welding fumes promote lung tumors in tumor susceptible A/J mice. Consumables devoid of Cr are being produced in an attempt to limit worker exposures to potentially carcinogenic metals. The aim of this study was to characterize a new copper-nickel (Cu-Ni) fume and then investigate if inhalation of this fume would promote lung tumors in mice using a two-stage (initiation-promotion) model. Male A/J mice (4 – 5 weeks) were initiated with 3-methylcholanthrene (10 µg/g intraperitoneally) or corn oil and beginning 1 week later were exposed to air or Cu-Ni welding fumes for 4 hours/day, 4 days/week, for 9 weeks. At 30 weeks, mice were sacrificed and lung tumor multiplicity and incidence were evaluated. MCA/Cu-Ni welding fume exposure significantly decreased tumor size and tumor number compared MCA/air controls (15.57 ± 0.75 tumors vs. 7.11 ± 0.93 tumors and 1.15 mm in diameter vs. 0.57 mm in diameter, respectively). Characterization of the fume indicated that most of the particles were between 0.1 and 1 µm in diameter, with a mass median aerodynamic diameter of 0.43 µm. Future studies are planned to investigate the pneumotoxicity of Cu-Ni fume in A/J mice.

Introduction

Welding, a method of joining metals, employs millions of workers around the world [1]. However, many types of welding produce significant amounts of fumes which are known to be hazardous to human health [2, 3]. Acute and chronic conditions such as metal fume fever, bronchitis, and increased infection incidence have been reported in welders [3-7]. However, welding fumes also cause lung cancer. Welding fumes are classified as *carcinogenic to humans* (Group 1) by the International Agency for Research on Cancer (IARC) and can contain metals such as iron (Fe), manganese (Mn), chromium (Cr), copper (Cu), and nickel (Ni). [1] Cr and Ni are also classified as Group 1 carcinogens [8]. The carcinogenicity of welding fumes is sometimes favored to be due to Cr^{6+} which is present in the fume. In 2006, the Occupational Safety and Health Administration (OSHA) reduced the Cr^{6+} concentration in the workplace from 52 to 5 $\mu\text{g}/\text{m}^3$. This reduction can be challenging to maintain with stainless steel welding. For this reason, newer welding consumables containing primarily Cu and Ni have been produced that may prove less hazardous to workers' health.

Epidemiological studies have investigated lung cancer after exposure to both mild steel (MS) and stainless steel (SS) welding fumes. The former fume is composed of entirely Fe and Mn, while the latter contains Fe, Ni, Cr, Cu, and Mn. Most notably, worker studies suggest that both MS and SS fume exposures increase lung cancer in welders, even though MS fume contains no known human carcinogens [9-12]. There are no epidemiological studies investigating worker exposure to fume from the newer Cu-Ni welding consumables and only limited *in vivo* and *in vitro* studies on the pneumotoxicity of the fume are available. There are no *in vivo* studies on the tumorigenic potential of this fume.

Previous studies in our laboratory have employed a two-stage (initiation-promotion) model of lung tumorigenesis to study welding fume exposure. It was demonstrated using a two-

stage initiation-promotion model that GMAW-SS fume promotes lung tumors in A/J mice [13, 14]. The aim of this study was to investigate if inhalation of a Cu-Ni welding fume would also promote lung tumor formation in A/J mice. Results of this study could help to clarify whether or not newer Cu-Ni welding consumables are safer alternatives to improve worker health.

Methods

Animals

Male A/J mice (age 4–5 week) were purchased from Jackson Laboratories (Bar Harbor, ME) and housed in an AAALAC International - specific pathogen-free, environmentally-controlled facility. All mice were free of endogenous pathogens including viruses, bacteria, mycoplasmas, and parasites. Mice were housed in groups of two in ventilated cages and provided high-efficiency particulate filtered air under a controlled light cycle (12 h light/12 h dark) at a standard temperature (22-24°C) and 30-70% relative humidity. Animals were acclimated to the animal facility for one week before beginning the experimental protocols and allowed access to a conventional diet (6% irradiated NIH-31 Diet, Envigo RMS, Inc.; Madison, WI) and tap water *ad libitum*. All procedures were performed using protocols approved by the National Institute for Occupational Safety and Health (NIOSH) Institutional Animal Care and Use Committee.

Welding fume inhalation exposure system

The design and construction of the welding fume aerosol generator were previously described [15]. This automated robotic welder continuously generated welding fumes by welding beads onto ¼ inch thick plates of mild steel. The welding wire used was 0.045 inch diameter Lincoln Electric Techalloy 413 MIG and the welding parameters were set to 25 volts DC, 300 inch per minute wire feed, 30 L/min of 75% argon – 25% helium shielding gas, and a typical welding current of 200 amps. The resulting fume was carried into a whole body exposure chamber through a ¾ inch flexible tube by maintaining the chamber at a negative pressure (0.70

inch H₂O). Particle concentrations within the exposure chamber were continuously monitored with a Data RAM (DR-40000 Thermo Electron Co; Franklin, MA), and gravimetric determinations (37 mm cassettes with 0.45 µm pore-size Teflon filters) were used to calibrate and verify the Data RAM readings each day. Gas generation, including carbon monoxide (CO), carbon dioxide (CO₂), oxygen (O₂), and ozone (O₃), was continuously monitored. During the welding exposure, O₂ levels were maintained above the OSHA minimal acceptable level. O₃, CO, CO₂ were below OSHA permissible exposure limits and NIOSH recommended exposure limits (REL) during the entire exposure duration. In the exposure chamber, CO and O₃ levels were not significantly higher than background. The exposure system was modified slightly from that described previously to reduce the travel time of the particulate fume from the welding torch to the exposure chamber [15].

Experimental protocol for welding fume metal analysis and characterization

A small amount of welding fume was collected gravimetrically onto 47-mm Nucleopore polycarbonate filters (Whatman; Clinton, PA) for field emission scanning electron microscopy (FESEM) to assess particle size and morphology. The particles were imaged using a Hitachi S4800 Field Emission Scanning Electron Microscope (Hitachi; Tokyo, Japan). For elemental analysis of Cu-Ni fume, generated particles were collected inside the exposure chamber onto 5.0 µm polyvinyl chloride membrane filters in 37-mm cassettes during three 30 minute collections. The particle samples were digested and the metals were analyzed by inductively coupled plasma atomic emission spectroscopy according to the NIOSH method 7303 for hot block/HCL/HNO₃ digestion (NIOSH, 1994) as previously described [15]. Metal content of blank filters also were analyzed for control purposes. To determine particle mass size distribution, a Micro-Orifice Uniform Deposit Impactor (MOUDI, model 110; MSP corp., Shoreview, Minn.) with additional

Nano-MOUDI stages (MSP model 115) was used. Lastly, welding fume samples were also analyzed using energy dispersive X-ray analysis (SEM-EDX; Princeton Gamma-Tech, Rocky Hill, N.J.) at 20 keV.

Experimental protocol for whole lung metal analysis

Weight-matched A/J mice were exposed by whole-body inhalation in individual steel mesh cages to Cu-Ni welding aerosols (mean concentration 43 mg/m³ over 4 hours) (n = 10) or filtered air (n = 6). Immediately following exposure (time zero), whole lungs were excised, trimmed, and lyophilized. The freeze-dried tissue was weighed then acid digested. Inductively coupled argon plasma atomic emission spectroscopy at NIOSH-Division of Applied Research and Technology (Cincinnati, OH) was used to determine the amount of Al, Ba, Ca, Co, Cr, Cu, Fe, K, Li, Mg, Mn, Ni, P, Pb, Sr, Ti, V, Zn and Zr present in the lung according to the draft NIOSH method 8200 used for bulk tissue samples (NIOSH 2003).

Experimental protocol for two-stage lung carcinogenesis bioassay in A/J mice

For the two-stage initiation-promotion protocol, 120 mice were weight-matched and randomized into four exposure groups (n = 30/group). On day 1, mice were intraperitoneally (IP) injected with the chemical initiator, 3-methylcholanthrene (MCA) (Sigma-Aldrich; St. Louis, MO) dissolved in corn oil (CO) (Sigma-Aldrich; St. Louis, MO) at a dose of 10 µg/g of body weight or CO alone (Figure 1B). MCA was chosen as the initiating agent based on the efficient response of the A/J mouse to this carcinogen in our previous oropharyngeal aspiration and inhalation studies [14, 16]. Beginning 1 week post-initiation, mice were exposed by whole-body inhalation to Cu-Ni WF aerosols or filtered air for 4 hours/day, 4 days/week, for 9 weeks at a target concentration of 40 mg/m³ (actual mean concentration 32.6 over 9 weeks). Throughout the study, mice were weighed biweekly including at the terminal sacrifice at 30-weeks post-

initiation. Mice were euthanized with sodium pentobarbital [100-300 mg/kg IP] (Vortech Pharmaceuticals; Dearborn, MI), weighed, and exsanguinated via the vena cava. All internal organs were examined for the presence of tumors. Then, the whole lung was excised and inflated with 10% neutral buffered formalin. Twenty-four hours post-fixation, lung tumors were counted. Lung tumor incidence was recorded as the percent of tumor-bearing mice out of the total, and lung tumor multiplicity was determined as the average tumor number per mouse lung including mice with no tumors. Any apparent merged tumors were counted as one tumor. Lungs were embedded in paraffin before a 5 μ m standardized section was cut and slides were made.

Welding fume particles in sections from exposed lungs were assessed using an enhanced dark-field optical system. Welding fume particles scatter light significantly greater than the surrounding tissues due to a significant difference in refractive index, nanometer size and the crystalline structure of the particles. The enhanced dark-field optical system images light scattered in the section and, thus, particles in the section stand-out from the surrounding tissues with high contrast. As has been described previously, this method of imaging can be used to scan lung sections at relatively low magnification to identify particles that would not be detected by other means [17-20]. Typically, the image intensity of particles in tissue sections is approximately 20-fold that of the embedded tissue [20]. Sections for dark-field examination were cut from paraffin blocks at 5 microns thickness and collected on ultrasonically cleaned, laser cut slides (Schott North America Inc, Elmsford, N.Y. 10523) to avoid contamination from the ground edges of traditional slides. After staining with Sirius Red-Hematoxylin, slides were dehydrated in xylene and coverslipped with PermOUNT (Fisher Scientific Co., Pittsburgh, PA) containing 5%, by volume xylene. Just before mounting, the xylene-PermOUNT was centrifuged at 10,000 x g for 10 minutes to remove contaminating particles in the PermOUNT. The optical microscopes consist of a

transmitted light microscope (Olympus B63 with motorized condenser, controller and reflected light system) and a CytoViva EDM (CytoViva, Auburn, AL 36830). The CytoViva EDM has a high signal-to-noise, dark-field illumination optical system adapted to an Olympus BX41 microscope which also includes a hyperspectral imaging camera with ENVI 4.8 analysis software and the CytoViva 3-D positioning and analysis software for serial section reconstruction. Both transmission light microscope and EDM were equipped with an Olympus DP73 digital camera with cellsens Dimension camera control and measurement software (Olympus America Inc., Center Valley, PA 18034). Images for both systems were taken at either high resolution 4800x3600 pixels or 2400x1800 pixels.

Statistical comparisons and analysis

Statistical analyses were performed using either JMP version 13, or SAS version 9.4 for Windows. Continuous variables were analyzed using treatment by day factorial analyses of variance (ANOVA), followed by Fishers LSD for pairwise comparisons. For some variables, a natural log transformation was performed on the data to reduce heterogeneous variance and meet the assumptions of an ANOVA. Gross tumor counts were analyzed using nonparametric Kruskal-Wallis tests and followed by pair-wise comparisons using the Wilcoxon Rank Sums test. Tumor incidence was analyzed using a Chi-square test in SAS 'Proc Freq,' while tumor multiplicity was analyzed using Poisson regression in SAS 'Proc Genmod.' In cases where over dispersion existed, a negative binomial regression was performed. Analyses were performed independently on CO and MCA-treated animals and only utilized data from those animals surviving to the 30-week time point. For tumor size comparisons between MCA-treated animals, a two-sided t test was performed only on data from animals with tumors. For all analyses, a $p < 0.05$ was set as the criteria for significance.

Results

Characterization of Generated Welding Fume

Elemental analysis indicated that GMAW-MS was primarily Cu and Ni (Table 1). Cu content by weight percent averaged 76.35% and Ni was 11.60 %. Approximately 5% of fume consisted of Ti and Mn and the remaining metal content of the fume was trace metals. Because welding is known to generate a significant number of nanosized particles, both MOUDI and Nano-MOUDI samplers were used to determine particle size distribution. Most of the particles were between 0.1 and 1 μm in diameter, with a mass median aerodynamic diameter of 0.43 μm (Figure 2).

Enhanced Dark-field Light Microscopy Imaging of Welding Fumes

Enhanced dark-field microscopy confirmed the deposition of Cu-Ni welding fume particles in fume-exposed animals as the particles scattered light at a much greater intensity than the surrounding lung tissues (Figure 3). The lung tissue adjacent to the fume deposits was made visible only by the addition of transmitted light. Welding particle deposits appeared almost exclusively inside macrophages, indicating this fume is phagocytosed by alveolar macrophages. Microscopy images of air-exposed mice showed intact lung tissue and the presence of macrophages devoid of any particulate matter. No difference was seen in microscopy images of MCA or CO-exposed mice, indicating that the MCA or CO exposure did not affect lung burden of fume.

Whole lung metal deposition after Cu-Ni fume inhalation

The lung metal deposition in A/J mice measured at time 0 after 4 hours of inhalation of Cu-Ni fume is shown in Table 2 and was calculated as done previously [16]. The most abundant metals measured were Cu ($5.11 \mu\text{g Cu} / 7.33 \mu\text{g total metal deposition} = 69.7 \%$) and Ni ($1.18 \mu\text{g Ni} / 7.33 \mu\text{g total metal deposition} = 16.1\%$), which equates to the elemental analysis of the GMAW-MS fume shown in Table 1.

Human relevance deposition calculation:

The analysis of the metals showed a cumulative increase of 7.33 µg of total Cu-Ni fume deposited in the lung from a single 4 hour exposure (Table 2). The alveolar deposition in the mice was equated to the human by the equations below using the previous threshold limit value-time weighted average (TLV-TWA) of 5 mg/m³ for total welding fume. Previously, we estimated that 70% of the total dose reached the alveolar space (7.33 µg/d x 0.70 = 5.13 µg/d) [21, 22]. The mice were exposed for 36 days (9 weeks at 4 days/week) for an approximate total alveolar deposition of 184.68 µg.

Estimated human daily deposition using previous welding fume TLV-TWA of 5 mg/m³:

Fume concentration x min volume x exposure duration x deposition efficiency = deposited human dose

5 mg/m³ x (20 l/min)(10⁻³ m³/l) x (8 hours/day)(60 minutes/hour) x 0.16 = 7.7 mg deposited per 8 hour day in humans

Estimated human equivalent deposition from quantified deposition in mouse using alveolar surface area (SA)[23]

$(SA_{\text{human}} \times \text{deposition}_{\text{mouse}}) / SA_{\text{mouse}} = \text{deposition}_{\text{human}}$

$(102 \text{ m}^2 \times 0.18468 \text{ mg}) / 0.05 \text{ m}^2 = 376.75 \text{ mg}$

376.75 mg / 7.7 mg/day = approximately 49 working days for a human working at 5 mg/m³ for 8 hours/day. While it is understood that welding is usually not done for 8 hours/day, and the exposure levels are likely not to consistently reach 5 mg/m³ as a TWA, the deposition in this study model was representative of cumulative exposure in a human.

Gross tumor multiplicity and incidence

Cu-Ni welding fume significantly decreased lung tumors in mice at 30 weeks after initiation with MCA (Figure 4). Lung tumor multiplicity was 15.57 ± 0.75 and 7.11 ± 0.93 for MCA/air and MCA/Cu-Ni fume, respectively ($p < 0.0001$). There was no effect of welding fume alone on tumor multiplicity (CO/air, 0.30 ± 0.12 ; CO/GMAW-MS, 0.07 ± 0.05). The percentage of tumor-bearing mice out of the total (tumor incidence) was 22 % in CO/air and 7 % in CO/GMAW-MS-exposed animals. This low tumor incidence in 35 to 36 week old, CO-exposed mice is consistent with previous studies in our lab as well as other reports in the literature [13, 24, 25]. As expected, tumor incidence was high in all MCA-initiated groups (100% for MCA/air and 93% for MCA/Cu-Ni fume groups), which confirmed the successful administration as well as its carcinogenic effectiveness in A/J mice. The total and average tumor number per treatment group across each of the individual lung lobes is reported in Table 3. MCA/air-exposed mice had significantly greater lung tumor multiplicity in the left, apical, diaphragmatic, and azygos lung regions compared to MCA/Cu-Ni fume ($p < 0.05$).

Figure 5 shows the gross lung morphology of a MCA/air-exposed lung (panel A) and a MCA/Cu-Ni – exposed lung (panel B) 24 hours post-fixation with formalin. Welding fume deposition was not grossly visible in any exposed mouse lungs but was visible by enhanced darkfield microscopy (Figure 3). Tumors appeared white in color and opaque on initial gross exam and became more well-defined after fixation which aided enumeration. At 30 weeks, tumors were on average 1.15 mm in diameter in MCA/air-exposed mice and 0.57 mm in diameter in MCA/Cu-Ni fume-exposed mice ($p < 0.0001$).

Morbidity and mortality

Initial body weights at week 0 (means $\pm$ standard error [SE]) were 15.64 ± 0.48 , 15.79 ± 0.31 , 15.76 ± 0.39 , and 16.13 ± 0.43 g for the CO/air, CO/Cu-Ni WF, MCA/air, and MCA/Cu-Ni

WF groups, respectively. Body weights increased steadily from week 0 to 30 and did not differ among exposure groups. At terminal sacrifice, body weights were 28.46 ± 0.43 , 27.77 ± 0.50 , 28.29 ± 0.52 , and 27.70 ± 0.64 g for the CO/air, CO/Cu-Ni WF, MCA/air, and MCA/Cu-Ni WF groups, respectively. Morbidity and mortality throughout the study was low (~7 %) and no abnormalities, such as other tumor types besides lung, were found at the terminal sacrifice at 30 weeks. In total, 9 mice died during the course of the study and were not included in the final analysis of the data. Deaths were distributed evenly across treatment groups. Necropsy determined that all 9 mice died from morbidities not associated with the experimental protocol.

Discussion

The novel findings in this study were that inhalation of a Cu-Ni welding fume significantly decreased lung tumor size and tumor number *in vivo* in a two-stage model of lung tumorigenesis. While MCA/air-exposed mice averaged 15.57 ± 0.75 tumors per mouse lung, MCA/Cu-Ni fume averaged 7.11 ± 0.93 tumors per lung ($p < 0.0001$). Notably, tumors in MCA/air mice averaged over 1 mm in diameter, while tumors in MCA/Cu-Ni appeared much smaller on gross examination and averaged just 0.57 mm in diameter ($p < 0.0001$). To our knowledge, this is the first *in vivo* inhalation study investigating a Cu-Ni welding fume.

The Cu-Ni welding fume in this study contains ~76% Cu and 12% Ni according to metal analysis. Comparatively less studies have investigated the Cu in welding fumes compared to other metals like Cr, Ni, and Fe. While some reports have indicated that Cu in welding fumes is a respiratory irritant and contributes to metal fume fever, other literature suggests Cu is relatively benign in the lungs and does not cause this condition [3, 26]. However, Markert et al. investigated the Cu in welding fumes and found that Cu alone was able to increase levels of C reactive protein (CRP) [27]. Increases in CRP are believed to represent an early stage of metal

fume fever. Additionally, elevated levels of Cu have been found in lung, prostate, breast, and brain cancers, and Cu chelators can be useful as anti-cancer therapies [28]. Significantly more literature is available investigating Ni in welding fumes, and Ni is classified as *carcinogenic to humans* by the IARC, as supported by many worker and animal studies [3, 8, 29-33]. Many studies have shown that Ni can damage DNA directly as well as through reactive oxygen species production, epigenetic effects, and chromosomal aberrations [8, 30, 31, 34-40]. Inhalation studies in humans and animals have shown that Ni is a lung irritant and can cause inflammation as well as adversely affect the immune system [3, 40]. Numerous worker and *in vivo* studies have shown that exposure to Ni-containing stainless-steel welding fumes increases lung cancer risk [3, 13, 14, 41]. *In vitro* studies have also shown that the Ni in stainless steel welding fumes may be mutagenic [30, 42]. However, because welding fume exposures do not represent pure exposure to Ni, this elevated risk cannot be definitely linked to Ni or any other single metal component of the fume [3, 31]. Moreover, in 2012, IARC concluded that high cytotoxic concentrations as well as the presence of inflammation may be needed to potentially see carcinogenic effects from Ni exposures [8, 35, 38, 43, 44].

Only two published studies have investigated the pneumotoxicity of a Cu-Ni welding fume. Antonini et al. 2014 investigated the pulmonary toxicity of a Cu-Ni based fume generated by shielded metal arc welding (SMAW) using both *in vitro* and *in vivo* assays [45]. This fume only contained trace amounts of Cr and yet caused a persistent increase in lung injury and inflammation even greater than SS and MS fumes. Interestingly, the Cu-Ni fume did not increase reactive oxygen species (ROS), so it was hypothesized that the toxicity was due to a direct cytotoxic effect. An *in vitro* study by Badding et al. found that the Cu-Ni fume was more cytotoxic than SS or MS fume, causing cell death and mitochondrial dysfunction at lower doses

than the other fumes [46]. The authors likewise noted that the fume did not cause ROS production but did impair ability of exposed macrophages to phagocytose bacteria. Hence, these studies suggest that Cu-Ni fume from SMAW may still be toxic and inflammatory in the lungs. However, it is important to note that the metal composition of the welding fumes used in these studies was more complex than the Cu-Ni fume in this study because it was produced by SMAW. The fume in the cited studies contained ~30% potassium and ~21% aluminum with only 13.4% and 6% Ni and Cu, respectively. Therefore, it is likely the pneumotoxicity of the Cu-Ni used in this study would differ. Additionally, no studies have investigated pneumotoxicity *in vivo* following inhalation exposure to the Cu-Ni fume produced by GMAW.

It is unclear why the Cu-Ni welding fume decreased lung tumor size and was not a lung tumor promoter in this study. However, this study highlights the need for ongoing future research investigating Cu-Ni welding fumes. Additional *in vivo* and *in vitro* studies can help determine the toxicity of this fume and in particular, clarify whether the Cu in welding fumes is beneficial, benign, or harmful to worker health. While the results of the present study suggest Cu-Ni welding fume may pose a smaller health threat to welders, additional studies are needed to better clarify this risk.

Bibliography

1. Guha N, Loomis D, Guyton KZ, Grosse Y, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, Vilahur N, Muller K, Straif K: **Carcinogenicity of welding, molybdenum trioxide, and indium tin oxide.** *Lancet Oncol* 2017, **18**:581-582.
2. Antonini JM: **Health effects of welding.** *Crit Rev Toxicol* 2003, **33**:61-103.
3. Antonini JM: **Health Effects Associated with Welding.** 2014:49-70.
4. Coggon D, Inskip H, Winter P, Pannett B: **Lobar pneumonia: an occupational disease in welders.** *Lancet* 1994, **344**:41-43.

5. Holm M, Kim JL, Lillienberg L, Storaas T, Jogi R, Svanes C, Schlunssen V, Forsberg B, Gislason T, Janson C, Toren K: **Incidence and prevalence of chronic bronchitis: impact of smoking and welding. The RHINE study.** *Int J Tuberc Lung Dis* 2012, **16**:553-557.
6. Marongiu A, Hasan O, Ali A, Bakhsh S, George B, Irfan N, Minelli C, Canova C, Schofield S, De Matteis S, Cullinan P: **Are welders more at risk of respiratory infections? Findings from a cross-sectional survey and analysis of medical records in shipyard workers: the WELSHIP project.** *Thorax* 2016, **71**:601-606.
7. Suri R, Periselneris J, Lanone S, Zeidler-Erdely PC, Melton G, Palmer KT, Andujar P, Antonini JM, Cohignac V, Erdely A, et al: **Exposure to welding fumes and lower airway infection with *Streptococcus pneumoniae*.** *J Allergy Clin Immunol* 2016, **137**:527-534.e527.
8. **Arsenic, metals, fibres, and dusts.** *IARC Monogr Eval Carcinog Risks Hum* 2012, **100**:11-465.
9. Melkild A, Langard S, Andersen A, Tonnessen JN: **Incidence of cancer among welders and other workers in a Norwegian shipyard.** *Scand J Work Environ Health* 1989, **15**:387-394.
10. Danielsen TE, Langard S, Andersen A, Knudsen O: **Incidence of cancer among welders of mild steel and other shipyard workers.** *Br J Ind Med* 1993, **50**:1097-1103.
11. Hansen KS, Lauritsen JM, Skytthe A: **Cancer incidence among mild steel and stainless steel welders and other metal workers.** *Am J Ind Med* 1996, **30**:373-382.

12. Siew SS, Kauppinen T, Kyyronen P, Heikkilä P, Pukkala E: **Exposure to iron and welding fumes and the risk of lung cancer.** *Scand J Work Environ Health* 2008, **34**:444-450.
13. Falcone LM, Erdely A, Meighan TG, Battelli LA, Salmen R, McKinney W, Stone S, Cumpston A, Cumpston J, Andrews RN, et al: **Inhalation of gas metal arc-stainless steel welding fume promotes lung tumorigenesis in A/J mice.** *Arch Toxicol* 2017, **91**:2953-2962.
14. Zeidler-Erdely PC, Meighan TG, Erdely A, Battelli LA, Kashon ML, Keane M, Antonini JM: **Lung tumor promotion by chromium-containing welding particulate matter in a mouse model.** *Part Fibre Toxicol* 2013, **10**:45.
15. Antonini JM, Afshari AA, Stone S, Chen B, Schwegler-Berry D, Fletcher WG, Goldsmith WT, Vandestouwe KH, McKinney W, Castranova V, Frazer DG: **Design, construction, and characterization of a novel robotic welding fume generator and inhalation exposure system for laboratory animals.** *J Occup Environ Hyg* 2006, **3**:194-203; quiz D145.
16. Falcone LM, Erdely A, Meighan TG, Battelli LA, Salmen R, McKinney W, Stone S, Cumpston A, Cumpston J, Andrews RN, et al: **Inhalation of gas metal arc-stainless steel welding fume promotes lung tumorigenesis in A/J mice.** *Arch Toxicol* 2017.
17. Ma J, Mercer RR, Barger M, Schwegler-Berry D, Cohen JM, Demokritou P, Castranova V: **Effects of amorphous silica coating on cerium oxide nanoparticles induced pulmonary responses.** *Toxicology and applied pharmacology* 2015, **288**:63-73.
18. McKinney W, Jackson M, Sager TM, Reynolds JS, Chen BT, Afshari A, Krajnak K, Waugh S, Johnson C, Mercer RR, et al: **Pulmonary and cardiovascular responses of**

- rats to inhalation of a commercial antimicrobial spray containing titanium dioxide nanoparticles.** *Inhal Toxicol* 2012, **24**:447-457.
19. Mercer RR, Scabilloni JF, Hubbs AF, Wang L, Battelli LA, McKinney W, Castranova V, Porter DW: **Extrapulmonary transport of MWCNT following inhalation exposure.** *Part Fibre Toxicol* 2013, **10**:38.
 20. Mercer RR, Scabilloni JF, Wang L, Battelli LA, Antonini JM, Roberts JR, Qian Y, Sisler JD, Castranova V, Porter DW, Hubbs AF: **The Fate of Inhaled Nanoparticles: Detection and Measurement by Enhanced Dark-field Microscopy.** *Toxicol Pathol* 2018, **46**:28-46.
 21. Erdely A, Hulderman T, Salmen-Muniz R, Liston A, Zeidler-Erdely PC, Chen BT, Stone S, Frazer DG, Antonini JM, Simeonova PP: **Inhalation exposure of gas-metal arc stainless steel welding fume increased atherosclerotic lesions in apolipoprotein E knockout mice.** *Toxicol Lett* 2011, **204**:12-16.
 22. Raabe OG, Al-Bayati, M.A., Teague, S.V., Rasolt, A., : **Regional deposition of inhaled monodisperse coarse and fine aerosol particles in small laboratory animals.** *Ann Occup Hyg* 1988, **32**:53-63.
 23. Stone KC, Mercer RR, Gehr P, Stockstill B, Crapo JD: **Allometric relationships of cell numbers and size in the mammalian lung.** *Am J Respir Cell Mol Biol* 1992, **6**:235-243.
 24. Groch KM, Khan MA, Brooks AL, Saffer JD: **Lung cancer response following inhaled radon in the A/J and C57BL/6J mouse.** *Int J Radiat Biol* 1997, **71**:301-308.
 25. Curtin GM, Higuchi MA, Ayres PH, Swauger JE, Mosberg AT: **Lung tumorigenicity in A/J and rasH2 transgenic mice following mainstream tobacco smoke inhalation.** *Toxicol Sci* 2004, **81**:26-34.

26. Borak J, Cohen H, Hethmon TA: **Copper exposure and metal fume fever: lack of evidence for a causal relationship.** *Aihaj* 2000, **61**:832-836.
27. Markert A, Baumann R, Gerhards B, Gube M, Kossack V, Kraus T, Brand P: **Single and Combined Exposure to Zinc- and Copper-Containing Welding Fumes Lead to Asymptomatic Systemic Inflammation.** *J Occup Environ Med* 2016, **58**:127-132.
28. Tisato F, Marzano C, Porchia M, Pellei M, Santini C: **Copper in diseases and treatments, and copper-based anticancer strategies.** *Med Res Rev* 2010, **30**:708-749.
29. **Chromium, nickel and welding.** *IARC Monogr Eval Carcinog Risks Hum* 1990, **49**:1-648.
30. Costa M: **Molecular mechanisms of nickel carcinogenesis.** *Annu Rev Pharmacol Toxicol* 1991, **31**:321-337.
31. Kasprzak KS, Sunderman FW, Jr., Salnikow K: **Nickel carcinogenesis.** *Mutat Res* 2003, **533**:67-97.
32. Shen HM, Zhang QF: **Risk assessment of nickel carcinogenicity and occupational lung cancer.** *Environ Health Perspect* 1994, **102 Suppl 1**:275-282.
33. Langard S: **Nickel-related cancer in welders.** *Sci Total Environ* 1994, **148**:303-309.
34. **Nickel compounds and metallic nickel.** *Rep Carcinog* 2011, **12**:280-283.
35. Cai Y, Zhuang Z: **[DNA damage in human peripheral blood lymphocyte caused by nickel and cadmium].** *Zhonghua Yu Fang Yi Xue Za Zhi* 1999, **33**:75-77.
36. Chiou YH, Wong RH, Chao MR, Chen CY, Liou SH, Lee H: **Nickel accumulation in lung tissues is associated with increased risk of p53 mutation in lung cancer patients.** *Environ Mol Mutagen* 2014, **55**:624-632.

37. Dumala N, Mangalampalli B, Chinde S, Kumari SI, Mahoob M, Rahman MF, Grover P: **Genotoxicity study of nickel oxide nanoparticles in female Wistar rats after acute oral exposure.** *Mutagenesis* 2017, **32**:417-427.
38. M'Bemba-Meka P, Lemieux N, Chakrabarti SK: **Nickel compound-induced DNA single-strand breaks in chromosomal and nuclear chromatin in human blood lymphocytes in vitro: role of oxidative stress and intracellular calcium.** *Mutat Res* 2005, **586**:124-137.
39. Tessier DM, Pascal LE: **Activation of MAP kinases by hexavalent chromium, manganese and nickel in human lung epithelial cells.** *Toxicol Lett* 2006, **167**:114-121.
40. Zhao J, Shi X, Castranova V, Ding M: **Occupational toxicology of nickel and nickel compounds.** *J Environ Pathol Toxicol Oncol* 2009, **28**:177-208.
41. Sorensen AR, Thulstrup AM, Hansen J, Ramlau-Hansen CH, Meersohn A, Skytthe A, Bonde JP: **Risk of lung cancer according to mild steel and stainless steel welding.** *Scand J Work Environ Health* 2007, **33**:379-386.
42. Hedenstedt A, Jenssen D, Lidesteen BM, Ramel C, Rannug U, Stern RM: **Mutagenicity of fume particles from stainless steel welding.** *Scand J Work Environ Health* 1977, **3**:203-211.
43. Pool-Zobel BL, Lotzmann N, Knoll M, Kuchenmeister F, Lambertz R, Leucht U, Schroder HG, Schmezer P: **Detection of genotoxic effects in human gastric and nasal mucosa cells isolated from biopsy samples.** *Environ Mol Mutagen* 1994, **24**:23-45.
44. Dally H, Hartwig A: **Induction and repair inhibition of oxidative DNA damage by nickel(II) and cadmium(II) in mammalian cells.** *Carcinogenesis* 1997, **18**:1021-1026.

45. Antonini JM, Badding MA, Meighan TG, Keane M, Leonard SS, Roberts JR: **Evaluation of the Pulmonary Toxicity of a Fume Generated from a Nickel-, Copper-Based Electrode to be Used as a Substitute in Stainless Steel Welding.** *Environ Health Insights* 2014, **8**:11-20.
46. Badding MA, Fix NR, Antonini JM, Leonard SS: **A comparison of cytotoxicity and oxidative stress from welding fumes generated with a new nickel-, copper-based consumable versus mild and stainless steel-based welding in RAW 264.7 mouse macrophages.** *PLoS One* 2014, **9**:e101310.

Figure legends

Figure 1. Timelines of experimental protocols. Panel A – Experimental protocol for whole lung metal analysis. Mice were exposed by whole-body inhalation to filtered air (n = 10) or Cu-Ni fume (n = 10) for 4 hours. Inductively coupled argon plasma, atomic emission spectroscopy was used to analyze metal content of lungs. Panel B - Experimental protocol for two-stage (initiation-promotion) bioassay. Mice received MCA (n = 60) or corn oil (n = 60) injections and beginning 1 week later were exposed to Cu-Ni fume or air inhalation 4 hours/day x 4 day/week x 9 weeks before terminal sacrifice at 30 weeks

Figure 2. Particle size distribution of Cu-Ni welding fume comparing mass concentration versus particle size as measured using the MOUDI and Nano-MOUDI impactor systems.

Figure 3. Panel A - Enhanced dark-field microscopy image of Cu-Ni welding fume deposits (arrows) in the alveoli of a mouse 30 weeks after a 9 week inhalation exposure to Cu-Ni fume. Panel B - Enhanced dark-field microscopy image showing no deposits in the alveoli of a mouse 30 weeks after a 9 week inhalation exposure of air.

Figure 4. Average tumor number per mouse lung (tumor multiplicity) upon gross examination in A/J mice following initiation-promotion study at 30 week sacrifice.

MCA/Cu-Ni fume significantly decreased lung tumor number compared to air controls (7.11 ± 0.93 and 15.57 ± 0.75 , respectively). As expected, mice treated with CO had low tumor number. Horizontal bars represent mean tumor numbers per group. Circles = CO/Air, squares = CO/Cu-Ni fume, upward triangles = MCA/air, downward triangles = MCA/Cu-Ni fume. $*p < 0.0001$ – compared to CO/air; $**p < 0.0001$ – compared to MCA/air

Figure 5. Gross images of A/J mouse lung exposed to MCA/air (panel A) or MCA/Cu-Ni welding fume (panel B). Images represent lung tumor morphology 24-h post-fixation.

Fixation allows for more accurate enumeration of tumors. Tumors (arrows) were on average ~1 mm in diameter in MCA/air mice and ~0.5 mm in diameter in MCA/Cu-Ni welding fume exposed mice.

Figures

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Tables.

Table 1. Metal composition of Cu-Ni fume

Metals Analyzed	Weight % of Metals
Cu	76.35
Ni	11.60
Fe	5.10
Ti	2.86
Mn	2.27

GMAW-MS fume was analyzed for aluminum (Al), barium (Ba), calcium (Ca), chromium (Cr), cobalt (Co), copper (Cu), iron (Fe), potassium (K), lithium (Li), manganese (Mn), magnesium (Mg), nickel (Ni), phosphorus (P), lead (Pb), strontium (Sr), titanium (Ti), vanadium (V), zinc (Zn), and zirconium (Zr) by Inductively Coupled Plasma-Atomic Emission Spectroscopy.

Samples were prepared according to the NIOSH method 7300 for bulk samples. Trace amounts (<1%) of Al, Ba, Ca, Co, Cr, K, Li, Mg, P, Pb, Sr, Ti, V, Zn, and Zr were found. Weight % is relative to all metals analyzed.

Table 2. Lung metal deposition in A/J mice after air or Cu-Ni fume inhalation for 4 hours at a concentration of 43 mg/m³

Exposure	Cu (µg/lung)	Ni (µg/lung)	Fe (µg/lung)	Ti (µg/lung)	Mn (µg/lung)
Air	0.30 ± 0.01	0.05 ± 0.02	9.95 ± 0.35	0.04 ± 0.02	0.03 ± 0.00
Cu-Ni	5.40 ± 0.17	1.23 ± 0.07	10.74 ± 0.27	0.16 ± 0.03	0.16 ± 0.00

Freeze-dried whole lung tissue was analyzed for aluminum (Al), barium (Ba), calcium (Ca), chromium (Cr), cobalt (Co), copper (Cu), iron (Fe), potassium (K), lithium (Li), manganese (Mn), magnesium (Mg), nickel (Ni), phosphorus (P), lead (Pb), strontium (Sr), titanium (Ti), vanadium (V), zinc (Zn), and zirconium (Zr) by Inductively Coupled Plasma-Atomic Emission Spectroscopy. Samples were prepared according to the draft NIOSH method 8200 for bulk tissue samples. Levels of Al, Ba, Ca, Co, Cr, Li, Mg, P, Pb, Sr, V, Zn and Zr were not included because they were not detectable, <0.1% in the fume analysis, or not significantly higher in exposed animals. *Note:* Values are mean ± standard error of the mean (n=6 air; n=10 Cu-Ni);

Table 3. Total and average (in parenthesis) tumor number in A/J mice across each of the individual lung lobes following GMAW-MS or air exposure 30 weeks post-initiation with MCA or corn oil

	n	Left	Apical	Cardiac	Diaphragmatic	Azygos
CO/air	27	4 (0.15 ± 0.07)	0	1 (0.04 ± 0.04)	2 (0.07 ± 0.05)	1 (0.04 ± 0.04)
CO/Cu-Ni	29	0	0	0	2 (0.07 ± 0.26)	0
MCA/air	28	133 (4.75 ± 0.41)*	54 (1.93 ± 0.21)**	68 (2.43 ± 0.31)	127 (4.54 ± 0.38)*	54 (1.93 ± 0.24)^
MCA/Cu-Ni	27	52 (1.93 ± 0.29)	24 (0.89 ± 0.21)	51 (1.89 ± 0.32)	38 (1.41 ± 0.28)	27 (1.00 ± 0.22)

CO – corn oil, Cu-Ni – copper-nickel welding fume, MCA – 3-methylchloanthrene

*p < 0.0001, ** p < 0.002, ^p < 0.006 – compared to MCA/Cu-Ni

Chapter 7: Conclusions

Significant advancements have been made in the field of welding fume toxicology research in the past few years. In 2017, welding fumes were officially classified as a Group 1 carcinogen after being considered *possibly carcinogenic to humans* (Group 2B) since 1990. Epidemiological and worker studies have been important for establishing the connection between welding and lung cancer. However, these studies have shown mixed results, which highlights the difficulties of epidemiological studies given the potential for confounders like smoking and asbestos, the possibility of mixed welding fume exposures, personal safety habits, genetics, and other risk factors. Nevertheless, epidemiological studies have demonstrated that welding fume exposure poses a serious health risk and highlights the need for controlled scientific studies like were presented in this dissertation.

Our *in vivo* studies have demonstrated that many types of welding fumes have toxic and tumorigenic potential. We have demonstrated that GMAW-MS, GMAW-SS, and Fe_2O_3 , an iron oxide found in many types of welding fumes, promote lung tumor formation in the A/J mouse model. We also showed that Fe_2O_3 was the most pneumotoxic metal oxide compared to NiO or $\text{Cr}_2\text{O}_3/\text{CaCrO}_4$ at doses relevant to their percentages in the fume. However, GMAW-SS was more pneumotoxic than any of the individual metal oxides, suggesting there may be a synergistic or additive toxicity of the metal oxides when they come together in the fume. In contrast, GMAW-MS did not cause significant inflammation or cytotoxicity despite the tumorigenic effect. Most surprisingly, we found that a Cu-Ni fume produced by GMAW reduced tumor size and tumor number *in vivo*.

There are a number of strengths as well as some limitations to this research. Many of these studies involved whole body inhalation exposures. *In vivo* inhalation exposures are most

similar to how workers are exposed, and the NIOSH inhalation facility is able to closely monitor these exposures to maintain a target welding fume concentration and monitor environmental conditions like temperature and gas production. These research projects also utilized a large sample size of nearly 1,000 A/J mice across all studies. The A/J mouse is a commonly used strain in lung cancer research. These mice develop lung tumors both spontaneously as well as rapidly in response to carcinogens following a hyperplasia to adenoma to adenocarcinoma progression [1, 2]. Lung tumorigenesis in this model is under complex genetic control involving the pulmonary adenoma susceptibility 1 (*Pas1*) locus and *Kras*. [3] In humans, *Kras* mutations are common in lung adenocarcinoma [4]. More so, in most cases, both human and A/J mouse lung tumors originate from atypical hyperplastic lesions in the periphery of the lung [4-7]. The research presented in this dissertation entirely utilized A/J mice and did not investigate tumorigenic potential in other strains. However, previous research in our lab comparing A/J mice to lung tumor resistant C57BL/6J mice showed that the latter strain had a smaller pneumotoxic response to welding fumes while the A/J mice demonstrated a possible tumorigenic effect of GMAW-SS fume exposure, making the A/J strain a better model for our studies. The potential spontaneous tumor development is a clear limitation to the A/J mouse model; yet, reported background tumor incidence is still relatively low at about 65% in 15 month old A/J mice. In our two-stage model, the tumor background incidence in control mice was also very low (often ~20% or less) in 30 week old mice. Regardless, in our studies, we saw clear and profound effects on lung tumors in response to welding fumes.

An additional limitation to this research was the fact that only male mice were used in our studies. While welding has traditionally been considered a male-dominated career, more women are choosing to enter the field. In a recent study investigating the health of a cohort of welders in

Canada, it was found that both sexes appeared to have similar health at first follow-up, although women reported higher rates of depression than men.[8] Future studies should continue to investigate potential health differences among welders of both sexes. These studies were also limited in that we did not use enough different doses to observe clear dose-response effects. Additionally, we did not mix exposures to different welding fumes or create combinations of metal oxides for dosing which would have enabled us to explore additive or synergistic effects. However, given the complications and lack of clarity from epidemiological studies, we sought to keep these studies simple and straightforward by beginning our studies with just one sex and limited exposure groups.

Currently, little is known concerning the mechanisms by which welding fumes act as lung carcinogens. In 2016, Smith et al. identified 10 key characteristics of human carcinogens, with the understanding that most human carcinogens exhibit at least one of these characteristics [9]. A recent report from Guyton et al. 2018 reviewed the literature on welding fumes and concluded that the two most likely key carcinogenic characteristics of welding fumes include their ability to be immunosuppressive and induce chronic inflammation [10]. This classification was based on evidence from multiple studies demonstrating increases in lung and systemic inflammation biomarkers in welders. However, *in vivo* studies such as presented in this dissertation indicate that not all welding fumes induce overt inflammation; we observed that GMAW-SS induced inflammation in A/J mice while GMAW-MS did not. Eight other key characteristics of human carcinogens are recognized which could represent mechanisms of welding fume tumorigenesis. These characteristics include electrophilic properties or the ability to be metabolically activated, genotoxicity, the ability to alter DNA repair or cause genomic instability, induction of epigenetic alterations, induction of oxidative stress, modulating receptor-

mediated effects, causing immortalization, and altering cell proliferation, cell death, or nutrient supply. It is possible welding fumes may cause tumorigenesis through one of these additional mechanisms. Future studies in our lab are planned at investigating potential epigenetic effects of welding fumes such as the presence of DNA methylation or histone modification.

The goal of this research is to better understand what welding fumes and component metals are most dangerous so that welders can ultimately be protected from adverse respiratory health effects like lung cancer, given that ventilation and personal protective equipment such as respirators are not sufficient. No ventilation is 100% effective, and there is evidence that some respirators are not entirely able to protect welders [11, 12]. More so, many welders do not wear personal protective equipment, with a recent study of a cohort of welders from Canada indicating that nearly 50% of welders wore no respiratory protection when welding [8]. From a public health standpoint, there is a need to inform welders of the risks of welding fume inhalation and offer them enhanced protection in the workplace. The research in this dissertation as well as ongoing studies will be significant in clarifying which welding fumes and their metal constituents are most hazardous to worker health. This understanding could more appropriately guide worksite regulations regarding safe levels of welding fumes or component metals and help lead to the creation of welding consumables that are devoid of the more hazardous metal oxide components. With a better understanding of the hazardous components of the fume, we can better protect or prevent exposure in welders and hopefully reduce lung cancer rates in this occupation.

Bibliography

1. Witschi H: **The complexities of an apparently simple lung tumor model: The A/J mouse.** *Exp Toxicol Pathol* 2005, **57 Suppl 1**:171-181.
2. Shimkin MB, Stoner GD: **Lung tumors in mice: application to carcinogenesis bioassay.** *Adv Cancer Res* 1975, **21**:1-58.
3. Gariboldi M, Manenti G, Canzian F, Falvella FS, Radice MT, Pierotti MA, Della Porta G, Binelli G, Dragani TA: **A major susceptibility locus to murine lung carcinogenesis maps on chromosome 6.** *Nat Genet* 1993, **3**:132-136.
4. Westra WH, Baas IO, Hruban RH, Askin FB, Wilson K, Offerhaus GJ, Slebos RJ: **K-ras oncogene activation in atypical alveolar hyperplasias of the human lung.** *Cancer Res* 1996, **56**:2224-2228.
5. Belinsky SA, Devereux TR, Foley JF, Maronpot RR, Anderson MW: **Role of the alveolar type II cell in the development and progression of pulmonary tumors induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in the A/J mouse.** *Cancer Res* 1992, **52**:3164-3173.
6. Westra WH: **Early glandular neoplasia of the lung.** *Respir Res* 2000, **1**:163-169.
7. Foley JF, Anderson MW, Stoner GD, Gaul BW, Hardisty JF, Maronpot RR: **Proliferative lesions of the mouse lung: progression studies in strain A mice.** *Exp Lung Res* 1991, **17**:157-168.
8. Cherry N, Arrandale V, Beach J, Galarneau JF, Mannette A, Rodgers L: **Health and Work in Women and Men in the Welding and Electrical Trades: How Do They Differ?** *Ann Work Expo Health* 2018.
9. Smith MT, Guyton KZ, Gibbons CF, Fritz JM, Portier CJ, Rusyn I, DeMarini DM, Caldwell JC, Kavlock RJ, Lambert PF, et al: **Key Characteristics of Carcinogens as a Basis for Organizing Data on Mechanisms of Carcinogenesis.** *Environ Health Perspect* 2016, **124**:713-721.
10. Guyton KZ, Rusyn I, Chiu WA, Corpet DE, van den Berg M, Ross MK, Christiani DC, Beland FA, Smith MT: **Application of the key characteristics of carcinogens in cancer hazard identification.** *Carcinogenesis* 2018.
11. Antonini JM: **Health Effects Associated with Welding.** 2014:49-70.
12. Chen HL, Chung SH, Jhuo ML: **Efficiency of different respiratory protective devices for removal of particulate and gaseous reactive oxygen species from welding fumes.** *Arch Environ Occup Health* 2013, **68**:101-106.